0000937834us-gaap:NonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-01-012023-03-31InterestRateSwaptionMemberus-gaap:NondesignatedMember2023-06-30

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________________
Form 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31,JUNE 30, 2023
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM                         TO
Commission file number: 000-55029
 ________________________________________
Metropolitan Life Insurance Company
(Exact name of registrant as specified in its charter)
New York 13-5581829
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
200 Park Avenue,New York,NY 10166-0188
(Address of principal executive offices) (Zip Code)
(212) 578-9500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
NoneN/AN/A
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes     No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes    No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes     No 
At May 9,August 8, 2023, 494,466,664 shares of the registrant’s common stock were outstanding, all of which were owned directly by MetLife, Inc.
REDUCED DISCLOSURE FORMAT
The registrant meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q and is, therefore, filing this Form 10-Q with the reduced disclosure format.




Table of Contents
 Page
Item 1.Financial Statements (Unaudited) (at March 31,June 30, 2023 and December 31, 2022 and for the Three Months and Six Months Ended March 31,June 30, 2023 and 2022)
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 5.
Item 6. 


Table of Contents
As used in this Form 10-Q, “MLIC,” the “Company,” “we,” “our” and “us” refer to Metropolitan Life Insurance Company, a New York corporation incorporated in 1868, and its subsidiaries. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”).
Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10‑Q, including Management’s Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” “are confident,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, future sales efforts, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.
Many factors determine Company results, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. We do not guarantee any future performance. Our results could differ materially from those we express or imply in forward-looking statements. The risks, uncertainties and other factors, including those relating to the COVID-19 pandemic, identified in Metropolitan Life Insurance Company’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:
(1) economic condition difficulties, including risks relating to public health, interest rates, credit spreads, equity, real estate, obligors and counterparties, government default, derivatives, and climate change;
(2) global capital and credit market adversity;
(3) credit facility inaccessibility;
(4) financial strength or credit ratings downgrades;
(5) unavailability, unaffordability, or inadequate reinsurance;reinsurance, including reinsurance risks that arise from reinsurers’ credit risk, and the potential shortfall or failure of risk mitigants to protect against such risks;
(6) statutory life insurance reserve financing costs or limited market capacity;
(7) legal, regulatory, and supervisory and enforcement policy changes;
(8) changes in tax rates, tax laws or interpretations;
(9) litigation and regulatory investigations;
(10) London Interbank Offered Rate discontinuation and transition to alternative reference rates;
(11) unsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;
(12) investment defaults, downgrades, or volatility;
(13) investment sales or lending difficulties;
(14) collateral or derivative-related payments;
(15) investment valuations, allowances, or impairments changes;
(16) claims or other results that differ from our estimates, assumptions, or models;
(17) business competition;
(18) catastrophes;
(19) climate changes or responses to it;
(20) deficiencies in our closed block;
(21) impairment of value of business acquired, value of distribution agreements acquired or value of customer relationships acquired;
2

Table of Contents
(22) product guarantee volatility, costs, and counterparty risks;
(23) risk management failures;
(24) insufficient protection from operational risks;
(25) failure to protect confidentiality and integrity of data or other cybersecurity or disaster recovery failures;
(26) accounting standards changes;
(27) excessive risk-taking; and
(28) marketing and distribution difficulties.
Metropolitan Life Insurance Company does not undertake any obligation to publicly correct or update any forward-looking statement if Metropolitan Life Insurance Company later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures Metropolitan Life Insurance Company makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.
Note Regarding Reliance on Statements in Our Contracts
See “Exhibits — Note Regarding Reliance on Statements in Our Contracts” for information regarding agreements included as exhibits to this Quarterly Report on Form 10-Q.
3

Table of Contents
Part I — Financial Information
Item 1. Financial Statements
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Interim Condensed Consolidated Balance Sheets
March 31,June 30, 2023 and December 31, 2022 (Unaudited)
(In millions, except share and per share data)
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
AssetsAssetsAssets
Investments:Investments:Investments:
Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $135 and $114, respectively;) and amortized cost: $162,095 and $160,477, respectively$150,960 $145,576 
Mortgage loans (net of allowance for credit loss of $587 and $448, respectively; includes $145 and $144, respectively, relating to variable interest entities)
64,053 62,570 
Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $142 and $114, respectively;) and amortized cost: $161,466 and $160,477, respectivelyFixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $142 and $114, respectively;) and amortized cost: $161,466 and $160,477, respectively$149,072 $145,576 
Mortgage loans (net of allowance for credit loss of $525 and $448, respectively; includes $150 and $144, respectively, relating to variable interest entities)
Mortgage loans (net of allowance for credit loss of $525 and $448, respectively; includes $150 and $144, respectively, relating to variable interest entities)
63,811 62,570 
Policy loansPolicy loans5,701 5,729 Policy loans5,692 5,729 
Real estate and real estate joint ventures (includes $1,380 and $1,358, respectively, relating to variable interest entities, $294 and $299, respectively, under the fair value option)8,492 8,416 
Real estate and real estate joint ventures (includes $1,329 and $1,358, respectively, relating to variable interest entities, $310 and $299, respectively, under the fair value option)Real estate and real estate joint ventures (includes $1,329 and $1,358, respectively, relating to variable interest entities, $310 and $299, respectively, under the fair value option)8,493 8,416 
Other limited partnership interestsOther limited partnership interests7,817 7,887 Other limited partnership interests7,877 7,887 
Short-term investments, at estimated fair valueShort-term investments, at estimated fair value2,046 2,759 Short-term investments, at estimated fair value3,456 2,759 
Other invested assets (net of allowance for credit loss of $14 and $19, respectively; includes $848 and $858, respectively, of leveraged and direct financing leases; $161 and $161, respectively, relating to variable interest entities)18,737 19,148 
Other invested assets (net of allowance for credit loss of $12 and $19, respectively; includes $846 and $858, respectively, of leveraged and direct financing leases; $160 and $161, respectively, relating to variable interest entities)Other invested assets (net of allowance for credit loss of $12 and $19, respectively; includes $846 and $858, respectively, of leveraged and direct financing leases; $160 and $161, respectively, relating to variable interest entities)18,326 19,148 
Total investmentsTotal investments257,806 252,085 Total investments256,727 252,085 
Cash and cash equivalents, principally at estimated fair valueCash and cash equivalents, principally at estimated fair value5,225 9,405 Cash and cash equivalents, principally at estimated fair value4,106 9,405 
Accrued investment incomeAccrued investment income2,080 1,949 Accrued investment income2,024 1,949 
Premiums, reinsurance and other receivablesPremiums, reinsurance and other receivables21,508 20,791 Premiums, reinsurance and other receivables20,753 20,791 
Market risk benefits, at estimated fair valueMarket risk benefits, at estimated fair value124 174 Market risk benefits, at estimated fair value163 174 
Deferred policy acquisition costs and value of business acquiredDeferred policy acquisition costs and value of business acquired3,757 3,757 Deferred policy acquisition costs and value of business acquired3,695 3,757 
Current income tax recoverableCurrent income tax recoverable123 165 Current income tax recoverable253 165 
Deferred income tax assetDeferred income tax asset2,675 2,920 Deferred income tax asset2,841 2,920 
Other assetsOther assets5,166 4,352 Other assets4,349 4,352 
Separate account assetsSeparate account assets88,357 89,241 Separate account assets84,910 89,241 
Total assetsTotal assets$386,821 $384,839 Total assets$379,821 $384,839 
Liabilities and EquityLiabilities and EquityLiabilities and Equity
LiabilitiesLiabilitiesLiabilities
Future policy benefitsFuture policy benefits$128,198 $126,914 Future policy benefits$126,814 $126,914 
Policyholder account balancesPolicyholder account balances104,954 103,407 Policyholder account balances104,789 103,407 
Market risk benefits, at estimated fair valueMarket risk benefits, at estimated fair value3,432 3,270 Market risk benefits, at estimated fair value2,942 3,270 
Other policy-related balancesOther policy-related balances8,214 7,931 Other policy-related balances8,286 7,931 
Policyholder dividends payablePolicyholder dividends payable237 240 Policyholder dividends payable237 240 
Payables for collateral under securities loaned and other transactionsPayables for collateral under securities loaned and other transactions13,443 14,171 Payables for collateral under securities loaned and other transactions12,695 14,171 
Short-term debtShort-term debt99 99 Short-term debt99 99 
Long-term debtLong-term debt1,887 1,676 Long-term debt1,886 1,676 
Other liabilitiesOther liabilities23,824 24,495 Other liabilities23,564 24,495 
Separate account liabilitiesSeparate account liabilities88,357 89,241 Separate account liabilities84,910 89,241 
Total liabilitiesTotal liabilities372,645 371,444 Total liabilities366,222 371,444 
Contingencies, Commitments and Guarantees (Note 16)Contingencies, Commitments and Guarantees (Note 16)Contingencies, Commitments and Guarantees (Note 16)
EquityEquityEquity
Metropolitan Life Insurance Company stockholder’s equity:Metropolitan Life Insurance Company stockholder’s equity:Metropolitan Life Insurance Company stockholder’s equity:
Common stock, par value $0.01 per share; 1,000,000,000 shares authorized; 494,466,664 shares issued and outstandingCommon stock, par value $0.01 per share; 1,000,000,000 shares authorized; 494,466,664 shares issued and outstandingCommon stock, par value $0.01 per share; 1,000,000,000 shares authorized; 494,466,664 shares issued and outstanding
Additional paid-in capitalAdditional paid-in capital12,476 12,476 Additional paid-in capital12,475 12,476 
Retained earningsRetained earnings8,315 9,022 Retained earnings8,374 9,022 
Accumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)(6,832)(8,320)Accumulated other comprehensive income (loss)(7,423)(8,320)
Total Metropolitan Life Insurance Company stockholder’s equityTotal Metropolitan Life Insurance Company stockholder’s equity13,964 13,183 Total Metropolitan Life Insurance Company stockholder’s equity13,431 13,183 
Noncontrolling interestsNoncontrolling interests212 212 Noncontrolling interests168 212 
Total equityTotal equity14,176 13,395 Total equity13,599 13,395 
Total liabilities and equityTotal liabilities and equity$386,821 $384,839 Total liabilities and equity$379,821 $384,839 
See accompanying notes to the interim condensed consolidated financial statements.
4

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
Three Months and Six Months Ended March 31,June 30, 2023 and 2022 (Unaudited)
(In millions)
Three Months
Ended
March 31,
Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
202320222023202220232022
RevenuesRevenuesRevenues
PremiumsPremiums$5,849 $5,906 Premiums$5,953 $5,664 $11,802 $11,570 
Universal life and investment-type product policy feesUniversal life and investment-type product policy fees430 479 Universal life and investment-type product policy fees422 467 852 946 
Net investment incomeNet investment income2,685 2,826 Net investment income2,873 2,442 5,558 5,268 
Other revenuesOther revenues415 411 Other revenues419 372 834 783 
Net investment gains (losses)Net investment gains (losses)(102)(226)Net investment gains (losses)(659)(83)(761)(309)
Net derivative gains (losses)Net derivative gains (losses)(560)121 Net derivative gains (losses)(232)586 (792)707 
Total revenuesTotal revenues8,717 9,517 Total revenues8,776 9,448 17,493 18,965 
ExpensesExpensesExpenses
Policyholder benefits and claimsPolicyholder benefits and claims6,223 6,651 Policyholder benefits and claims6,436 6,010 12,659 12,661 
Policyholder liability remeasurement (gains) lossesPolicyholder liability remeasurement (gains) losses(57)(29)Policyholder liability remeasurement (gains) losses17 (12)(40)(41)
Market risk benefits remeasurement (gains) lossesMarket risk benefits remeasurement (gains) losses244 (1,361)Market risk benefits remeasurement (gains) losses(670)(730)(426)(2,091)
Interest credited to policyholder account balancesInterest credited to policyholder account balances831 502 Interest credited to policyholder account balances893 565 1,724 1,067 
Policyholder dividendsPolicyholder dividends123 161 Policyholder dividends116 153 239 314 
Other expensesOther expenses1,548 1,308 Other expenses1,396 1,393 2,944 2,701 
Total expensesTotal expenses8,912 7,232 Total expenses8,188 7,379 17,100 14,611 
Income (loss) before provision for income taxIncome (loss) before provision for income tax(195)2,285 Income (loss) before provision for income tax588 2,069 393 4,354 
Provision for income tax expense (benefit)Provision for income tax expense (benefit)(104)403 Provision for income tax expense (benefit)78 385 (26)788 
Net income (loss)Net income (loss)(91)1,882 Net income (loss)510 1,684 419 3,566 
Less: Net income (loss) attributable to noncontrolling interestsLess: Net income (loss) attributable to noncontrolling interests(2)— Less: Net income (loss) attributable to noncontrolling interests43 41 
Net income (loss) attributable to Metropolitan Life Insurance CompanyNet income (loss) attributable to Metropolitan Life Insurance Company$(89)$1,882 Net income (loss) attributable to Metropolitan Life Insurance Company$467 $1,682 $378 $3,564 
Comprehensive income (loss)Comprehensive income (loss)$1,398 $(167)Comprehensive income (loss)$(81)$(1,081)$1,317 $(1,248)
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income taxLess: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax(1)— Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax43 42 
Comprehensive income (loss) attributable to Metropolitan Life Insurance CompanyComprehensive income (loss) attributable to Metropolitan Life Insurance Company$1,399 $(167)Comprehensive income (loss) attributable to Metropolitan Life Insurance Company$(124)$(1,083)$1,275 $(1,250)
See accompanying notes to the interim condensed consolidated financial statements.

5

Table of Contents

Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Interim Condensed Consolidated Statements of Equity
ThreeSix Months Ended March 31,June 30, 2023 and 2022 (Unaudited)
(In millions)
Common
Stock
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Metropolitan Life
Insurance Company
Stockholder’s Equity
Noncontrolling
Interests
Total
Equity
Common
Stock
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Metropolitan Life
Insurance Company
Stockholder’s Equity
Noncontrolling
Interests
Total
Equity
Balance at December 31, 2022Balance at December 31, 2022$$12,476 $9,022 $(8,320)$13,183 $212 $13,395 Balance at December 31, 2022$$12,476 $9,022 $(8,320)$13,183 $212 $13,395 
Dividends to MetLife, Inc.Dividends to MetLife, Inc.(618)(618)(618)Dividends to MetLife, Inc.(618)(618)(618)
Change in equity of noncontrolling interestsChange in equity of noncontrolling interests— Change in equity of noncontrolling interests— 
Net income (loss)Net income (loss)(89)(89)(2)(91)Net income (loss)(89)(89)(2)(91)
Other comprehensive income (loss), net of income taxOther comprehensive income (loss), net of income tax1,488 1,488 1,489 Other comprehensive income (loss), net of income tax1,488 1,488 1,489 
Balance at March 31, 2023Balance at March 31, 2023$$12,476 $8,315 $(6,832)$13,964 $212 $14,176 Balance at March 31, 2023$$12,476 $8,315 $(6,832)$13,964 $212 $14,176 
Returns of capitalReturns of capital(1)(1)(1)
Dividends to MetLife, Inc.Dividends to MetLife, Inc.(408)(408)(408)
Change in equity of noncontrolling interestsChange in equity of noncontrolling interests— (87)(87)
Net income (loss)Net income (loss)467 467 43 510 
Other comprehensive income (loss), net of income taxOther comprehensive income (loss), net of income tax(591)(591)(591)
Balance at June 30, 2023Balance at June 30, 2023$$12,475 $8,374 $(7,423)$13,431 $168 $13,599 
Common
Stock
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Metropolitan Life
Insurance Company
Stockholder’s Equity
Noncontrolling
Interests
Total
Equity
Common
Stock
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Metropolitan Life
Insurance Company
Stockholder’s Equity
Noncontrolling
Interests
Total
Equity
Balance at December 31, 2021Balance at December 31, 2021$$12,464 $6,933 $(1,055)$18,347 $174 $18,521 Balance at December 31, 2021$$12,464 $6,933 $(1,055)$18,347 $174 $18,521 
Capital contributions from MetLife, Inc.Capital contributions from MetLife, Inc.Capital contributions from MetLife, Inc.
Dividends to MetLife, Inc.Dividends to MetLife, Inc.(881)(881)(881)Dividends to MetLife, Inc.(881)(881)(881)
Change in equity of noncontrolling interestsChange in equity of noncontrolling interests— (20)(20)Change in equity of noncontrolling interests— (20)(20)
Net income (loss)Net income (loss)1,882 1,882 — 1,882 Net income (loss)1,882 1,882 1,882 
Other comprehensive income (loss), net of income taxOther comprehensive income (loss), net of income tax(2,049)(2,049)(2,049)Other comprehensive income (loss), net of income tax(2,049)(2,049)(2,049)
Balance at March 31, 2022Balance at March 31, 2022$$12,465 $7,934 $(3,104)$17,300 $154 $17,454 Balance at March 31, 2022$$12,465 $7,934 $(3,104)$17,300 $154 $17,454 
Capital contributions from MetLife, Inc.Capital contributions from MetLife, Inc.11 11 11 
Dividends to MetLife, Inc.Dividends to MetLife, Inc.(681)(681)(681)
Change in equity of noncontrolling interestsChange in equity of noncontrolling interests— (2)(2)
Net income (loss)Net income (loss)1,682 1,682 1,684 
Other comprehensive income (loss), net of income taxOther comprehensive income (loss), net of income tax(2,765)(2,765)(2,765)
Balance at June 30, 2022Balance at June 30, 2022$$12,476 $8,935 $(5,869)$15,547 $154 $15,701 

See accompanying notes to the interim condensed consolidated financial statements.
6

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Interim Condensed Consolidated Statements of Cash Flows
ThreeSix Months Ended March 31, June 30, 2023 and 2022 (Unaudited)
(In millions)
Three Months
Ended
March 31,
Six Months
Ended
June 30,
20232022 20232022
Net cash provided by (used in) operating activitiesNet cash provided by (used in) operating activities$199 $1,000 Net cash provided by (used in) operating activities$2,088 $1,422 
Cash flows from investing activitiesCash flows from investing activitiesCash flows from investing activities
Sales, maturities and repayments of:Sales, maturities and repayments of:Sales, maturities and repayments of:
Fixed maturity securities available-for-saleFixed maturity securities available-for-sale10,356 11,324 Fixed maturity securities available-for-sale16,676 27,410 
Equity securitiesEquity securities30 57 Equity securities52 82 
Mortgage loansMortgage loans1,146 3,038 Mortgage loans2,903 5,667 
Real estate and real estate joint venturesReal estate and real estate joint ventures73 Real estate and real estate joint ventures25 431 
Other limited partnership interestsOther limited partnership interests155 594 Other limited partnership interests304 732 
Short-term investmentsShort-term investments2,042 4,982 Short-term investments3,018 6,044 
Purchases and originations of:Purchases and originations of:Purchases and originations of:
Fixed maturity securities available-for-saleFixed maturity securities available-for-sale(11,590)(12,780)Fixed maturity securities available-for-sale(17,635)(23,277)
Equity securitiesEquity securities(4)(2)Equity securities(11)(40)
Mortgage loansMortgage loans(2,700)(2,571)Mortgage loans(4,212)(7,175)
Real estate and real estate joint venturesReal estate and real estate joint ventures(193)(112)Real estate and real estate joint ventures(379)(263)
Other limited partnership interestsOther limited partnership interests(174)(232)Other limited partnership interests(397)(491)
Short-term investmentsShort-term investments(1,321)(2,027)Short-term investments(3,743)(2,829)
Cash received in connection with freestanding derivativesCash received in connection with freestanding derivatives259 784 Cash received in connection with freestanding derivatives381 1,542 
Cash paid in connection with freestanding derivativesCash paid in connection with freestanding derivatives(921)(1,181)Cash paid in connection with freestanding derivatives(1,334)(2,323)
Receipts on loans to affiliatesReceipts on loans to affiliates100 — 
Purchases of loans to affiliatesPurchases of loans to affiliates— (18)Purchases of loans to affiliates— (19)
Net change in policy loansNet change in policy loans28 50 Net change in policy loans37 70 
Net change in other invested assetsNet change in other invested assets(11)(13)Net change in other invested assets(307)20 
Net change in property, equipment and leasehold improvementsNet change in property, equipment and leasehold improvementsNet change in property, equipment and leasehold improvements
Other, netOther, netOther, net16 
Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activities(2,884)1,971 Net cash provided by (used in) investing activities(4,502)5,593 
Cash flows from financing activitiesCash flows from financing activitiesCash flows from financing activities
Policyholder account balances:
Deposits22,131 22,773 
Withdrawals(22,491)(20,482)
Policyholder account balances - depositsPolicyholder account balances - deposits39,547 46,102 
Policyholder account balances - withdrawalsPolicyholder account balances - withdrawals(40,094)(44,260)
Net change in payables for collateral under securities loaned and other transactionsNet change in payables for collateral under securities loaned and other transactions(728)(983)Net change in payables for collateral under securities loaned and other transactions(1,476)(7,377)
Long-term debt issuedLong-term debt issued211 — Long-term debt issued210 
Long-term debt repaidLong-term debt repaid— (3)Long-term debt repaid— (10)
Financing element on certain derivative instruments and other derivative related transactions, netFinancing element on certain derivative instruments and other derivative related transactions, net(2)144 Financing element on certain derivative instruments and other derivative related transactions, net(50)200 
Dividends paid to MetLife, Inc.Dividends paid to MetLife, Inc.(618)(881)Dividends paid to MetLife, Inc.(1,026)(1,562)
Other, netOther, net(13)Other, net(16)
Net cash provided by (used in) financing activitiesNet cash provided by (used in) financing activities(1,495)555 Net cash provided by (used in) financing activities(2,884)(6,919)
Effect of change in foreign currency exchange rates on cash and cash equivalents balancesEffect of change in foreign currency exchange rates on cash and cash equivalents balances— (2)Effect of change in foreign currency exchange rates on cash and cash equivalents balances(1)(9)
Change in cash and cash equivalentsChange in cash and cash equivalents(4,180)3,524 Change in cash and cash equivalents(5,299)87 
Cash and cash equivalents, beginning of periodCash and cash equivalents, beginning of period9,405 9,957 Cash and cash equivalents, beginning of period9,405 9,957 
Cash and cash equivalents, end of periodCash and cash equivalents, end of period$5,225 $13,481 Cash and cash equivalents, end of period$4,106 $10,044 
Supplemental disclosures of cash flow informationSupplemental disclosures of cash flow informationSupplemental disclosures of cash flow information
Net cash paid (received) for:Net cash paid (received) for:Net cash paid (received) for:
InterestInterest$14 $Interest$62 $49 
Income taxIncome tax$$12 Income tax$216 $170 
Non-cash transactions:Non-cash transactions:Non-cash transactions:
Capital contributions from MetLife, Inc.Capital contributions from MetLife, Inc.$— $Capital contributions from MetLife, Inc.$— $12 
Increase in equity securities due to in-kind distributions received from other limited partnership interest$18 $42 
Increase in policyholder account balances associated with funding agreement backed notes issued but not settled$795 $— 
Transfer of fixed maturity securities available-for-sale from an affiliateTransfer of fixed maturity securities available-for-sale from an affiliate$502 $— Transfer of fixed maturity securities available-for-sale from an affiliate$502 $— 
Increase in policyholder account balances in connection with affiliated reinsurance transactionsIncrease in policyholder account balances in connection with affiliated reinsurance transactions$502 $— Increase in policyholder account balances in connection with affiliated reinsurance transactions$502 $— 
Real estate and real estate joint ventures acquired in satisfaction of debtReal estate and real estate joint ventures acquired in satisfaction of debt$$129 
Transfer of fixed maturity securities available-for-sale to an affiliateTransfer of fixed maturity securities available-for-sale to an affiliate$— $189 Transfer of fixed maturity securities available-for-sale to an affiliate$— $189 
Transfer of fair value option securities from an affiliateTransfer of fair value option securities from an affiliate$— $186 Transfer of fair value option securities from an affiliate$— $186 
Increase in policyholder account balances associated with funding agreement backed notes issued but not settledIncrease in policyholder account balances associated with funding agreement backed notes issued but not settled$— $184 
See accompanying notes to the interim condensed consolidated financial statements.
7

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies
Business
Metropolitan Life Insurance Company and its subsidiaries (collectively, “MLIC” or the “Company”) is a provider of insurance, annuities, employee benefits and asset management and is organized into two segments: U.S. and MetLife Holdings. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”).
Basis of Presentation
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.
The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. Except for balances affected by the adoption of Accounting Standards Update (“ASU”) 2018-12 noted below, the December 31, 2022 consolidated balance sheet data was derived from audited consolidated financial statements included in Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2022 Annual Report.
Adoption of ASU 2018-12 - Targeted Improvements to the Accounting for Long-Duration Contracts
Effective January 1, 2023, the Company adopted ASU 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, as amended by ASU 2019-09, Financial Services—Insurance (Topic 944): Effective Date; ASU 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application; and ASU 2022-05, Financial Services—Insurance (Topic 944): Transition for Sold Contracts (“LDTI”), with a transition date of January 1, 2021 (the “Transition Date”). Adoption of LDTI impacted the Company’s accounting and presentation related to long-duration insurance contracts and certain related balances for the years ended December 31, 2022 and 2021. Amounts within these interim condensed consolidated financial statements which were previously presented, have been revised to conform with the current year accounting and presentation under LDTI. Disclosures as of the Transition Date are reflected in summary within “— Recent Accounting Pronouncements — Adoption of ASU 2018-12 - Targeted Improvements to the Accounting for Long-Duration Contracts,” and in further detail (at the disaggregated level) within Notes 3, 4, 5 and 7.
Consolidation
The accompanying interim condensed consolidated financial statements include the accounts of Metropolitan Life Insurance Company and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated.
The Company uses the equity method of accounting or the fair value option (“FVO”) for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period.
Since the Company is a member of a controlled group of affiliated companies, its results may not be indicative of those of a stand-alone entity.
8

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Revisions
Cash flows from short term investments in the prior years’ Interim Condensed Consolidated Statement of Cash Flows, which were previously presented net, have been revised to gross presentation to conform with the current year presentation. The revision in presentation was not material to the previously presented financial statements.
Pending Reinsurance Transaction
In May 2023, the Company entered into a definitive agreement with a subsidiary of Global Atlantic Financial Group, a retirement and life insurance company, to reinsure an in-force block of universal life, variable universal life, universal life with secondary guarantees, and fixed annuities, which are reported in the MetLife Holdings segment. At the closing of the transaction, the Company will enter into a reinsurance agreement on a coinsurance basis for the general account products, and on a modified coinsurance basis for the separate account products, representing total liabilities of approximately $13.0 billion. Under the terms of such agreement, assets primarily consisting of fixed maturity securities available-for-sale and mortgage loans supporting the general account liabilities will be transferred to the reinsurer at closing, reduced by an approximately $1.8 billion pre-tax ceding commission. The Company will retain separate account assets of approximately $4.8 billion under the modified coinsurance arrangement.
The transaction is expected to close in the second half of 2023 and is subject to regulatory approvals and satisfaction of other closing conditions. See Note 9 for additional information on assets to be transferred to the reinsurer at closing, including associated impairments recorded to net investment gains (losses).
Summary of Significant Accounting Policies
The following table presents the Company’s significant accounting policies which have changed as a result of the adoption of LDTI with cross-references to the notes which provide additional information on such policies.
Accounting PolicyNote
Future Policy Benefit Liabilities3
Policyholder Account Balances4
Market Risk Benefits5
Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue7
Derivatives10
Future Policy Benefit Liabilities
Traditional Non-participating and Limited-payment Long-duration products
The Company establishes future policy benefit liabilities (“FPBs”) for amounts payable under traditional non-participating and limited-payment long-duration insurance and reinsurance policies which include, but are not limited to, pension risk transfers, structured settlements, institutional income annuities and long-term care products. Generally, amounts are payable over an extended period of time and the related liabilities are calculated as the present value of future expected benefits and claim settlement expenses to be paid, reduced by the present value of future expected net premiums.
FPBs are measured as cohorts (e.g., groups of long-duration contracts), with the exception of pension risk transfers and longevity reinsurance solutions contracts, each of which are generally considered their own cohort. Contracts from different subsidiaries or branches, issue years, benefit currency and product types are not grouped together in the same cohort.
Such liabilities are established based on methods and underlying assumptions in accordance with GAAP and applicable actuarial standards. A net premium ratio (“NPR”) approach is utilized, where net premiums (i.e., the portion of gross premiums required to fund expected insurance benefits and claim settlement expenses) under the contract are accrued each period as an FPB. The NPR used to accrue the FPB in each period is determined by using the historical and present value of expected future benefits and claim settlement expenses for the cohort divided by the historical and present value of expected future gross premiums for the cohort.
9

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Cash flow assumptions are incorporated into the calculation of a cohort's NPR and FPB reserve. These assumptions are used to project the amount and timing of expected benefits and claim settlement expenses to be paid and the expected amount of premiums to be collected for a cohort. The principal inputs and assumptions used in the establishment of FPBs are actual premiums, actual benefits, in-force policies, and best estimate cash flow assumptions to project future premium and benefit amounts. The Company’s primary best estimate cash flow assumptions include expectations related to mortality, morbidity, termination, claim settlement expense, policy lapse, renewal, retirement, disability incidence, disability terminations, inflation and other contingent events as appropriate to the respective product type and geographical area. Upon transition to LDTI, generally, the NPR and FPB reserve are updated retrospectively on a quarterly basis for actual experience and at least once a year for any changes in future cash flow assumptions, except for claim settlement expenses, for which the Company has elected to lock in assumptions at the Transition Date or inception (for contracts sold after the Transition Date), as allowed by LDTI. The resulting remeasurement (gain) loss is recorded through net income and reflects the impact on the change in the NPR based on experience at end of the quarter applied to the cumulative premiums received from the inception of the cohort (or from the Transition Date for contracts issued prior to the Transition Date) to the beginning of the quarter. The total contractual profit pattern is recognized over the expected life of the cohort by retrospectively updating the NPR. If net premiums exceed gross premiums (i.e., expected benefits exceed expected gross premiums), the FPB is increased, and a corresponding adjustment is recognized immediately in net income.
The change in FPB reflected in the statement of operations is calculated using a locked-in discount rate. For products issued prior to the Transition Date, a cohort level locked-in discount rate was developed that reflects the interest accretion rates that were locked in at inception of the underlying contracts (unless there was a historical premium deficiency event that resulted in updating the interest accretion rate prior to the Transition Date), or the acquisition date for contracts acquired through an assumed in-force reinsurance transaction or a business combination. For contracts issued subsequent to the Transition Date, the upper-medium grade discount rate used for interest accretion is locked in for the cohort and represents the original upper-medium grade discount rate at the issue date of the underlying contracts. The FPB for all cohorts is remeasured to a current upper-medium grade discount rate at each reporting date through other comprehensive income (loss) (“OCI”).
The Company generally interprets the upper-medium grade discount rate to be a rate comparable to that of a U.S. corporate single A rate that reflects the duration characteristics of the liability. The upper-medium grade discount rate for the products that are included in the disaggregated rollforwards in Note 3 which are issued in the U.S. is determined by using observable market data, including published single A base curves. The last liquid point on the upper-medium grade discount curve grades to an ultimate forward rate, which is derived using assumptions of economic growth, inflation, and a long-term upper-medium grade spread.
For limited-payment long-duration contracts, the collection of premiums does not represent the completion of the earnings process, therefore, any gross premiums received in excess of net premiums is deferred and amortized as a deferred profit liability (“DPL”). The DPL is presented within FPBs and is amortized in proportion to either the present value of expected benefit payments or insurance in-force of each cohort to ensure that profits are recognized over the life of the underlying policies in that cohort, regardless of when premiums are received. This amortization of the DPL is recorded through net income within policyholder benefits and claims. Consistent with the Company’s measurement of traditional long-duration products, management also recognizes a FPB reserve for limited-payment contracts that is representative of the difference between the present value of expected future benefit payments and the present value of expected future net premiums, subject to retrospective remeasurement through net income and OCI, as described above. The DPL is also subject to retrospective remeasurement through net income, however, it is not remeasured for changes in discount rates.
10

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Traditional participating products
The Company establishes FPBs for traditional participating contracts in the U.S., which include whole and term life participating contracts in both the open and closed block using a net premium approach, similar to traditional non-participating contracts. However, for participating contracts, the discount rate and actuarial assumptions are locked in at inception, include a provision for adverse deviation, and all changes in the associated FPBs are reported within policyholder benefits and claims. See Note 8 for additional information on the closed block. For traditional participating contracts, the Company reviews its estimates of actuarial liabilities for future benefits and compares them with current best estimate assumptions. The Company revises estimates, to increase FPBs, if the Company determines that the liabilities previously established for future benefit payments less future expected net premiums in the aggregate for this line of business prove inadequate.
Additional Insurance Liabilities
Liabilities for universal, variable universal, and variable life policies with secondary guarantees (“ULSG”) and paid-up guarantees are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the life of the contract based on total expected assessments. The additional insurance liabilities are updated retrospectively on a quarterly basis for actual experience and at least once a year for any changes in future cash flow assumptions. The assumptions used in estimating the secondary and paid-up guarantee liabilities are investment income, mortality, lapse, and premium payment pattern and persistency. The assumptions of investment performance and volatility for variable products are consistent with historical experience of appropriate underlying equity indices, such as the S&P Global Ratings (“S&P”) 500 Index. The benefits used in calculating the liabilities are based on the average benefits payable over a range of scenarios.
The resulting remeasurement (gain) loss recorded through net income reflects the impact on the change in the ratio of benefits payable to total assessments over the life of the contract based on experience at end of the quarter applied to the cumulative assessments received as of the beginning of the quarter.
Premium Deficiency Reserves on Short-Duration Contracts
Premium deficiency reserves may be established for short-duration contracts to provide for expected future losses and certain expenses that exceed unearned premiums. These reserves are based on actuarial estimates of the amount of loss inherent in that period, including losses incurred for which claims have not been reported. The provisions for unreported claims are calculated using studies that measure the historical length of time between the incurred date of a claim and its eventual reporting to the Company. Anticipated investment income is considered in the calculation of premium deficiency losses for short-duration contracts.
Policyholder Account Balances
Policyholder account balances (“PABs”) represents the amount held by the Company on behalf of the policyholder at each reporting date. This amount includes deposits received from the policyholder, interest credited to the policyholder’s account balance, net of charges assessed against the account balance and any policyholder withdrawals. This balance also includes liabilities for structured settlement and institutional income annuities, and certain other contracts, that do not contain significant insurance risk, as well as the estimated fair value of embedded derivatives associated with indexed annuity products.
Market Risk Benefits
As defined by LDTI, market risk benefits (“MRBs”) are contracts or contract features that guarantee benefits, such as guaranteed minimum benefits, in addition to an account balance, which expose insurance companies to other than nominal capital market risk (equity price, interest rate, and/or foreign currency exchange risk) and subsequently protect the contractholder from the same risk. These contracts and contract features were generally recorded as embedded derivatives or additional insurance liabilities prior to the Transition Date. Certain contracts may have multiple contract features or guarantees. In these cases, each feature is separately evaluated to determine whether it meets the definition of an MRB at contract inception. If a contract includes multiple benefits that meet the definition of an MRB, those benefits are aggregated and measured as a single compound MRB.
11

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
All identified MRBs are required to be measured at estimated fair value, whether the contract or contract feature represents a direct, assumed or ceded capital market risk. All MRBs in an asset position are aggregated and presented as an asset, and all MRBs in a liability position are aggregated and presented as a liability. Changes in the estimated fair value of MRBs are recognized in net income, except for the portion of the fair value change attributable to the change in nonperformance risk of the Company which is recorded as a separate component of OCI.
The Company generally uses an attributed fee approach to value MRBs, where the attributed fee is determined at contract inception by estimating the fair value of expected future benefits and the expected future fees. The attributed fee percentage is the portion of the expected future fees due from contractholders deemed necessary at contract inception to fund all future expected benefits. This typically results in a zero fair value for the MRB at inception. The estimated fair value of the expected future benefits is estimated using a stochastically-generated set of risk-neutral scenarios. Once calculated, the attributed fee percentage is fixed and does not change over the life of the contract. All fees due from contractholders in excess of the attributed fees are reported in universal life and investment-type product policy fees.
Other Policy-Related Balances
Other policy-related balances include policy and contract claims, premiums received in advance, unearned revenue (“UREV”) liabilities, obligations assumed under structured settlement assignments, policyholder dividends due and unpaid and policyholder dividends left on deposit.
The liability for policy and contract claims generally relates to incurred but not reported (“IBNR”) death and dental claims. In addition, generally included in other policy-related balances are claims which have been reported but not yet settled for death and dental. The liability for these claims is based on the Company’s estimated ultimate cost of settling all claims. The Company derives estimates for the development of IBNR claims principally from analyses of historical patterns of claims by business line. The methods used to determine these estimates are continually reviewed. Adjustments resulting from this continuous review process and differences between estimates and payments for claims are recognized in policyholder benefits and claims expense in the period in which the estimates are changed or payments are made.
The Company accounts for the prepayment of premiums on its individual life, group life and health contracts as premiums received in advance. These amounts are then recognized in premiums when due.
The UREV liability relates to universal life and investment-type products and represents policy charges for services to be provided in future periods. The charges are deferred as unearned revenue and amortized on a basis consistent with the methodologies and assumptions used for amortizing deferred policy acquisition costs (“DAC”) for the related contracts. Changes in the UREV liability for each period (representing deferrals less amortization) are reported in universal life and investment-type product policy fees.
Recognition of Insurance Revenues and Deposits
Premiums related to whole and term life products, individual disability, individual and group fixed annuities (including pension risk transfers, certain structured settlements and certain income annuities), long-term care and participating products are recognized as revenues when due from policyholders. Policyholder benefits and expenses are provided to recognize profits over the estimated lives of the insurance policies. When premiums are due over a significantly shorter period than the period over which benefits are provided, any excess profit is deferred as a DPL and recognized into earnings in a constant relationship to insurance in-force or, for annuities, the present value of expected future policy benefit payments.
Premiums related to short-duration non-medical health and disability contracts are recognized on a pro rata basis over the applicable contract term. Unearned premiums, representing the portion of premium written related to the unexpired coverage, are reflected as liabilities until earned.
Deposits related to universal life and investment-type products are credited to PABs. Revenues from such contracts consist of fees for mortality, policy administration and surrender charges and are recorded in universal life and investment-type product policy fees in the period in which services are provided. All fees due from contractholders in excess of the attributed fees on contracts with MRBs are reported in universal life and investment-type product policy fees. Amounts that are charged to earnings include interest credited and benefit claims incurred in excess of related PABs.
All revenues and expenses are presented net of reinsurance, as applicable.
12

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles
The Company incurs significant costs in connection with acquiring new and renewal insurance business. Costs that are related directly to the successful acquisition or renewal of insurance contracts are capitalized as DAC. Such costs include:
incremental direct costs of contract acquisition, such as commissions;
the portion of an employee’s total compensation and benefits related to time spent selling, underwriting or processing the issuance of new and renewal insurance business only with respect to actual policies acquired or renewed; and
other essential direct costs that would not have been incurred had a policy not been acquired or renewed.
All other acquisition-related costs, including those related to general advertising and solicitation, market research, agent training, product development, unsuccessful sales and underwriting efforts, as well as all indirect costs, are expensed as incurred.
Value of business acquired (“VOBA”) is an intangible asset resulting from a business combination that represents the excess of book value over the estimated fair value of acquired insurance, annuity, and investment-type contracts in-force at the acquisition date. The estimated fair value of the acquired liabilities is based on projections, by each block of business, of future policy and contract charges, premiums, mortality and morbidity, separate account performance, surrenders, operating expenses, investment returns, nonperformance risk adjustment and other factors. Actual experience with the purchased business may vary from these projections. VOBA is subject to periodic recoverability testing for traditional life and limited-payment contracts, as well as universal life type contracts.
Beginning on the Transition Date, DAC and VOBA for most long-duration products are amortized on a constant-level basis that approximates straight-line amortization on an individual contract basis. The DAC and VOBA related to U.S. annuities are amortized over expected benefit payments, and for all other long-duration products are generally amortized in proportion to policy count. For short-duration products, DAC and VOBA are amortized in proportion to actual and expected future earned premiums.
DAC and VOBA are aggregated on the financial statements for reporting purposes. See Note 7 for additional information on DAC and VOBA amortization. Amortization of DAC and VOBA is included in other expenses.
The Company generally has two different types of sales inducements which are included in other assets: (i) the policyholder receives a bonus whereby the policyholder’s initial account balance is increased by an amount equal to a specified percentage of the customer’s deposit; and (ii) the policyholder receives a higher interest rate using a dollar cost averaging method than would have been received based on the normal general account interest rate credited. The Company defers sales inducements and amortizes them over the life of the policy using the same methodologies and assumptions used to amortize DAC for the related contracts. The amortization of sales inducements is included in policyholder benefits and claims. Each year, or more frequently if circumstances indicate a potential recoverability issue exists, the Company reviews deferred sales inducements (“DSI”) to determine the recoverability of the asset. DSI assets were $48$47 million and $49 million at March 31,June 30, 2023 and December 31, 2022, respectively.
Value of distribution agreements acquired (“VODA”) is reported in other assets and represents the present value of expected future profits associated with the expected future business derived from the distribution agreements acquired as part of a business combination. Value of customer relationships acquired (“VOCRA”) is also reported in other assets and represents the present value of the expected future profits associated with the expected future business acquired through existing customers of the acquired company or business. The VODA and VOCRA associated with past business combinations are amortized over the assets’ useful lives ranging from 10 to 30 years and such amortization is included in other expenses. Each year, or more frequently if circumstances indicate a possible impairment exists, the Company reviews VODA and VOCRA to determine whether the asset is impaired.
13

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Reinsurance
For each of its reinsurance agreements, the Company determines whether the agreement provides indemnification against loss or liability relating to insurance risk in accordance with applicable accounting standards. Cessions under reinsurance agreements do not discharge the Company’s obligations as the primary insurer. The Company reviews all contractual features, including those that may limit the amount of insurance risk to which the reinsurer is subject or features that delay the timely reimbursement of claims.
The reinsurance recoverable for traditional non-participating and limited-payment contracts is generally measured using a net premium methodology to accrue the projected net gain or loss on reinsurance in proportion to the gross premiums of the underlying reinsured cohorts; and is updated retrospectively on a quarterly basis for actual experience and at least once a year for any changes in cash flow assumptions. The locked-in discount rate used to measure changes in the reinsurance recoverable recorded in net income was established at the Transition Date, or at the inception of the reinsurance coverage for new reinsurance agreements entered into subsequent to the Transition Date. The reinsurance recoverable is remeasured to an upper-medium grade discount rate through OCI at each reporting date, similar to the underlying reinsured contracts. The reinsurance recoverable for other long-duration contracts and associated contract features is measured using assumptions and methods generally consistent with the underlying direct policies.
For reinsurance of existing in-force blocks of long-duration contracts that transfer significant insurance risk, the difference, if any, between the amounts paid (received), and the liabilities ceded (assumed) related to the underlying reinsured contracts is considered the net cost of reinsurance at the inception of the reinsurance agreement. The net cost of reinsurance is amortized on a basis consistent with the methodologies and assumptions used for amortizing DAC related to the underlying reinsured contracts. Subsequent amounts paid (received) on the reinsurance of in-force blocks, as well as amounts paid (received) related to new business, are recorded as ceded (assumed) premiums; and ceded (assumed) premiums, reinsurance and other receivables (future policy benefits) are established.
For prospective reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) are recorded as ceded (assumed) premiums and ceded (assumed) unearned premiums. Ceded (assumed) unearned premiums are reflected as a component of premiums, reinsurance and other receivables (future policy benefits). Such amounts are amortized through earned premiums over the remaining contract period in proportion to the amount of insurance protection provided. For retroactive reinsurance of short-duration contracts that meet the criteria for reinsurance accounting, amounts paid (received) in excess of the related insurance liabilities ceded (assumed) are recognized immediately as a loss and are reported in the appropriate line item within the statement of operations. Any gain on such retroactive agreement is deferred and is amortized as part of DAC, primarily using the recovery method.
Amounts currently recoverable under reinsurance agreements are included in premiums, reinsurance and other receivables and amounts currently payable are included in other liabilities. Assets and liabilities relating to reinsurance agreements with the same reinsurer may be recorded net on the balance sheet, if a right of offset exists within the reinsurance agreement. In the event that reinsurers do not meet their obligations to the Company under the terms of the reinsurance agreements, or when events or changes in circumstances indicate that its carrying amount may not be recoverable, reinsurance recoverable balances could become uncollectible. In such instances, reinsurance recoverable balances are stated net of allowances for uncollectible reinsurance, consistent with credit loss guidance which requires recording an allowance for credit loss (“ACL”).
The funds withheld liability represents amounts withheld by the Company in accordance with the terms of the reinsurance agreements. The Company withholds the funds rather than transferring the underlying investments and, as a result, records funds withheld liability within other liabilities. The Company recognizes interest on funds withheld, included in other expenses, at rates defined by the terms of the agreement which may be contractually specified or directly related to the investment portfolio. See Note 1 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report for information on funds withheld assets.
Premiums, fees and policyholder benefits and claims include amounts assumed under reinsurance agreements and are net of reinsurance ceded. Amounts received from reinsurers for policy administration are reported in other expenses.
14

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
If the Company determines that a reinsurance agreement does not expose the reinsurer to a reasonable possibility of a significant loss from insurance risk, the Company records the agreement using the deposit method of accounting. Deposits received are included in other liabilities and deposits made are included within premiums, reinsurance and other receivables. As amounts are paid or received, consistent with the underlying contracts, the deposit assets or liabilities are adjusted. Interest on such deposits is recorded as other revenues or other expenses, as appropriate. Periodically, the Company evaluates the adequacy of the expected payments or recoveries and adjusts the deposit asset or liability through other revenues or other expenses, as appropriate.
Derivatives
Freestanding Derivatives
Freestanding derivatives are carried on the Company’s balance sheet either as assets within other invested assets or as liabilities within other liabilities at estimated fair value. The Company does not offset the estimated fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement.
Accruals on derivatives are generally recorded in accrued investment income or within other liabilities. However, accruals that are not scheduled to settle within one year are included with the derivative’s carrying value in other invested assets or other liabilities.
If a derivative is not designated as an accounting hedge or its use in managing risk does not qualify for hedge accounting, changes in the estimated fair value of the derivative are reported in net derivative gains (losses) except as follows:
Statement of Operations Presentation:Derivative:
Net investment incomeEconomic hedges of equity method investments in joint ventures
Economic hedges of fair value option securities (“FVO Securities”) which are linked to equity indices
Hedge Accounting
To qualify for hedge accounting, at the inception of the hedging relationship, the Company formally documents its risk management objective and strategy for undertaking the hedging transaction, as well as its designation of the hedge. Hedge designation and financial statement presentation of changes in estimated fair value of the hedging derivatives are as follows:
Fair value hedge - a hedge of the estimated fair value of a recognized asset or liability - in the same line item as the earnings effect of the hedged item. The carrying value of the hedged recognized asset or liability is adjusted for changes in its estimated fair value due to the hedged risk.
Cash flow hedge - a hedge of a forecasted transaction or of the variability of cash flows to be received or paid related to a recognized asset or liability - in OCI and reclassified into the statement of operations when the Company’s earnings are affected by the variability in cash flows of the hedged item.
The changes in estimated fair values of the hedging derivatives are exclusive of any accruals that are separately reported on the statement of operations within interest income or interest expense to match the location of the hedged item.
In its hedge documentation, the Company sets forth how the hedging instrument is expected to hedge the designated risks related to the hedged item and sets forth the method that will be used to retrospectively and prospectively assess the hedging instrument’s effectiveness. A derivative designated as a hedging instrument must be assessed as being highly effective in offsetting the designated risk of the hedged item. Hedge effectiveness is formally assessed at inception and at least quarterly throughout the life of the designated hedging relationship. Assessments of hedge effectiveness are also subject to interpretation and estimation and different interpretations or estimates may have a material effect on the amount reported in net income.
15

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
The Company discontinues hedge accounting prospectively when: (i) it is determined that the derivative is no longer highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item; (ii) the derivative expires, is sold, terminated, or exercised; (iii) it is no longer probable that the hedged forecasted transaction will occur; or (iv) the derivative is de-designated as a hedging instrument.
When hedge accounting is discontinued because it is determined that the derivative is not highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized in net derivative gains (losses). The carrying value of the hedged recognized asset or liability under a fair value hedge is no longer adjusted for changes in its estimated fair value due to the hedged risk, and the cumulative adjustment to its carrying value is amortized into income over the remaining life of the hedged item. The changes in estimated fair value of derivatives related to discontinued cash flow hedges remain in OCI unless it is probable that the hedged forecasted transaction will not occur.
When hedge accounting is discontinued because it is no longer probable that the forecasted transactions will occur on the anticipated date or within two months of that date, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized currently in net derivative gains (losses). Deferred gains and losses of a derivative recorded in OCI pursuant to the discontinued cash flow hedge of a forecasted transaction that is no longer probable of occurring are recognized immediately in net investment gains (losses).
In all other situations in which hedge accounting is discontinued, the derivative is carried at its estimated fair value on the balance sheet, with changes in its estimated fair value recognized in the current period as net derivative gains (losses).
Embedded Derivatives
As discussed above, certain guarantees previously accounted for as embedded derivatives are accounted for as MRBs upon adoption of LDTI. The Company issues certain products and investment contracts and is a party to certain reinsurance agreements that have embedded derivatives. The Company assesses each identified embedded derivative to determine whether it is required to be bifurcated. The embedded derivative is bifurcated from the host contract and accounted for as a freestanding derivative if:
the contract or contract feature does not meet the definition of a MRB (as a result of the adoption of LDTI);
the combined instrument is not accounted for in its entirety at estimated fair value with changes in estimated fair value recorded in earnings;
the terms of the embedded derivative are not clearly and closely related to the economic characteristics of the host contract; and
a separate instrument with the same terms as the embedded derivative would qualify as a derivative instrument.
Such embedded derivatives are carried on the balance sheet at estimated fair value with the host contract and changes in their estimated fair value are generally reported in net derivative gains (losses). If the Company is unable to properly identify and measure an embedded derivative for separation from its host contract, the entire contract is carried on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income. Additionally, the Company may elect to carry an entire contract on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income if that contract contains an embedded derivative that requires bifurcation.
Recent Accounting Pronouncements
Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of ASUs to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s interim condensed consolidated financial statements.
16

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Adoption of ASU 2018-12 - Targeted Improvements to the Accounting for Long-Duration Contracts
The Company adopted LDTI effective January 1, 2023 with a Transition Date of January 1, 2021. The standard required a full retrospective transition approach for MRBs, and allowed for a transition method election for FPBs and DAC, as well as other balances that have historically been amortized in a manner consistent with DAC. The Company has elected the modified retrospective transition approach for all FPBs, DAC, and related balances on all long-duration contracts, subject to the transition provisions. Additionally, an amendment in LDTI allowed entities to make an accounting policy election to exclude certain sold or disposed contracts or legal entities from application of the transition guidance. The Company did not make such an election.
Under the modified retrospective approach, the Company was required to establish LDTI-compliant FPBs, DAC and related balances for the Company’s Transition Date opening balance sheet by utilizing the Company’s December 31, 2020 balances with certain adjustments as described below.
17

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
The following table presents a summary of the Transition Date impacts associated with the implementation of LDTI to the consolidated balance sheet:
Premiums, Reinsurance and Other ReceivablesDeferred Policy Acquisition Costs and Value of Business AcquiredDeferred Tax AssetOther
Assets
Future Policy BenefitsPolicyholder Account BalancesMarket Risk Benefit LiabilitiesDeferred Income Tax LiabilityRetained EarningsAccumulated Other Comprehensive Income (Loss)
(In millions)
Balances as reported, December 31, 2020$21,478 $2,649 $— $4,158 $133,921 $96,635 $— $1,980 $10,548 $11,662 
Reclassification of carrying amount of contracts and contract features that are market risk benefits(59)— — — (1,447)(495)1,883 — — — 
Adjustments for the difference between previous carrying amount and fair value measurement for market risk benefits— — — — — — 4,906 (1,030)(3,897)21 
Removal of related amounts in accumulated other comprehensive income— 1,482 — 29 (6,835)— — 1,751 — 6,595 
Adjustment of future policy benefits to remeasure cohorts where net premiums exceed gross premiums under the modified retrospective approach32 — — — 89 — — (12)(45)— 
Effect of remeasurement of future policy benefits to an upper-medium grade discount rate403 — — — 25,208 — — (5,209)— (19,596)
Adjustments for the cumulative effect of adoption on additional insurance assets and liabilities29 — — — 36 — — — (7)
Other balance sheet reclassifications and adjustments upon adoption of the LDTI standard12 2,518 — (4,794)4,794 — 2,520 10 — 
Balances as adjusted, January 1, 2021$21,885 $4,143 $2,518 $4,187 $146,178 $100,934 $6,789 $— $6,616 $(1,325)

18

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
The Transition Date impacts associated with the implementation of LDTI were applied as follows:
Market Risk Benefits (See Note 5)
The full retrospective transition approach for MRBs required assessing products to determine whether contract or contract features expose the Company to other than nominal capital market risk. The population of MRBs identified was then reviewed to determine the historical measurement model prior to adoption of LDTI. If the MRB was a bifurcated embedded derivative prior to the adoption of LDTI, the existing measurement approach was retained, except that the fair value of the MRB at inception was recalculated to isolate the contract issue date nonperformance risk of the Company.
If, prior to the adoption of LDTI, the MRB was partially a bifurcated embedded derivative (e.g., a contract with multiple features where one was a bifurcated embedded derivative and one was an additional insurance liability), or was accounted for under a different model, the at-inception attributed fee ratio was calculated for every identified MRB, and using the at inception attributed fee ratio, the fair value of the MRB at the contract issue date was calculated to isolate the contract issue date nonperformance risk of the Company.
At the Transition Date, the impacts to the financial statements of the full retrospective approach for MRBs include the following:
The amounts previously recorded for these contracts within additional insurance liabilities, embedded derivatives, and other insurance liabilities were reclassified to MRB liabilities;
The difference between the fair value of the MRBs and the previously recorded carrying value at the Transition Date, excluding the cumulative effect of changes in nonperformance risk of the Company, was recorded as an adjustment to the opening balance of retained earnings; and
The cumulative effect of changes in nonperformance risk between the contract issue date and the Transition Date was recorded as an adjustment to opening accumulated OCI (“AOCI”) as of the Transition Date.
Future Policy Benefits (See Note 3)
Traditional Non-participating Long-duration products
Loss recognition balances related to unrealized investment gains associated with certain long-duration products previously recorded in AOCI were removed;
Contracts in-force as of the Transition Date were grouped into cohorts; a revised NPR was calculated for each cohort using the existing Transition Date balance, best estimate cash flow assumptions without a provision for adverse deviation, and the historical discount rates used for the contracts within the cohort prior to the adoption of LDTI (the “locked-in” discount rate). For any cohorts where the net premiums exceeded gross premiums (NPR exceeded 100%), the FPB was increased for the excess of net premiums over gross premiums, with a corresponding adjustment recorded to opening retained earnings as of the Transition Date;
The difference between the FPB balance calculated at the current upper-medium grade discount rate and the FPB balance calculated at the locked-in discount rate was recorded as an adjustment to opening AOCI as of the Transition Date; and
Corresponding adjustments were made to ceded reinsurance balances.
Limited-payment Long-duration products
Limited-payment long-duration products transition to LDTI follows a similar approach to traditional non-participating products, except that these product cohorts may have a DPL which is adjusted at the Transition Date. If an increase to FPB depleted the DPL, the remaining adjustment was recorded to opening retained earnings as of the Transition Date.
Additional insurance liabilities
The contracts and contract features that met the definition of a MRB were reclassified;
19

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
The impact of updating assessments used in the calculation of the additional insurance liabilities to reflect the constant margin amortization basis for UREV liabilities was recorded as an adjustment to opening retained earnings and AOCI; and
Corresponding adjustments were made to ceded reinsurance balances.
DAC and other balances to be amortized in a manner consistent with DAC (VOBA, DSI and UREV) (See Note 7 for information on DAC, VOBA and UREV)
The opening balances of these accounts were adjusted for removal of the related amounts in AOCI, as these balances are no longer amortized using expected future gross premiums, margins, profits or earned premiums.
Other balance sheet reclassifications and adjustments at LDTI adoption (See Notes 3, 4 and 7)
Individual income annuities reclassification
Prior to the Transition Date, the Company classified all structured settlement and institutional income annuity products within FPBs. While the pre-LDTI GAAP reserving model was the same for these products, upon transition to LDTI, the reserving model for a subset of these products changed, requiring the Company to reclassify $4.7 billion of FPBs to PABs at the Transition Date.
Other reclassifications and adjustments
Other minor reclassifications and adjustments were made to conform to LDTI presentation requirements.
The following table presents the effects of the retrospective application of the adoption of the new LDTI accounting guidance to the Company’s previously reported consolidated balance sheet:
December 31, 2022
As Previously ReportedAdoption
Adjustment
Post
Adoption
(In millions)
Assets
Premiums, reinsurance and other receivables$20,704 $87 $20,791 
Market risk benefits$— $174 $174 
Deferred policy acquisition costs and value of business acquired$5,263 $(1,506)$3,757 
Deferred income tax asset$2,661 $259 $2,920 
Other assets$4,367 $(15)$4,352 
Total assets$385,840 $(1,001)$384,839 
Liabilities
Future policy benefits$133,725 $(6,811)$126,914 
Policyholder account balances$99,967 $3,440 $103,407 
Market risk benefits$— $3,270 $3,270 
Other policy-related balances$7,863 $68 $7,931 
Other liabilities$24,489 $$24,495 
Total liabilities$371,471 $(27)$371,444 
Equity
Retained earnings$10,572 $(1,550)$9,022 
Accumulated other comprehensive income (loss)$(8,896)$576 $(8,320)
Total Metropolitan Life Insurance Company stockholder’s equity$14,157 $(974)$13,183 
Total equity$14,369 $(974)$13,395 
Total liabilities and equity$385,840 $(1,001)$384,839 
20

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
The following table presents the effects of the retrospective application of the adoption of the new LDTI accounting guidance to the Company’s previously reported interim condensed consolidated statement of operations and comprehensive income (loss):
Three Months Ended March 31, 2022Three Months Ended June 30, 2022Six Months Ended June 30, 2022
As Previously ReportedAdoption
Adjustment
Post
Adoption
As Previously ReportedAdoption
Adjustment
Post
Adoption
As Previously ReportedAdoption
Adjustment
Post
Adoption
(In millions)(In millions)
RevenuesRevenuesRevenues
PremiumsPremiums$5,910 $(4)$5,906 Premiums$5,668 $(4)$5,664 $11,578 $(8)$11,570 
Universal life and investment-type product policy feesUniversal life and investment-type product policy fees$524 $(45)$479 Universal life and investment-type product policy fees$515 $(48)$467 $1,039 $(93)$946 
Other revenuesOther revenues$412 $(1)$411 Other revenues$373 $(1)$372 $785 $(2)$783 
Net investment gains (losses)$(226)$— $(226)
Net derivative gains (losses)Net derivative gains (losses)$181 $(60)$121 Net derivative gains (losses)$345 $241 $586 $526 $181 $707 
Total revenuesTotal revenues$9,627 $(110)$9,517 Total revenues$9,260 $188 $9,448 $18,887 $78 $18,965 
ExpensesExpensesExpenses
Policyholder benefits and claimsPolicyholder benefits and claims$6,561 $90 $6,651 Policyholder benefits and claims$5,936 $74 $6,010 $12,497 $164 $12,661 
Policyholder liability remeasurement (gains) lossesPolicyholder liability remeasurement (gains) losses$— $(29)$(29)Policyholder liability remeasurement (gains) losses$— $(12)$(12)$— $(41)$(41)
Market risk benefits remeasurement (gains) lossesMarket risk benefits remeasurement (gains) losses$— $(1,361)$(1,361)Market risk benefits remeasurement (gains) losses$— $(730)$(730)$— $(2,091)$(2,091)
Interest credited to policyholder account balancesInterest credited to policyholder account balances$491 $11 $502 Interest credited to policyholder account balances$530 $35 $565 $1,021 $46 $1,067 
Policyholder dividendsPolicyholder dividends$159 $$161 Policyholder dividends$154 $(1)$153 $313 $$314 
Other expensesOther expenses$1,299 $$1,308 Other expenses$1,419 $(26)$1,393 $2,718 $(17)$2,701 
Total expensesTotal expenses$8,510 $(1,278)$7,232 Total expenses$8,039 $(660)$7,379 $16,549 $(1,938)$14,611 
Income (loss) from before provisions for income taxes$1,117 $1,168 $2,285 
Income (loss) before provision for income taxIncome (loss) before provision for income tax$1,221 $848 $2,069 $2,338 $2,016 $4,354 
Provision for income tax expense (benefit)Provision for income tax expense (benefit)$158 $245 $403 Provision for income tax expense (benefit)$207 $178 $385 $365 $423 $788 
Net income (loss)Net income (loss)$959 $923 $1,882 Net income (loss)$1,014 $670 $1,684 $1,973 $1,593 $3,566 
Net income (loss) attributable to Metropolitan Life Insurance CompanyNet income (loss) attributable to Metropolitan Life Insurance Company$959 $923 $1,882 Net income (loss) attributable to Metropolitan Life Insurance Company$1,012 $670 $1,682 $1,971 $1,593 $3,564 
Comprehensive income (loss)Comprehensive income (loss)$(4,278)$4,111 $(167)Comprehensive income (loss)$(7,443)$6,362 $(1,081)$(11,721)$10,473 $(1,248)
Comprehensive income (loss) attributable to Metropolitan Life Insurance CompanyComprehensive income (loss) attributable to Metropolitan Life Insurance Company$(4,278)$4,111 $(167)Comprehensive income (loss) attributable to Metropolitan Life Insurance Company$(7,445)$6,362 $(1,083)$(11,723)$10,473 $(1,250)
21

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
The following table presents the effects of the retrospective application of the adoption of the new LDTI accounting guidance to the Company’s previously reported interim condensed consolidated statements of equity:
As Previously ReportedAdoption
Adjustment
Post
Adoption
As Previously ReportedAdoption
Adjustment
Post
Adoption
(In millions)(In millions)
Retained EarningsRetained EarningsRetained Earnings
Balance at December 31, 2021Balance at December 31, 2021$10,868 $(3,935)$6,933 Balance at December 31, 2021$10,868 $(3,935)$6,933 
Net income (loss)Net income (loss)$959 $923 $1,882 Net income (loss)$959 $923 $1,882 
Balance at March 31, 2022Balance at March 31, 2022$10,946 $(3,012)$7,934 Balance at March 31, 2022$10,946 $(3,012)$7,934 
Net income (loss)Net income (loss)$1,012 $670 $1,682 
Balance at June 30, 2022Balance at June 30, 2022$11,277 $(2,342)$8,935 
Balance at December 31, 2022Balance at December 31, 2022$10,572 $(1,550)$9,022 Balance at December 31, 2022$10,572 $(1,550)$9,022 
Accumulated Other Comprehensive Income (Loss)Accumulated Other Comprehensive Income (Loss)Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2021Balance at December 31, 2021$9,917 $(10,972)$(1,055)Balance at December 31, 2021$9,917 $(10,972)$(1,055)
Other comprehensive income (loss), net of income taxOther comprehensive income (loss), net of income tax$(5,237)$3,188 $(2,049)Other comprehensive income (loss), net of income tax$(5,237)$3,188 $(2,049)
Balance at March 31, 2022Balance at March 31, 2022$4,680 $(7,784)$(3,104)Balance at March 31, 2022$4,680 $(7,784)$(3,104)
Other comprehensive income (loss), net of income taxOther comprehensive income (loss), net of income tax$(8,457)$5,692 $(2,765)
Balance at June 30, 2022Balance at June 30, 2022$(3,777)$(2,092)$(5,869)
Balance at December 31, 2022Balance at December 31, 2022$(8,896)$576 $(8,320)Balance at December 31, 2022$(8,896)$576 $(8,320)
Total Metropolitan Life Insurance Company Stockholders’ EquityTotal Metropolitan Life Insurance Company Stockholders’ EquityTotal Metropolitan Life Insurance Company Stockholders’ Equity
Balance at December 31, 2021Balance at December 31, 2021$33,254 $(14,907)$18,347 Balance at December 31, 2021$33,254 $(14,907)$18,347 
Balance at March 31, 2022Balance at March 31, 2022$28,096 $(10,796)$17,300 Balance at March 31, 2022$28,096 $(10,796)$17,300 
Balance at June 30, 2022Balance at June 30, 2022$19,981 $(4,434)$15,547 
Balance at December 31, 2022Balance at December 31, 2022$14,157 $(974)$13,183 Balance at December 31, 2022$14,157 $(974)$13,183 
Total EquityTotal EquityTotal Equity
Balance at December 31, 2021Balance at December 31, 2021$33,428 $(14,907)$18,521 Balance at December 31, 2021$33,428 $(14,907)$18,521 
Balance at March 31, 2022Balance at March 31, 2022$28,250 $(10,796)$17,454 Balance at March 31, 2022$28,250 $(10,796)$17,454 
Balance at June 30, 2022Balance at June 30, 2022$20,135 $(4,434)$15,701 
Balance at December 31, 2022Balance at December 31, 2022$14,369 $(974)$13,395 Balance at December 31, 2022$14,369 $(974)$13,395 
The following table presents the effects of the retrospective application of the adoption of the new LDTI accounting guidance to the Company’s previously reported interim condensed consolidated statement of cash flows:
Three Months Ended March 31, 2022Six Months Ended June 30, 2022
As Previously ReportedAdoption
Adjustment
Post
Adoption
As Previously ReportedAdoption
Adjustment
Post
Adoption
(In millions)(In millions)
Cash flows from operating activitiesCash flows from operating activities
Net cash provided by (used in) operating activitiesNet cash provided by (used in) operating activities$853 $147 $1,000 Net cash provided by (used in) operating activities$1,160 $262 $1,422 
Cash flows from financing activitiesCash flows from financing activitiesCash flows from financing activities
Policyholder account balances - depositsPolicyholder account balances - deposits$22,794 $(21)$22,773 Policyholder account balances - deposits$46,124 $(22)$46,102 
Policyholder account balances - withdrawalsPolicyholder account balances - withdrawals$(20,356)$(126)$(20,482)Policyholder account balances - withdrawals$(44,020)$(240)$(44,260)
Net cash provided by (used in) financing activitiesNet cash provided by (used in) financing activities$702 $(147)$555 Net cash provided by (used in) financing activities$(6,657)$(262)$(6,919)
22

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Other Adopted Accounting Pronouncements
The table below describes the impacts of the other ASUs adopted by the Company.
StandardDescriptionEffective Date and
Method of Adoption
Impact on Financial Statements
ASU 2022-02, Financial Instruments—Credit Losses
(Topic 326): Troubled Debt Restructurings and Vintage Disclosures

The amendments in the new ASU eliminate the accounting guidance for troubled debt restructurings by creditors that have adopted the current expected credit loss guidance while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. In addition, the amendments require that a public business entity disclose current-period gross write-offs by year of origination for financing receivables and net investment in leases.January 1, 2023, the Company adopted, using a prospective approach.The adoption of the new guidance has reduced the complexity involved with evaluating and accounting for certain loan modifications. The Company has included the required disclosures within its interim condensed consolidated financial statements.
ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting; as clarified and amended by ASU 2021-01, Reference Rate Reform (Topic 848): Scope; as amended by ASU 2022-06, Reference Rate Reform (Topic 848)—Deferral of the Sunset Date of Topic 848
The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, with certain exceptions. ASU 2021-01 amends the scope of the recent reference rate reform guidance. New optional expedients allow derivative instruments impacted by changes in the interest rate used for margining, discounting, or contract price alignment to qualify for certain optional relief. The amendments in ASU 2022-06 extend the sunset date of the reference rate reform optional expedients and exceptions to December 31, 2024.Effective for contract modifications made between March 12, 2020 and December 31, 2024.The guidance has reduced the operational and financial impacts of contract modifications that replace a reference rate, such as London Interbank Offered Rate, affected by reference rate reform.

Contract modifications for invested assets and derivative instrumentsto replace reference rates affected by the reform occurred during 2021 and 2022 and have continued into 2023. Based on actions taken to date, the adoption of the guidance has not had a material impact on the Company’s consolidated financial statements. The Company does not expect the adoption of this guidance to have a material ongoing impact on its interim condensed consolidated financial statements.
23

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Future Adoption of Accounting Pronouncements
ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s interim condensed consolidated financial statements or disclosures. ASUs issued but not yet adopted as of March 31,June 30, 2023 that are currently being assessed and may or may not have a material impact on the Company’s interim condensed consolidated financial statements or disclosures are summarized in the table below.
StandardDescriptionEffective Date and
Method of Adoption
Impact on Financial Statements
ASU 2023-02, Investments—Equity Method and Joint Ventures
(Topic 323): Accounting for Investments in Tax Credit Structures Using the Proportional Amortization Method

The amendments in this update permit reporting entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. In addition, disclosures describing the nature of the investments and related income tax credits and benefits will be required.January 1, 2024, to be applied on either a modified retrospective or a retrospective basis subject to certain exceptions (with early adoption permitted).The Company is currently evaluating the impact of the guidance on its interim condensed consolidated financial statements.
ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to
Contractual Sale Restrictions
The amendments in this update clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. In addition, the amendments clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments also require entities that hold equity securities subject to contractual sale restrictions to make disclosures about the fair value of such equity securities, the nature and remaining duration of the restriction(s) and the circumstances that could cause a lapse in the restriction(s).January 1, 2024, to be applied prospectively with any adjustments from the adoption of the amendments
recognized in earnings and disclosed on the date of adoption (with early adoption permitted).
The Company is continuing to evaluate the impact of the guidance, and it does not expect the adoption of the guidance to have a material impact on its interim condensed consolidated financial statements.

24

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information
The Company is organized into two segments: U.S. and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other.
U.S.
The U.S. segment offers a broad range of protection products and services aimed at serving the financial needs of customers throughout their lives. These products are sold to corporations and their respective employees, other institutions and their respective members, as well as individuals. The U.S. segment is organized into two businesses: Group Benefits and Retirement and Income Solutions (“RIS”).
The Group Benefits business offers products such as term, variable and universal life insurance, dental, group and individual disability and accident & health insurance.
The RIS business offers a broad range of life and annuity-based insurance and investment products, including stable value and pension risk transfer products, institutional income annuities, structured settlements, benefit funding solutions and capital markets investment products.
MetLife Holdings
The MetLife Holdings segment consists of operations relating to products and businesses that the Company no longer actively markets. These include variable, universal, term and whole life insurance, variable, fixed and index-linked annuities and long-term care insurance.
Corporate & Other
Corporate & Other contains various start-up, developing and run-off businesses, including the Company’s ancillary non-U.S. operations. Also included in Corporate & Other are: the excess capital, as well as certain charges and activities, not allocated to the segments (including enterprise-wide strategic initiatives), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, and the elimination of intersegment amounts (which generally relate to affiliated reinsurance and intersegment loans, bearing interest rates commensurate with related borrowings).
Financial Measures and Segment Accounting Policies
Adjusted earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also the Company’s GAAP measure of segment performance and is reported below. Adjusted earnings should not be viewed as a substitute for net income (loss). The Company believes the presentation of adjusted earnings, as the Company measures it for management purposes, enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business.
The adoption of LDTI impacted the Company’s calculation of adjusted earnings. With the adoption of LDTI, the measurement model was simplified for DAC and VOBA, and most embedded derivatives were reclassified as MRBs. As a result, the Company updated its calculation of adjusted earnings to remove certain adjustments related to the amortization of DAC, VOBA and related intangibles and adjusted for changes in measurement of certain guarantees. Under LDTI, adjusted earnings excludes changes in fair value associated with MRBs, changes in discount rates on certain annuitization guarantees, losses at contract inception for certain single premium business, and asymmetrical accounting associated with in-force reinsurance. All periods presented herein reflect the updated calculation of adjusted earnings.
Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax.
These financial measures focus on the Company’s primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.
25

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), MRBs remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.
Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment.
Other revenues include settlements of foreign currency earnings hedges.
Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, and (iii) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
Interest credited to PABs excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments.
Divested businesses are those that have been or will be sold or exited by MLIC but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MLIC that do not meet the criteria to be included in results of discontinued operations under GAAP.
Other adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income and interest credited to PABs excludes certain amounts related to contractholder-directed equity securities.
Other revenues include fee revenue on synthetic guaranteed interest contracts (“GICs”) accounted for as freestanding derivatives.
Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.
The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.
Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for thethree months and six months ended March 31,June 30, 2023 and 2022. The segment accounting policies are the same as those used to prepare the Company’s interim condensed consolidated financial statements, except for adjusted earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below.
Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in MetLife’s and the Company’s businesses.
26

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
MetLife’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. MetLife’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards. The adoption of LDTI resulted in changes to the economic capital model. The changes related to this adoption do not represent a change in the composition of the segments and, in accordance with GAAP guidance for segment reporting, the Company will apply the changes to the economic capital model prospectively and did not update the economic model for 2022 and 2021.
Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings.
Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. With the adoption of LDTI, net investment income was reallocated for certain segments to reflect the impact of the change to certain liability balances, with no impact to consolidated net investment income. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing.
Three Months Ended March 31, 2023U.S.MetLife
Holdings
Corporate
& Other
TotalAdjustments
Total
Consolidated
Three Months Ended June 30, 2023Three Months Ended June 30, 2023U.S.MetLife
Holdings
Corporate
& Other
TotalAdjustmentsTotal
Consolidated
(In millions)(In millions)
RevenuesRevenuesRevenues
PremiumsPremiums$5,270 $578 $$5,849 $— $5,849 Premiums$5,368 $585 $— $5,953 $— $5,953 
Universal life and investment-type product policy feesUniversal life and investment-type product policy fees285 145 — 430 — 430 Universal life and investment-type product policy fees283 138 422 — 422 
Net investment incomeNet investment income1,854 989 43 2,886 (201)2,685 Net investment income1,980 1,044 46 3,070 (197)2,873 
Other revenuesOther revenues242 56 122 420 (5)415 Other revenues250 50 122 422 (3)419 
Net investment gains (losses)Net investment gains (losses)— — — — (102)(102)Net investment gains (losses)— — — — (659)(659)
Net derivative gains (losses)Net derivative gains (losses)— — — — (560)(560)Net derivative gains (losses)— — — — (232)(232)
Total revenuesTotal revenues7,651 1,768 166 9,585 (868)8,717 Total revenues7,881 1,817 169 9,867 (1,091)8,776 
ExpensesExpensesExpenses
Policyholder benefits and claims and policyholder dividendsPolicyholder benefits and claims and policyholder dividends5,227 1,116 — 6,343 6,346 Policyholder benefits and claims and policyholder dividends5,425 1,123 6,549 6,552 
Policyholder liability remeasurement (gains) lossesPolicyholder liability remeasurement (gains) losses(72)15 — (57)— (57)Policyholder liability remeasurement (gains) losses(5)22 — 17 — 17 
Market risk benefit remeasurement (gains) lossesMarket risk benefit remeasurement (gains) losses— — — — 244 244 Market risk benefit remeasurement (gains) losses— — — — (670)(670)
Interest credited to policyholder account balancesInterest credited to policyholder account balances609 155 66 830 831 Interest credited to policyholder account balances657 156 81 894 (1)893 
Capitalization of DACCapitalization of DAC(25)— (52)(77)— (77)Capitalization of DAC(10)(3)(12)— (12)
Amortization of DAC and VOBAAmortization of DAC and VOBA14 59 77 — 77 Amortization of DAC and VOBA14 56 74 — 74 
Interest expense on debtInterest expense on debt24 30 — 30 Interest expense on debt27 34 — 34 
Other expensesOther expenses1,106 206 201 1,513 1,518 Other expenses920 187 247 1,354 (54)1,300 
Total expensesTotal expenses6,862 1,554 243 8,659 253 8,912 Total expenses7,005 1,548 357 8,910 (722)8,188 
Provision for income tax expense (benefit)Provision for income tax expense (benefit)165 41 (75)131 (235)(104)Provision for income tax expense (benefit)184 53 (80)157 (79)78 
Adjusted earningsAdjusted earnings$624 $173 $(2)795 Adjusted earnings$692 $216 $(108)800 
Adjustments to:Adjustments to:Adjustments to:
Total revenuesTotal revenues(868)Total revenues(1,091)
Total expensesTotal expenses(253)Total expenses722 
Provision for income tax (expense) benefitProvision for income tax (expense) benefit235 Provision for income tax (expense) benefit79 
Net income (loss)Net income (loss)$(91)$(91)Net income (loss)$510 $510 
27

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
Three Months Ended March 31, 2022U.S.MetLife
Holdings
Corporate
& Other
TotalAdjustments
Total
Consolidated
Three Months Ended June 30, 2022Three Months Ended June 30, 2022U.S.MetLife
Holdings
Corporate
& Other
TotalAdjustments
Total
Consolidated
(In millions)(In millions)
RevenuesRevenuesRevenues
PremiumsPremiums$5,284 $622 $— $5,906 $— $5,906 Premiums$5,042 $622 $— $5,664 $— $5,664 
Universal life and investment-type product policy feesUniversal life and investment-type product policy fees286 193 — 479 — 479 Universal life and investment-type product policy fees277 190 — 467 — 467 
Net investment incomeNet investment income1,629 1,264 64 2,957 (131)2,826 Net investment income1,477 1,133 (49)2,561 (119)2,442 
Other revenuesOther revenues242 43 126 411 — 411 Other revenues219 27 126 372 — 372 
Net investment gains (losses)Net investment gains (losses)— — — — (226)(226)Net investment gains (losses)— — — — (83)(83)
Net derivative gains (losses)Net derivative gains (losses)— — — — 121 121 Net derivative gains (losses)— — — — 586 586 
Total revenuesTotal revenues7,441 2,122 190 9,753 (236)9,517 Total revenues7,015 1,972 77 9,064 384 9,448 
ExpensesExpensesExpenses
Policyholder benefits and claims and policyholder dividendsPolicyholder benefits and claims and policyholder dividends5,577 1,226 — 6,803 6,812 Policyholder benefits and claims and policyholder dividends4,980 1,176 — 6,156 6,163 
Policyholder liability remeasurement (gains) lossesPolicyholder liability remeasurement (gains) losses(45)16 — (29)— (29)Policyholder liability remeasurement (gains) losses(23)11 — (12)— (12)
Market risk benefit remeasurement (gains) lossesMarket risk benefit remeasurement (gains) losses— — — — (1,361)(1,361)Market risk benefit remeasurement (gains) losses— — — — (730)(730)
Interest credited to policyholder account balancesInterest credited to policyholder account balances362 161 524 (22)502 Interest credited to policyholder account balances405 161 571 (6)565 
Capitalization of DACCapitalization of DAC(23)— (4)(27)— (27)Capitalization of DAC(12)(23)(34)— (34)
Amortization of DAC and VOBAAmortization of DAC and VOBA15 65 — 80 — 80 Amortization of DAC and VOBA12 63 76 — 76 
Interest expense on debtInterest expense on debt21 24 — 24 Interest expense on debt22 25 — 25 
Other expensesOther expenses861 201 169 1,231 — 1,231 Other expenses823 190 311 1,324 1,326 
Total expensesTotal expenses6,749 1,670 187 8,606 (1,374)7,232 Total expenses6,186 1,604 316 8,106 (727)7,379 
Provision for income tax expense (benefit)Provision for income tax expense (benefit)143 91 (71)163 240 403 Provision for income tax expense (benefit)173 73 (94)152 233 385 
Adjusted earningsAdjusted earnings$549 $361 $74 984 Adjusted earnings$656 $295 $(145)806 
Adjustments to:Adjustments to:Adjustments to:
Total revenuesTotal revenues(236)Total revenues384 
Total expensesTotal expenses1,374 Total expenses727 
Provision for income tax (expense) benefitProvision for income tax (expense) benefit(240)Provision for income tax (expense) benefit(233)
Net income (loss)Net income (loss)$1,882 $1,882 Net income (loss)$1,684 $1,684 
28

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
Six Months Ended June 30, 2023U.S.MetLife
Holdings
Corporate
& Other
TotalAdjustments
Total
Consolidated
(In millions)
Revenues
Premiums$10,638 $1,163 $$11,802 $— $11,802 
Universal life and investment-type product policy fees568 283 852 — 852 
Net investment income3,834 2,033 89 5,956 (398)5,558 
Other revenues492 106 244 842 (8)834 
Net investment gains (losses)— — — — (761)(761)
Net derivative gains (losses)— — — — (792)(792)
Total revenues15,532 3,585 335 19,452 (1,959)17,493 
Expenses
Policyholder benefits and claims and policyholder dividends10,652 2,239 12,892 12,898 
Policyholder liability remeasurement (gains) losses(77)37 — (40)— (40)
Market risk benefit remeasurement (gains) losses— — — — (426)(426)
Interest credited to policyholder account balances1,266 311 147 1,724 — 1,724 
Capitalization of DAC(35)(55)(89)— (89)
Amortization of DAC and VOBA28 115 151 — 151 
Interest expense on debt51 64 — 64 
Other expenses2,026 393 448 2,867 (49)2,818 
Total expenses13,867 3,102 600 17,569 (469)17,100 
Provision for income tax expense (benefit)349 94 (155)288 (314)(26)
Adjusted earnings$1,316 $389 $(110)1,595 
Adjustments to:
Total revenues(1,959)
Total expenses469 
Provision for income tax (expense) benefit314 
Net income (loss)$419 $419 
29

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
Six Months Ended June 30, 2022U.S.MetLife
Holdings
Corporate
& Other
TotalAdjustments
Total
Consolidated
(In millions)
Revenues
Premiums$10,326 $1,244 $— $11,570 $— $11,570 
Universal life and investment-type product policy fees563 383 — 946 — 946 
Net investment income3,106 2,397 15 5,518 (250)5,268 
Other revenues461 70 252 783 — 783 
Net investment gains (losses)— — — — (309)(309)
Net derivative gains (losses)— — — — 707 707 
Total revenues14,456 4,094 267 18,817 148 18,965 
Expenses
Policyholder benefits and claims and policyholder dividends10,557 2,402 — 12,959 16 12,975 
Policyholder liability remeasurement (gains) losses(68)27 — (41)— (41)
Market risk benefit remeasurement (gains) losses— — — — (2,091)(2,091)
Interest credited to policyholder account balances767 322 1,095 (28)1,067 
Capitalization of DAC(35)(27)(61)— (61)
Amortization of DAC and VOBA27 128 156 — 156 
Interest expense on debt43 49 — 49 
Other expenses1,684 391 480 2,555 2,557 
Total expenses12,935 3,274 503 16,712 (2,101)14,611 
Provision for income tax expense (benefit)316 164 (165)315 473 788 
Adjusted earnings$1,205 $656 $(71)1,790 
Adjustments to:
Total revenues148 
Total expenses2,101 
Provision for income tax (expense) benefit(473)
Net income (loss)$3,566 $3,566 
The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
U.S.U.S.$219,424 $220,658 U.S.$213,680 $220,658 
MetLife HoldingsMetLife Holdings135,580 133,393 MetLife Holdings134,893 133,393 
Corporate & OtherCorporate & Other31,817 30,788 Corporate & Other31,248 30,788 
TotalTotal$386,821 $384,839 Total$379,821 $384,839 
3. Future Policy Benefits
The Company establishes liabilities for amounts payable under insurance policies. These liabilities are comprised of traditional and limited-payment contracts and associated DPLs, additional insurance liabilities, participating life and short-duration contracts.
The LDTI transition adjustments related to traditional and limited-payment contracts, DPLs, and additional insurance liabilities, as well as the associated ceded recoverables, as described in Note 1, were as follows at the Transition Date:
2830

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Future Policy Benefits (continued)


U.S.
Annuities
MetLife Holdings
Long-Term Care
MetLife Holdings
Participating
Life
Other Long-DurationShort-Duration and OtherTotal
(In millions)
Balance, future policy benefits, at December 31, 2020$54,535 $14,281 $45,349 $9,625 $10,131 $133,921 
Removal of additional insurance liabilities for separate presentation (1)(4)— — (2,925)— (2,929)
Subtotal - pre-adoption balance, excluding additional liabilities54,531 14,281 45,349 6,700 10,131 130,992 
Removal of related amounts in accumulated other comprehensive income(5,571)(1,210)— (54)— (6,835)
Adjustment of future policy benefits to remeasure cohorts where net premiums exceed gross premiums under the modified retrospective approach41 — — 48 — 89 
Effect of remeasurement of future policy benefits to an upper-medium grade discount rate15,011 8,270 — 1,927 — 25,208 
Other balance sheet reclassifications and adjustments upon adoption of the LDTI standard(4,747)— — (47)— (4,794)
Removal of remeasured deferred profit liabilities for separate presentation (1)(2,413)— — (250)— (2,663)
Balance, traditional and limited-payment contracts, at January 1, 2021$56,852 $21,341 $45,349 $8,324 $10,131 $141,997 
Balance, deferred profit liabilities at January 1, 2021$2,413 $— $— $250 $— $2,663 
Balance, ceded recoverables on traditional and limited-payment contracts at December 31, 2020$203 $— $752 $955 
Effect of remeasurement of the ceded recoverable to an upper-medium grade discount rate135 — 268 403 
Adjustments for loss contracts (with net premiums in excess of gross premiums) under the modified retrospective approach— — 32 32 
Adjustments for the cumulative effect of adoption on ceded recoverables on traditional and limited-payment contract— 20 26 
Balance ceded recoverables on traditional and limited-payment contracts at January 1, 2021$344 $— $1,072 $1,416 
The LDTI transition adjustments related to traditional and limited-payment contracts, DPLs, and additional insurance liabilities, as well as the associated ceded recoverables, as described in Note 1, were as follows at the Transition Date:
U.S.
Annuities
MetLife Holdings
Long-Term Care
MetLife Holdings
Participating
Life
Other Long-DurationShort-Duration and OtherTotal
(In millions)
Balance, future policy benefits, at December 31, 2020$54,535 $14,281 $45,349 $9,625 $10,131 $133,921 
Removal of additional insurance liabilities for separate presentation (1)(4)— — (2,925)— (2,929)
Subtotal - pre-adoption balance, excluding additional liabilities54,531 14,281 45,349 6,700 10,131 130,992 
Removal of related amounts in AOCI(5,571)(1,210)— (54)— (6,835)
Adjustment of future policy benefits to remeasure cohorts where net premiums exceed gross premiums under the modified retrospective approach41 — — 48 — 89 
Effect of remeasurement of future policy benefits to an upper-medium grade discount rate15,011 8,270 — 1,927 — 25,208 
Other balance sheet reclassifications and adjustments upon adoption of the LDTI standard(4,747)— — (47)— (4,794)
Removal of remeasured deferred profit liabilities for separate presentation (1)(2,413)— — (250)— (2,663)
Balance, traditional and limited-payment contracts, at January 1, 2021$56,852 $21,341 $45,349 $8,324 $10,131 $141,997 
Balance, deferred profit liabilities at January 1, 2021$2,413 $— $— $250 $— $2,663 
Balance, ceded recoverables on traditional and limited-payment contracts at December 31, 2020$203 $— $752 $955 
Effect of remeasurement of the ceded recoverable to an upper-medium grade discount rate135 — 268 403 
Adjustments for loss contracts (with net premiums in excess of gross premiums) under the modified retrospective approach— — 32 32 
Adjustments for the cumulative effect of adoption on ceded recoverables on traditional and limited-payment contract— 20 26 
Balance ceded recoverables on traditional and limited-payment contracts at January 1, 2021$344 $— $1,072 $1,416 
__________________
(1) LDTI requires separate disaggregated rollforwards of the additional insurance liabilities balance and the traditional and limited-payment FPBs. Therefore, the additional insurance liabilities and DPL amounts that are recorded in the FPB financial statement line item are removed to derive the opening balance of traditional and limited-payment contracts at the Transition Date.
2931

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Future Policy Benefits (continued)


MetLife Holdings
Universal and Variable
 Universal Life
Other
Long-Duration
Total
(In millions)
Additional insurance liabilities at December 31, 2020$1,478 $1,451 $2,929 
Reclassification of carrying amount of contracts and contract features that are market risk benefits— (1,447)(1,447)
Adjustments for the cumulative effect of adoption on additional insurance liabilities36 — 36 
Additional insurance liabilities at January 1, 2021$1,514 $$1,518 
Ceded recoverables on additional insurance liabilities at December 31, 2020$554 $— $554 
Adjustments for the cumulative effect of adoption on ceded recoverables on additional insurance liabilities— 
Ceded recoverables on additional insurance liabilities at January 1, 2021$563 $— $563 
Balance, traditional and limited-payment contracts, at January 1, 2021$141,997 
Balance, deferred profit liabilities at January 1, 20212,663 
Balance, additional insurance liabilities at January 1, 20211,518 
Total future policy benefits at January 1, 2021$146,178 
__________________
The Company’s future policy benefits on the interim condensed consolidated balance sheets was as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
Traditional and Limited-Payment Contracts:Traditional and Limited-Payment Contracts:Traditional and Limited-Payment Contracts:
U.S. - AnnuitiesU.S. - Annuities$48,491 $47,990 U.S. - Annuities$47,299 $47,990 
MetLife Holdings - Long-term careMetLife Holdings - Long-term care14,617 13,845 MetLife Holdings - Long-term care14,498 13,845 
Deferred Profit Liabilities:Deferred Profit Liabilities:Deferred Profit Liabilities:
U.S. - AnnuitiesU.S. - Annuities2,865 2,699 U.S. - Annuities2,868 2,699 
Additional Insurance Liabilities:Additional Insurance Liabilities:Additional Insurance Liabilities:
MetLife Holdings - Universal and variable universal lifeMetLife Holdings - Universal and variable universal life1,686 1,641 MetLife Holdings - Universal and variable universal life1,763 1,641 
MetLife Holdings - Participating lifeMetLife Holdings - Participating life44,163 44,434 MetLife Holdings - Participating life43,981 44,434 
Other long-duration (1)Other long-duration (1)6,303 6,297 Other long-duration (1)6,216 6,297 
Short-duration and otherShort-duration and other10,073 10,008 Short-duration and other10,189 10,008 
TotalTotal$128,198 $126,914 Total$126,814 $126,914 
__________________
(1) This balance represents liabilities for various smaller product lines across both segments, as well as Corporate & Other.
Rollforwards - Traditional and Limited-Payment Contracts
The following information about the direct and assumed liability for future policy benefits includes disaggregated rollforwards of expected future net premiums and expected future benefits. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses.
3032

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Future Policy Benefits (continued)


U.S. - Annuities
The U.S segment’s annuities products include pension risk transfers, certain structured settlements and certain institutional income annuities, which are mainly single premium spread-based products. Information regarding these products was as follows:
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(Dollars in millions)(Dollars in millions)
Present Value of Expected Net PremiumsPresent Value of Expected Net PremiumsPresent Value of Expected Net Premiums
Balance, beginning of period, at current discount rate at balance sheet dateBalance, beginning of period, at current discount rate at balance sheet date$— $— Balance, beginning of period, at current discount rate at balance sheet date$— $— 
Balance, beginning of period, at original discount rateBalance, beginning of period, at original discount rate$— $— Balance, beginning of period, at original discount rate$— $— 
Effect of actual variances from expected experience (1)Effect of actual variances from expected experience (1)— Effect of actual variances from expected experience (1)— 
Adjusted balanceAdjusted balance— Adjusted balance— 
IssuancesIssuances66 48 Issuances183 82 
Net premiums collectedNet premiums collected(68)(48)Net premiums collected(185)(82)
Ending balance at original discount rateEnding balance at original discount rate— — Ending balance at original discount rate— — 
Balance, end of period, at current discount rate at balance sheet dateBalance, end of period, at current discount rate at balance sheet date$— $— Balance, end of period, at current discount rate at balance sheet date$— $— 
Present Value of Expected Future Policy BenefitsPresent Value of Expected Future Policy BenefitsPresent Value of Expected Future Policy Benefits
Balance, beginning of period, at current discount rate at balance sheet dateBalance, beginning of period, at current discount rate at balance sheet date$48,190 $54,172 Balance, beginning of period, at current discount rate at balance sheet date$48,190 $54,172 
Balance, beginning of period, at original discount rateBalance, beginning of period, at original discount rate$49,194 $42,453 Balance, beginning of period, at original discount rate$49,194 $42,453 
Effect of actual variances from expected experience (1)Effect of actual variances from expected experience (1)(262)(77)Effect of actual variances from expected experience (1)(299)(114)
Adjusted balanceAdjusted balance48,932 42,376 Adjusted balance48,895 42,339 
Issuances Issuances64 48  Issuances183 85 
Interest accrual Interest accrual600 523  Interest accrual1,196 1,042 
Benefit payments Benefit payments(1,309)(914) Benefit payments(2,386)(1,816)
Ending balance at original discount rateEnding balance at original discount rate48,287 42,033 Ending balance at original discount rate47,888 41,650 
Effect of changes in discount rate assumptionsEffect of changes in discount rate assumptions281 6,549 Effect of changes in discount rate assumptions(385)1,645 
Balance, end of period, at current discount rate at balance sheet dateBalance, end of period, at current discount rate at balance sheet date48,568 48,582 Balance, end of period, at current discount rate at balance sheet date47,503 43,295 
Cumulative amount of fair value hedging adjustmentsCumulative amount of fair value hedging adjustments(77)367 Cumulative amount of fair value hedging adjustments(204)52 
Net liability for future policy benefits, exclusive of net premiums48,491 48,949 
Less: Reinsurance recoverable— 271 
Net liability for future policy benefits, exclusive of net premiums, after reinsurance$48,491 $48,678 
Net liability for future policy benefitsNet liability for future policy benefits47,299 43,347 
Less: Reinsurance recoverablesLess: Reinsurance recoverables— 230 
Net liability for future policy benefits, net of reinsuranceNet liability for future policy benefits, net of reinsurance$47,299 $43,117 
Undiscounted - Expected future benefit paymentsUndiscounted - Expected future benefit payments$94,225 $83,794 Undiscounted - Expected future benefit payments$93,997 $83,006 
Discounted - Expected future benefit payments (at current discount rate at balance sheet date)Discounted - Expected future benefit payments (at current discount rate at balance sheet date)$48,568 $48,582 Discounted - Expected future benefit payments (at current discount rate at balance sheet date)$47,503 $43,295 
Weighted-average duration of the liabilityWeighted-average duration of the liability10 years11 yearsWeighted-average duration of the liability9 years10 years
Weighted-average interest accretion (original locked-in) rateWeighted-average interest accretion (original locked-in) rate5.1 %5.1 %Weighted-average interest accretion (original locked-in) rate5.1 %5.1 %
Weighted-average current discount rate at balance sheet dateWeighted-average current discount rate at balance sheet date5.2 %3.7 %Weighted-average current discount rate at balance sheet date5.4 %4.8 %
__________________
(1)    For the threesix months ended March 31,June 30, 2023, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the U.S. segment’s annuities products of $196$225 million. For the threesix months ended March 31,June 30, 2022, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the U.S. segment’s annuities products of $35$48 million.
Significant Methodologies and Assumptions
The principal inputs used in the establishment of the FPB for the U.S. segment’s annuities products include actual premiums, actual benefits, in-force data, locked-in claim-related expense, the locked-in interest accretion rate, the current upper-medium grade discount rate at the balance sheet date and best estimate mortality assumptions.
For the three months ended March 31, 2023, the effect of actual variances from expected experience was primarily driven by favorable mortality and the amendment of an affiliated reinsurance treaty.
3133

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Future Policy Benefits (continued)


For the threesix months ended March 31, 2022,June 30, 2023, the net effect of actual variances from expected experience was primarily driven by increasedfavorable mortality and the amendment of an affiliated reinsurance treaty. For the six months ended June 30, 2022, the net effect of actual variances from expected experience was primarily driven by favorable mortality.
MetLife Holdings - Long-term Care
The MetLife Holdings segment’s long-term care products offer protection against potentially high costs of long-term health care services. Information regarding these products was as follows:
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(Dollars in millions)(Dollars in millions)
Present Value of Expected Net PremiumsPresent Value of Expected Net PremiumsPresent Value of Expected Net Premiums
Balance, beginning of period, at current discount rate at balance sheet dateBalance, beginning of period, at current discount rate at balance sheet date$5,775 $7,058 Balance, beginning of period, at current discount rate at balance sheet date$5,775 $7,058 
Balance, beginning of period, at original discount rateBalance, beginning of period, at original discount rate$5,807 $5,699 Balance, beginning of period, at original discount rate$5,807 $5,699 
Effect of actual variances from expected experienceEffect of actual variances from expected experience26 87 Effect of actual variances from expected experience83 106 
Adjusted balanceAdjusted balance5,833 5,786 Adjusted balance5,890 5,805 
Interest accrualInterest accrual75 74 Interest accrual149 147 
Net premiums collectedNet premiums collected(146)(145)Net premiums collected(293)(288)
Ending balance at original discount rateEnding balance at original discount rate5,762 5,715 Ending balance at original discount rate5,746 5,664 
Effect of changes in discount rate assumptionsEffect of changes in discount rate assumptions104 796 Effect of changes in discount rate assumptions288 
Balance, end of period, at current discount rate at balance sheet dateBalance, end of period, at current discount rate at balance sheet date$5,866 $6,511 Balance, end of period, at current discount rate at balance sheet date$5,749 $5,952 
Present Value of Expected Future Policy BenefitsPresent Value of Expected Future Policy BenefitsPresent Value of Expected Future Policy Benefits
Balance, beginning of period, at current discount rate at balance sheet dateBalance, beginning of period, at current discount rate at balance sheet date$19,619 $27,627 Balance, beginning of period, at current discount rate at balance sheet date$19,619 $27,627 
Balance, beginning of period, at original discount rateBalance, beginning of period, at original discount rate$20,165 $19,406 Balance, beginning of period, at original discount rate$20,165 $19,406 
Effect of actual variances from expected experienceEffect of actual variances from expected experience28 96 Effect of actual variances from expected experience99 116 
Adjusted balanceAdjusted balance20,193 19,502 Adjusted balance20,264 19,522 
Interest accrual Interest accrual266 257  Interest accrual534 515 
Benefit payments Benefit payments(191)(170) Benefit payments(382)(345)
Ending balance at original discount rateEnding balance at original discount rate20,268 19,589 Ending balance at original discount rate20,416 19,692 
Effect of changes in discount rate assumptionsEffect of changes in discount rate assumptions215 4,677 Effect of changes in discount rate assumptions(169)1,088 
Balance, end of period, at current discount rate at balance sheet dateBalance, end of period, at current discount rate at balance sheet date20,483 24,266 Balance, end of period, at current discount rate at balance sheet date20,247 20,780 
Net liability for future policy benefits, exclusive of net premiums$14,617 $17,755 
Net liability for future policy benefitsNet liability for future policy benefits$14,498 $14,828 
Undiscounted:Undiscounted:Undiscounted:
Expected future gross premiumsExpected future gross premiums$11,053 $11,209 Expected future gross premiums$10,893 $11,062 
Expected future benefit paymentsExpected future benefit payments$45,741 $45,898 Expected future benefit payments$45,653 $45,787 
Discounted (at current discount rate at balance sheet date):Discounted (at current discount rate at balance sheet date):Discounted (at current discount rate at balance sheet date):
Expected future gross premiumsExpected future gross premiums$7,295 $8,210 Expected future gross premiums$7,089 $7,501 
Expected future benefit paymentsExpected future benefit payments$20,483 $24,266 Expected future benefit payments$20,247 $20,780 
Weighted-average duration of the liabilityWeighted-average duration of the liability15 years17 yearsWeighted-average duration of the liability15 years16 years
Weighted -average interest accretion (original locked-in) rateWeighted -average interest accretion (original locked-in) rate5.4 %5.5 %Weighted -average interest accretion (original locked-in) rate5.4 %5.5 %
Weighted-average current discount rate at balance sheet dateWeighted-average current discount rate at balance sheet date5.3 %3.9 %Weighted-average current discount rate at balance sheet date5.5 %5.0 %
Significant Methodologies and Assumptions
The principal inputs used in the establishment of the FPB reserve for long-term care products include actual premiums, actual benefits, in-force data, locked-in claim-related expense, the locked-in interest accretion rate, current upper-medium grade discount rate at the balance sheet date and best estimate assumptions. The best estimate assumptions include mortality, lapse, incidence, claim utilization, claim cost inflation, claim continuance, and premium rate increases.
3234

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Future Policy Benefits (continued)


RollforwardsRollforward - Additional Insurance Liabilities
The Company establishes additional insurance liabilities for annuitization, death or other insurance benefits for universal life and variable universal life contract features where the Company guarantees to the contractholder either a secondary guarantee or a guaranteed paid-up benefit. The policy can remain in force, even if the base policy account value is zero, as long as contractual secondary guarantee requirements have been met.
The following information about the direct liability for additional insurance liabilities includes a disaggregated rollforwards.rollforward. The products grouped within these rollforwardsthe rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses.
MetLife Holdings
The MetLife Holdings segment’s universal life and variable universal life products offer a contract feature where the Company guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding these additional insurance liabilities was as follows:
Three Months
 Ended
 March 31,
Six Months
 Ended
June 30,
2023202220232022
Universal and Variable Universal LifeUniversal and Variable Universal Life
(Dollars in millions)(Dollars in millions)
Balance, beginning of periodBalance, beginning of period$1,642 $1,623 Balance, beginning of period$1,642 $1,623 
Less: AOCI adjustmentLess: AOCI adjustment(63)66 Less: AOCI adjustment(63)66 
Balance, beginning of period, before AOCI adjustmentBalance, beginning of period, before AOCI adjustment1,705 1,557 Balance, beginning of period, before AOCI adjustment1,705 1,557 
Effect of actual variances from expected experienceEffect of actual variances from expected experience14 Effect of actual variances from expected experience14 
Adjusted balanceAdjusted balance1,719 1,566 Adjusted balance1,711 1,571 
Assessments accrualAssessments accrual24 23 Assessments accrual47 46 
Interest accrualInterest accrual22 20 Interest accrual44 40 
Excess benefits paidExcess benefits paid(29)(19)Excess benefits paid(41)(34)
Balance, end of period, before AOCI adjustmentBalance, end of period, before AOCI adjustment1,736 1,590 Balance, end of period, before AOCI adjustment1,761 1,623 
Add: AOCI adjustmentAdd: AOCI adjustment(50)23 Add: AOCI adjustment(35)
Balance, end of periodBalance, end of period1,686 1,613 Balance, end of period1,763 1,588 
Less: Reinsurance recoverable636 619 
Less: Reinsurance recoverablesLess: Reinsurance recoverables649 613 
Balance, end of period, net of reinsuranceBalance, end of period, net of reinsurance$1,050 $994 Balance, end of period, net of reinsurance$1,114 $975 
Weighted-average duration of the liabilityWeighted-average duration of the liability17 years18 yearsWeighted-average duration of the liability17 years18 years
Weighted-average interest accretion rateWeighted-average interest accretion rate5.2 %5.2 %Weighted-average interest accretion rate5.2 %5.2 %
Significant Methodologies and Assumptions
Liabilities for ULSG and paid-up guarantees are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the life of the contract based on total expected assessments.
The guaranteed benefits are estimated over a range of scenarios. The significant assumptions used in estimating the ULSG and paid-up guarantee liabilities are investment income, mortality, lapses, and premium payment pattern and persistency. In addition, projected earned rate and crediting rates are used to project the account values and excess death benefits and assessments. The discount rate is equal to the crediting rate for each annual cohort and is locked-in at inception.
3335

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Future Policy Benefits (continued)


The Company’s revenue and interest recognized in the interim condensed consolidated statements of operations and comprehensive income (loss) for long-duration contracts, excluding MetLife Holdings’ participating life contracts, were as follows:
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
Gross Premiums or Assessments (1)Interest Expense (2)Gross Premiums or Assessments (1)Interest Expense (2)Gross Premiums or Assessments (1)Interest Expense (2)Gross Premiums or Assessments (1)Interest Expense (2)
(In millions)(In millions)
Traditional and Limited-Payment Contracts:Traditional and Limited-Payment Contracts:Traditional and Limited-Payment Contracts:
U.S. - AnnuitiesU.S. - Annuities$41 $600 $61 $523 U.S. - Annuities$168 $1,196 $89 $1,042 
MetLife Holdings - Long-term careMetLife Holdings - Long-term care183 $191 183 183 MetLife Holdings - Long-term care366 385 367 368 
Deferred Profit Liabilities:Deferred Profit Liabilities:Deferred Profit Liabilities:
U.S. - AnnuitiesU.S. - AnnuitiesN/A$35 N/A34 U.S. - AnnuitiesN/A70 N/A67 
Additional Insurance Liabilities:Additional Insurance Liabilities:Additional Insurance Liabilities:
MetLife Holdings - Universal and variable universal lifeMetLife Holdings - Universal and variable universal life120 22 122 20 MetLife Holdings - Universal and variable universal life236 44 246 40 
Other long duration Other long duration164 76 177 76  Other long duration400 152 350 151 
Total Total$508 $924 $543 $836  Total$1,170 $1,847 $1,052 $1,668 
__________________
(1) Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income.
(2) Interest expense is included in policyholder benefits and claims.
Liabilities for Unpaid Claims and Claim Expenses
Rollforward of Claims and Claim Adjustment Expenses
Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows:
Three Months 
 Ended 
 March 31,
Six Months
Ended
June 30,
2023202220232022
(In millions)(In millions)
Balance, beginning of periodBalance, beginning of period$11,300 $10,820 Balance, beginning of period$11,300 $10,820 
Less: Reinsurance recoverablesLess: Reinsurance recoverables1,633 1,857 Less: Reinsurance recoverables1,633 1,857 
Net balance, beginning of periodNet balance, beginning of period9,667 8,963 Net balance, beginning of period9,667 8,963 
Incurred related to:Incurred related to:Incurred related to:
Current periodCurrent period5,151 5,377 Current period10,270 10,217 
Prior periods (1)Prior periods (1)(28)230 Prior periods (1)(32)267 
Total incurredTotal incurred5,123 5,607 Total incurred10,238 10,484 
Paid related to:Paid related to:Paid related to:
Current periodCurrent period(2,025)(2,102)Current period(5,919)(5,860)
Prior periodsPrior periods(2,999)(2,947)Prior periods(4,020)(4,002)
Total paidTotal paid(5,024)(5,049)Total paid(9,939)(9,862)
Net balance, end of periodNet balance, end of period9,766 9,521 Net balance, end of period9,966 9,585 
Add: Reinsurance recoverablesAdd: Reinsurance recoverables1,816 1,843 Add: Reinsurance recoverables1,794 1,755 
Balance, end of period (included in future policy benefits and other policy-related balances)Balance, end of period (included in future policy benefits and other policy-related balances)$11,582 $11,364 Balance, end of period (included in future policy benefits and other policy-related balances)$11,760 $11,340 
______________
3436

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Future Policy Benefits (continued)


(1)For the threesix months ended March 31,June 30, 2023, incurred claims and claim adjustment expenses associated with prior periods decreased due to favorable claims experience in the current period. For the threesix months ended March 31,June 30, 2022, incurred claims and claim adjustment expenses include expenses associated with prior periods but reported in the respective current period, which contain impacts related to the COVID-19 pandemic, partially offset by additional premiums recorded for experience-rated contracts that are not reflected in the table above.
4. Policyholder Account Balances
The Company establishes liabilities for PABs which are generally equal to the account value, and which includes accrued interest credited, but excludes the impact of any applicable charge that may be incurred upon surrender.
The LDTI transition adjustments related to PABs, as described in Note 1, were as follows at the Transition Date:
U.S.
Group Life
U.S.
Capital Markets Investment Products and Stable Value GICs
U.S.
Annuities and Risk Solutions
MetLife Holdings AnnuitiesOtherTotal
(In millions)
Balance at December 31, 2020$7,585 $60,641 $5,316 $15,012 $8,081 $96,635 
Reclassification of carrying amount of contracts and contract features that are market risk benefits— — (1)(494)— (495)
Other balance sheet reclassifications and adjustments upon adoption of the LDTI standard— — 4,747 — 47 4,794 
Balance at January 1, 2021$7,585 $60,641 $10,062 $14,518 $8,128 $100,934 
The Company’s PABs on the interim condensed consolidated balance sheets were as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
U.S:U.S:U.S:
Group LifeGroup Life$7,888 $7,954 Group Life$7,795 $7,954 
Capital Markets Investment Products and Stable Value GICsCapital Markets Investment Products and Stable Value GICs58,110 58,508 Capital Markets Investment Products and Stable Value GICs58,490 58,508 
Annuities and Risk SolutionsAnnuities and Risk Solutions10,450 10,244 Annuities and Risk Solutions10,404 10,244 
MetLife Holdings - AnnuitiesMetLife Holdings - Annuities12,143 12,598 MetLife Holdings - Annuities11,741 12,598 
OtherOther16,363 14,103 Other16,359 14,103 
TotalTotal$104,954 $103,407 Total$104,789 $103,407 
Rollforwards
The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance.
3537

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
U.S.
Group Life
The U.S. segment’s group life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account of variable life insurance products. Information regarding this liability was as follows:
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(Dollars in millions)(Dollars in millions)
Balance, beginning of periodBalance, beginning of period$7,954 $7,889 Balance, beginning of period$7,954 $7,889 
DepositsDeposits830 869 Deposits1,644 1,682 
Policy chargesPolicy charges(160)(150)Policy charges(318)(304)
Surrenders and withdrawalsSurrenders and withdrawals(782)(664)Surrenders and withdrawals(1,573)(1,335)
Benefit paymentsBenefit payments(1)(4)Benefit payments(6)(6)
Net transfers from (to) separate accountsNet transfers from (to) separate accounts— Net transfers from (to) separate accounts— 
Interest creditedInterest credited46 31 Interest credited93 63 
Balance, end of periodBalance, end of period$7,888 $7,971 Balance, end of period$7,795 $7,989 
Weighted-average annual crediting rateWeighted-average annual crediting rate2.3 %1.6 %Weighted-average annual crediting rate2.4 %1.6 %
Cash surrender valueCash surrender value$7,827 $7,917 Cash surrender value$7,732 $7,934 
Information regarding the Company’s net amount at risk, excluding offsets from ceded reinsurance, if any, for the U.S. segment’s group life products was as follows at:
March 31,
20232022
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
(In millions)
Net amount at risk$249,463 N/A$240,610 N/A
June 30,
20232022
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
(In millions)
Net amount at risk$251,590 N/A$242,758 N/A
__________________
(1)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.

3638

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
The U.S. segment’s group life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:
Range of GMCRRange of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)(In millions)
March 31, 2023
June 30, 2023June 30, 2023
Equal to or greater than 0% but less than 2%Equal to or greater than 0% but less than 2%$— $— $935 $4,640 $5,575 Equal to or greater than 0% but less than 2%$— $— $910 $4,615 $5,525 
Equal to or greater than 2% but less than 4%Equal to or greater than 2% but less than 4%1,277 10 63 1,352 Equal to or greater than 2% but less than 4%1,252 10 63 1,327 
Equal to or greater than 4%Equal to or greater than 4%759 43 33 836 Equal to or greater than 4%746 43 34 824 
Products with either a fixed rate or no guaranteed minimum crediting rateProducts with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A125 Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A119 
TotalTotal$2,036 $11 $1,041 $4,675 $7,888 Total$1,998 $11 $1,016 $4,651 $7,795 
March 31, 2022
June 30, 2022June 30, 2022
Equal to or greater than 0% but less than 2%Equal to or greater than 0% but less than 2%$5,318 $131 $— $132 $5,581 Equal to or greater than 0% but less than 2%$5,354 $68 $63 $130 $5,615 
Equal to or greater than 2% but less than 4%Equal to or greater than 2% but less than 4%1,355 51 16 — 1,422 Equal to or greater than 2% but less than 4%1,338 52 23 — 1,413 
Equal to or greater than 4%Equal to or greater than 4%808 — — 30 838 Equal to or greater than 4%800 — — 31 831 
Products with either a fixed rate or no guaranteed minimum crediting rateProducts with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A130 Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A130 
TotalTotal$7,481 $182 $16 $162 $7,971 Total$7,492 $120 $86 $161 $7,989 
Capital Markets Investment Products and Stable Value GICs
The U.S. segment’s capital markets investment products and stable value GICs PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows:
Six Months
Ended
June 30,
20232022
(Dollars in millions)
Balance, beginning of period$58,508 $58,495 
Deposits34,800 43,004 
Surrenders and withdrawals(36,458)(41,717)
Interest credited890 467 
Effect of foreign currency translation and other, net750 (1,011)
Balance, end of period$58,490 $59,238 
Weighted-average annual crediting rate3.1 %1.6 %
Cash surrender value$1,776 $1,733 
3739

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
Capital Markets Investment Products and Stable Value GICs
The U.S. segment’s capital markets investment products and stable value GICs PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows:
Three Months
Ended
March 31,
20232022
(Dollars in millions)
Balance, beginning of period$58,508 $58,495 
Deposits19,546 21,693 
Surrenders and withdrawals(20,825)(19,053)
Interest credited422 216 
Effect of foreign currency translation and other, net459 (167)
Balance, end of period$58,110 $61,184 
Weighted-average annual crediting rate2.9 %1.5 %
Cash surrender value$1,565 $1,822 
The U.S. segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:
Range of GMCRRange of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)(In millions)
March 31, 2023
June 30, 2023June 30, 2023
Equal to or greater than 0% but less than 2%Equal to or greater than 0% but less than 2%$— $— $$1,835 $1,836 Equal to or greater than 0% but less than 2%$— $— $$2,595 $2,596 
Products with either a fixed rate or no guaranteed minimum crediting rateProducts with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A56,274 Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A55,894 
TotalTotal$— $— $$1,835 $58,110 Total$— $— $$2,595 $58,490 
March 31, 2022
June 30, 2022June 30, 2022
Equal to or greater than 0% but less than 2%Equal to or greater than 0% but less than 2%$— $300 $3,024 $1,158 $4,482 Equal to or greater than 0% but less than 2%$— $— $22 $3,376 $3,398 
Products with either a fixed rate or no guaranteed minimum crediting rateProducts with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A56,702 Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A55,840 
TotalTotal$— $300 $3,024 $1,158 $61,184 Total$— $— $22 $3,376 $59,238 
38

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
Annuities and Risk Solutions
The U.S. segment’s annuities and risk solutions PABs include certain structured settlements and institutional income annuities, and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows:
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(Dollars in millions)(Dollars in millions)
Balance, beginning of periodBalance, beginning of period$10,244 $10,009 Balance, beginning of period$10,244 $10,009 
DepositsDeposits240 26 Deposits348 119 
Policy chargesPolicy charges(43)(41)Policy charges(87)(82)
Surrenders and withdrawalsSurrenders and withdrawals(40)(40)Surrenders and withdrawals(88)(72)
Benefit paymentsBenefit payments(134)(143)Benefit payments(271)(272)
Net transfers from (to) separate accountsNet transfers from (to) separate accounts55 (2)Net transfers from (to) separate accounts54 (1)
Interest creditedInterest credited107 95 Interest credited213 192 
OtherOther21 (82)Other(9)(149)
Balance, end of periodBalance, end of period$10,450 $9,822 Balance, end of period$10,404 $9,744 
Weighted-average annual crediting rateWeighted-average annual crediting rate4.1 %3.9 %Weighted-average annual crediting rate4.2 %4.0 %
Cash surrender valueCash surrender value$6,621 $5,602 Cash surrender value$6,672 $5,656 
40

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
Information regarding the Company’s net amount at risk, excluding offsets from ceded reinsurance, if any, for the U.S. segment’s annuities and risk solutions products was as follows at:
March 31,
20232022
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
(In millions)
Net amount at risk$35,177 N/A$33,538 N/A
June 30,
20232022
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits
(In millions)
Net amount at risk$36,065 N/A$35,226 N/A
__________________
(1)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.
The U.S. segment’s annuities and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:
Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)
June 30, 2023
Equal to or greater than 0% but less than 2%$— $— $53 $1,406 $1,459 
Equal to or greater than 2% but less than 4%227 35 44 448 754 
Equal to or greater than 4%3,673 117 14 3,810 
Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A4,381 
Total$3,900 $152 $111 $1,860 $10,404 
June 30, 2022
Equal to or greater than 0% but less than 2%$— $— $116 $537 $653 
Equal to or greater than 2% but less than 4%302 40 38 423 803 
Equal to or greater than 4%3,637 123 3,766 
Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A4,522 
Total$3,939 $163 $155 $965 $9,744 
39
41

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
The U.S. segment’s annuities and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:
Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)
March 31, 2023
Equal to or greater than 0% but less than 2%$— $— $58 $1,394 $1,452 
Equal to or greater than 2% but less than 4%230 39 40 441 750 
Equal to or greater than 4%3,689 120 12 3,826 
Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A4,422 
Total$3,919 $159 $110 $1,840 $10,450 
March 31, 2022
Equal to or greater than 0% but less than 2%$— $— $115 $493 $608 
Equal to or greater than 2% but less than 4%301 36 40 421 798 
Equal to or greater than 4%3,634 125 3,764 
Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A4,652 
Total$3,935 $161 $156 $918 $9,822 
MetLife Holdings
Annuities
The MetLife Holdings segment’s annuities PABs primarily includes fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows:
Three Months
Ended
March 31,
20232022
(Dollars in millions)
Balance, beginning of period$12,598 $13,692 
Deposits41 65 
Policy charges(3)(3)
Surrenders and withdrawals(510)(315)
Benefit payments(117)(109)
Net transfers from (to) separate accounts35 66 
Interest credited90 94 
Other(11)
Balance, end of period$12,143 $13,479 
Weighted-average annual crediting rate2.9 %2.8 %
Cash surrender value$11,309 $12,391 
40

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
Six Months
Ended
June 30,
20232022
(Dollars in millions)
Balance, beginning of period$12,598 $13,692 
Deposits129 140 
Policy charges(6)(7)
Surrenders and withdrawals(1,004)(636)
Benefit payments(218)(205)
Net transfers from (to) separate accounts47 134 
Interest credited182 188 
Other13 (21)
Balance, end of period$11,741 $13,285 
Weighted-average annual crediting rate3.0 %2.9 %
Cash surrender value$10,964 $12,256 
Information regarding the Company’s net amount at risk, excluding offsets from ceded reinsurance, if any, for the MetLife Holdings segment’s annuities products was as follows at:
March 31,
20232022
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits (2)
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits (2)
(In millions)
Net amount at risk (3)$3,600 $788 $2,003 $711 
June 30,
20232022
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits (2)
In the
Event of Death (1)
At
Annuitization or Exercise of Other Living Benefits (2)
(In millions)
Net amount at risk (3)$3,246 $770 $4,086 $1,091 
__________________
(1)For benefits that are payable in the event of death, the net amount at risk is generally defined as the current death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.
(2)For benefits that are payable in the event of annuitization or exercise of other living benefits, the net amount at risk is generally defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates or to provide other living benefits. This amount represents the Company’s potential economic exposure in the event all contractholders were to annuitize or to exercise other living benefits at the balance sheet date.
(3)Includes amounts for certain variable annuities with guarantees, which are also disclosed in “MetLife Holdings – Annuities” in Note 5, due to contracts recorded as PABs, along with related guarantees recorded as MRBs.
42

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Policyholder Account Balances (continued)
The MetLife Holdings segment’s annuities account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:
Range of GMCRRange of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)(In millions)
March 31, 2023
June 30, 2023June 30, 2023
Equal to or greater than 0% but less than 2%Equal to or greater than 0% but less than 2%$658 $90 $136 $24 $908 Equal to or greater than 0% but less than 2%$444 $158 $219 $25 $846 
Equal to or greater than 2% but less than 4%Equal to or greater than 2% but less than 4%6,516 3,197 371 36 10,120 Equal to or greater than 2% but less than 4%3,914 5,441 390 72 9,817 
Equal to or greater than 4%Equal to or greater than 4%587 44 — 637 Equal to or greater than 4%609 14 — 626 
Products with either a fixed rate or no guaranteed minimum crediting rateProducts with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A478 Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A452 
TotalTotal$7,761 $3,331 $513 $60 $12,143 Total$4,967 $5,602 $623 $97 $11,741 
March 31, 2022
June 30, 2022June 30, 2022
Equal to or greater than 0% but less than 2%Equal to or greater than 0% but less than 2%$1,038 $$13 $11 $1,069 Equal to or greater than 0% but less than 2%$1,017 $$12 $11 $1,047 
Equal to or greater than 2% but less than 4%Equal to or greater than 2% but less than 4%10,595 282 177 11,055 Equal to or greater than 2% but less than 4%10,544 266 146 10,957 
Equal to or greater than 4%Equal to or greater than 4%615 40 — — 655 Equal to or greater than 4%611 40 — — 651 
Products with either a fixed rate or no guaranteed minimum crediting rateProducts with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A700 Products with either a fixed rate or no guaranteed minimum crediting rateN/AN/AN/AN/A630 
TotalTotal$12,248 $329 $190 $12 $13,479 Total$12,172 $313 $158 $12 $13,285 
4143

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Market Risk Benefits
The Company establishes liabilities for variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets.
The LDTI transition adjustments related to market risk benefit liabilities, as described in Note 1, were as follows at the Transition Date:
MetLife Holdings
Annuities
OtherTotal
(In millions)
Direct and assumed MRB liabilities at December 31, 2020$— $— $— 
Reclassification of carrying amount of contracts and contract features that are market risk benefits1,882 1,883 
Adjustments for the cumulative effect of changes in nonperformance risk between contract issue date and Transition Date(9)(17)(26)
Adjustments for the difference between the fair value of the MRB balance, excluding the cumulative effect of changes in nonperformance risk, and the historical carrying value4,728 204 4,932 
Direct and assumed MRB liabilities at January 1, 2021$6,601 $188 $6,789 
The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
AssetLiabilityNetAssetLiabilityNetAssetLiabilityNetAssetLiabilityNet
(In millions)(In millions)
MetLife Holdings - AnnuitiesMetLife Holdings - Annuities$108 $3,363 $3,255 $153 $3,224 $3,071 MetLife Holdings - Annuities$146 $2,906 $2,760 $153 $3,224 $3,071 
OtherOther16 69 53 21 46 25 Other17 36 19 21 46 25 
TotalTotal$124 $3,432 $3,308 $174 $3,270 $3,096 Total$163 $2,942 $2,779 $174 $3,270 $3,096 
4244

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Market Risk Benefits (continued)
Rollforwards
The following information about the direct liability for MRBs includes a disaggregated rollforward. The products grouped within this rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business.
MetLife Holdings - Annuities
The MetLife Holdings segment’s variable annuity products offer contract features where the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantees contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. Information regarding MetLife Holdings annuities products was as follows:
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(In millions)(In millions)
Balance, beginning of periodBalance, beginning of period$3,071 $5,715 Balance, beginning of period$3,071 $5,715 
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit riskBalance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$3,164 $6,017 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$3,164 $6,017 
Attributed fees collectedAttributed fees collected80 79 Attributed fees collected160 158 
Benefit paymentsBenefit payments(10)(10)Benefit payments(21)(21)
Effect of changes in interest ratesEffect of changes in interest rates344 (1,365)Effect of changes in interest rates(15)(2,555)
Effect of changes in capital marketsEffect of changes in capital markets(303)275 Effect of changes in capital markets(504)1,062 
Effect of changes in equity index volatilityEffect of changes in equity index volatility(121)39 Effect of changes in equity index volatility(98)53 
Actual policyholder behavior different from expected behaviorActual policyholder behavior different from expected behavior21 (11)Actual policyholder behavior different from expected behavior44 
Effect of foreign currency translation and other, net (1)Effect of foreign currency translation and other, net (1)251 (112)Effect of foreign currency translation and other, net (1)174 (290)
Effect of changes in risk marginEffect of changes in risk margin(90)Effect of changes in risk margin(35)(140)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit riskBalance, end of period, before the cumulative effect of changes in the instrument-specific credit risk3,429 4,822 Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk2,869 4,287 
Cumulative effect of changes in the instrument-specific credit riskCumulative effect of changes in the instrument-specific credit risk(174)(207)Cumulative effect of changes in the instrument-specific credit risk(109)(209)
Balance, end of periodBalance, end of period$3,255 $4,615 Balance, end of period$2,760 $4,078 
__________________
(1) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility.
Information regarding the Company’s net amount at risk, excluding offsets from hedging, and the weighted-average attained age of the contractholder for the MetLife Holdings segment’s annuities products was as follows at:
March 31,June 30,
2023202220232022
In the Event of Death (1)At Annuitization or Exercise of Other Living Benefits (2)In the Event of Death (1)At Annuitization or Exercise of Other Living Benefits (2)In the Event of Death (1)At Annuitization or Exercise of Other Living Benefits (2)In the Event of Death (1)At Annuitization or Exercise of Other Living Benefits (2)
(Dollars in millions)(Dollars in millions)
Net amount at risk (3)Net amount at risk (3)$3,600 $788 $2,003 $711 Net amount at risk (3)$3,246 $770 $4,086 $1,091 
Weighted-average attained age of contractholdersWeighted-average attained age of contractholders70 years70 years69 years69 yearsWeighted-average attained age of contractholders70 years70 years69 years69 years
__________________
4345

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Market Risk Benefits (continued)
(1)    For those guarantees of benefits that are payable in the event of death, the net amount at risk is generally defined as the current guaranteed minimum death benefit in excess of the current account balance at the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts at the balance sheet date.
(2)    For benefits that are payable in the event of annuitization or exercise of other living benefits, the net amount at risk is generally defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates or to provide other living benefits. This amount represents the Company’s potential economic exposure in the event all contractholders were to annuitize or to exercise other living benefits at the balance sheet date.
(3) Includes amounts for certain variable annuities with guarantees, which are also disclosed in “MetLife Holdings – Annuities” in Note 4, due to contracts recorded as PABs, along with related guarantees recorded as MRBs.
Significant Methodologies and Assumptions
The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI.
The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates.
Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 11 for additional information on significant unobservable inputs.
The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc.
Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees.
These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions including, but not limited to, changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI.
4446

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Market Risk Benefits (continued)
Other
In addition to the disaggregated MRB product rollforward above, the Company offers other products with guaranteed minimum benefit features. These MRBs are measured at estimated fair value with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 11 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding this liability was as follows:
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(In millions)(In millions)
Balance, beginning of periodBalance, beginning of period$25 $286 Balance, beginning of period$25 $286 
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit riskBalance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$34 $322 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$34 $322 
Attributed fees collectedAttributed fees collected— Attributed fees collected
Effect of changes in interest ratesEffect of changes in interest rates21 (59)Effect of changes in interest rates(126)
Effect of changes in capital marketsEffect of changes in capital markets— (5)Effect of changes in capital markets— (3)
Actual policyholder behavior different from expected behaviorActual policyholder behavior different from expected behavior(23)(4)Actual policyholder behavior different from expected behavior(26)(4)
Effect of foreign currency translation and other, netEffect of foreign currency translation and other, net35 (41)Effect of foreign currency translation and other, net15 (111)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit riskBalance, end of period, before the cumulative effect of changes in the instrument-specific credit risk68 213 Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk26 79 
Cumulative effect of changes in the instrument-specific credit riskCumulative effect of changes in the instrument-specific credit risk(15)(25)Cumulative effect of changes in the instrument-specific credit risk(7)(14)
Balance, end of periodBalance, end of period$53 $188 Balance, end of period$19 $65 
6. Separate Accounts
Separate account assets consist of investment accounts established and maintained by the Company. The separate account investment objectives are directed by the contractholder. An equivalent amount is reported as separate account liabilities. These accounts are reported separately from the general account assets and liabilities.
Separate Account Liabilities
The Company’s separate account liabilities on the interim condensed consolidated balance sheets were as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
U.S.:U.S.:U.S.:
Stable Value and Risk SolutionsStable Value and Risk Solutions$40,677 $43,249 Stable Value and Risk Solutions$37,042 $43,249 
AnnuitiesAnnuities12,219 11,694 Annuities11,792 11,694 
MetLife Holdings - AnnuitiesMetLife Holdings - Annuities29,261 28,443 MetLife Holdings - Annuities29,553 28,443 
OtherOther6,200 5,855 Other6,523 5,855 
TotalTotal$88,357 $89,241 Total$84,910 $89,241 
4547

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Separate Accounts (continued)
Rollforwards
The following information about the separate account liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business.
The separate account liabilities are primarily comprised of the following: U.S. stable value and risk solutions contracts, U.S. annuities participating and non-participating group contracts and MetLife Holdings variable annuities.
The balances of and changes in separate account liabilities were as follows:
U.S.
Stable Value and Risk Solutions
U.S.
Annuities
MetLife Holdings
Annuities
U.S.
Stable Value and Risk Solutions
U.S.
Annuities
MetLife Holdings
Annuities
(In millions)(In millions)
Three Month Ended March 31, 2023
Six Months Ended June 30, 2023Six Months Ended June 30, 2023
Balance, beginning of periodBalance, beginning of period$43,249 $11,694 $28,443 Balance, beginning of period$43,249 $11,694 $28,443 
Premiums and depositsPremiums and deposits645 78 67 Premiums and deposits1,069 120 139 
Policy chargesPolicy charges(57)(6)(149)Policy charges(121)(11)(305)
Surrenders and withdrawalsSurrenders and withdrawals(3,417)(135)(660)Surrenders and withdrawals(7,532)(360)(1,359)
Benefit paymentsBenefit payments(21)— (120)Benefit payments(44)— (242)
Investment performanceInvestment performance1,079 505 1,716 Investment performance1,145 448 2,924 
Net transfers from (to) general accountNet transfers from (to) general account(57)(36)Net transfers from (to) general account(57)(47)
Effect of foreign currency translation and other, netEffect of foreign currency translation and other, net(744)81 — Effect of foreign currency translation and other, net(667)(102)— 
Balance, end of periodBalance, end of period$40,677 $12,219 $29,261 Balance, end of period$37,042 $11,792 $29,553 
Three Months Ended March 31, 2022
Six Months Ended June 30, 2022Six Months Ended June 30, 2022
Balance, beginning of periodBalance, beginning of period$54,391 $21,292 $40,096 Balance, beginning of period$54,391 $21,292 $40,096 
Premiums and depositsPremiums and deposits1,792 620 72 Premiums and deposits2,939 730 146 
Policy chargesPolicy charges(70)(8)(174)Policy charges(137)(13)(344)
Surrenders and withdrawalsSurrenders and withdrawals(3,082)(5,820)(864)Surrenders and withdrawals(3,946)(6,379)(1,591)
Benefit paymentsBenefit payments(24)— (124)Benefit payments(43)— (230)
Investment performanceInvestment performance(2,030)(1,141)(2,931)Investment performance(3,899)(2,387)(7,839)
Net transfers from (to) general accountNet transfers from (to) general account63 (62)(66)Net transfers from (to) general account60 (59)(135)
Effect of foreign currency translation and other, netEffect of foreign currency translation and other, net(1,258)24 — Effect of foreign currency translation and other, net(5,186)(156)
Balance, end of periodBalance, end of period$49,782 $14,905 $36,009 Balance, end of period$44,179 $13,028 $30,106 
Cash surrender value at March 31, 2023 (1)$36,594 N/A$29,115 
Cash surrender value at March 31, 2022 (1)$41,427 N/A$35,794 
Cash surrender value at June 30, 2023 (1)Cash surrender value at June 30, 2023 (1)$32,886 N/A$29,471 
Cash surrender value at June 30, 2022 (1)Cash surrender value at June 30, 2022 (1)$39,752 N/A$29,927 
_____________
(1)    Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges.
4648

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Separate Accounts (continued)
Separate Account Assets
The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at:
March 31, 2023June 30, 2023
U.S.MetLife HoldingsTotalU.S.MetLife HoldingsTotal
(In millions)(In millions)
Fixed maturity securities AFS:
Fixed maturity securities:Fixed maturity securities:
Bonds:Bonds:Bonds:
Foreign governmentForeign government$577 $— $577 Foreign government$527 $— $527 
U.S. government and agencyU.S. government and agency11,128 — 11,128 U.S. government and agency10,111 — 10,111 
Public utilitiesPublic utilities1,264 — 1,264 Public utilities1,141 — 1,141 
MunicipalsMunicipals504 — 504 Municipals392 — 392 
Corporate bonds:Corporate bonds:Corporate bonds:
MaterialsMaterials211 — 211 Materials172 — 172 
CommunicationsCommunications1,084 — 1,084 Communications1,000 — 1,000 
ConsumerConsumer2,299 — 2,299 Consumer2,010 — 2,010 
EnergyEnergy890 — 890 Energy841 — 841 
FinancialFinancial3,095 — 3,095 Financial2,789 — 2,789 
Industrial and otherIndustrial and other888 — 888 Industrial and other787 — 787 
TechnologyTechnology700 — 700 Technology610 — 610 
ForeignForeign2,370 — 2,370 Foreign2,126 — 2,126 
Total corporate bondsTotal corporate bonds11,537 — 11,537 Total corporate bonds10,335 — 10,335 
Total bondsTotal bonds25,010 — 25,010 Total bonds22,506 — 22,506 
Mortgage-backed securitiesMortgage-backed securities11,645 — 11,645 Mortgage-backed securities10,594 — 10,594 
Asset-backed securities and collateralized loan obligationsAsset-backed securities and collateralized loan obligations2,730 — 2,730 Asset-backed securities and collateralized loan obligations2,566 — 2,566 
Redeemable preferred stockRedeemable preferred stock— Redeemable preferred stock10 — 10 
Total fixed maturity securities AFS39,390 — 39,390 
Total fixed maturity securitiesTotal fixed maturity securities35,676 — 35,676 
Equity securities:Equity securities:Equity securities:
Common stock:Common stock:Common stock:
Industrial, miscellaneous and all otherIndustrial, miscellaneous and all other2,611 — 2,611 Industrial, miscellaneous and all other2,670 — 2,670 
Banks, trust and insurance companiesBanks, trust and insurance companies496 — 496 Banks, trust and insurance companies492 — 492 
Public utilitiesPublic utilities71 — 71 Public utilities72 — 72 
Non-redeemable preferred stockNon-redeemable preferred stock— Non-redeemable preferred stock— — — 
Mutual fundsMutual funds4,607 34,333 38,940 Mutual funds4,731 34,887 39,618 
Total equity securitiesTotal equity securities7,787 34,333 42,120 Total equity securities7,965 34,887 42,852 
Other invested assetsOther invested assets1,337 — 1,337 Other invested assets1,667 — 1,667 
Total investmentsTotal investments48,514 34,333 82,847 Total investments45,308 34,887 80,195 
Other assetsOther assets5,510 — 5,510 Other assets4,715 — 4,715 
TotalTotal$54,024 $34,333 $88,357 Total$50,023 $34,887 $84,910 
4749

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Separate Accounts (continued)
December 31, 2022
U.S.MetLife HoldingsTotal
(In millions)
Fixed maturity securities AFS:
Bonds:
Foreign government$588 $— $588 
U.S. government and agency11,189 — 11,189 
Public utilities1,174 — 1,174 
Municipals475 — 475 
Corporate bonds:
Materials242 — 242 
Communications1,174 — 1,174 
Consumer2,365 — 2,365 
Energy861 — 861 
Financial3,495 — 3,495 
Industrial and other876 — 876 
Technology711 — 711 
Foreign2,451 — 2,451 
Total corporate bonds12,175 — 12,175 
Total bonds25,601 — 25,601 
Mortgage-backed securities12,202 — 12,202 
Asset-backed securities and collateralized loan obligations2,763 — 2,763 
Redeemable preferred stock— 
Total fixed maturity securities AFS40,570 — 40,570 
Equity securities:
Common stock:
Industrial, miscellaneous and all other2,853 — 2,853 
Banks, trust and insurance companies586 — 586 
Public utilities94 — 94 
Non-redeemable preferred stock— 
Mutual funds4,355 33,231 37,586 
Total equity securities7,890 33,231 41,121 
Other invested assets1,636 — 1,636 
Total investments50,096 33,231 83,327 
Other assets5,914 — 5,914 
Total$56,010 $33,231 $89,241 
4850

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue
The transition adjustments related to DAC, VOBA, and UREV, as described in Note 1, were as follows at the Transition Date:
U.S.MetLife HoldingsTotal
(In millions)
DAC:
Balance at December 31, 2020$378 $2,248 $2,626 
Removal of related amounts in AOCI— 1,480 1,480 
Other adjustments upon adoption of the LDTI standard— 12 12 
Balance at January 1, 2021$378 $3,740 $4,118 
VOBA:
Balance at December 31, 2020$20 $$23 
Removal of related amounts in AOCI— 
Balance at January 1, 2021$20 $$25 
UREV:
Balance at December 31, 2020$22 $157 $179 
Removal of related amounts in AOCI— — — 
Balance at January 1, 2021$22 $157 $179 
4951

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue (continued)
DAC and VOBA
Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at:
U.S.MetLife Holdings (1)Corporate & OtherTotalU.S.MetLife Holdings (1)Corporate & OtherTotal
(In millions)(In millions)
DAC:DAC:DAC:
Balance at January 1, 2023Balance at January 1, 2023$401 $3,220 $120 $3,741 Balance at January 1, 2023$401 $3,220 $120 $3,741 
CapitalizationsCapitalizations25 — 52 77 Capitalizations35 (1)55 89 
AmortizationAmortization(13)(59)(4)(76)Amortization(27)(115)(8)(150)
Balance at March 31, 2023$413 $3,161 $168 $3,742 
Balance at June 30, 2023Balance at June 30, 2023$409 $3,104 $167 $3,680 
Balance at January 1, 2022Balance at January 1, 2022$384 $3,457 $$3,847 Balance at January 1, 2022$384 $3,457 $$3,847 
CapitalizationsCapitalizations23 — 27 Capitalizations35 (1)27 61 
AmortizationAmortization(14)(65)— (79)Amortization(26)(128)(1)(155)
Balance at March 31, 2022$393 $3,392 $10 $3,795 
Balance at June 30, 2022Balance at June 30, 2022$393 $3,328 $32 $3,753 
VOBA:VOBA:VOBA:
Balance at January 1, 2023Balance at January 1, 2023$16 $— $— $16 Balance at January 1, 2023$16 $— $— $16 
AmortizationAmortization(1)— — (1)Amortization(1)— — (1)
Balance at March 31, 2023$15 $— $— $15 
Balance at June 30, 2023Balance at June 30, 2023$15 $— $— $15 
Balance at January 1, 2022Balance at January 1, 2022$18 $— $— $18 Balance at January 1, 2022$18 $— $— $18 
AmortizationAmortization(1)— — (1)Amortization(1)— — (1)
Balance at March 31, 2022$17 $— $— $17 
Balance at June 30, 2022Balance at June 30, 2022$17 $— $— $17 
Total DAC and VOBA:Total DAC and VOBA:Total DAC and VOBA:
Balance at March 31, 2023$3,757 
Balance at March 31, 2022$3,812 
Balance at June 30, 2023Balance at June 30, 2023$3,695 
Balance at June 30, 2022Balance at June 30, 2022$3,770 
Balance at December 31, 2022Balance at December 31, 2022$3,757 Balance at December 31, 2022$3,757 
__________________
(1)Includes DAC balances primarily related to universal life, variable universal life, whole life, term life and variable annuities products.
Significant Methodologies and Assumptions
The Company amortizes DAC and VOBA related to long-duration contracts over the estimated lives of the contracts in proportion to benefits in-force for U.S. annuities and policy count for all other products. The amortization amount is calculated using the same cohorts as the corresponding liabilities on a quarterly basis, using an amortization rate that includes current period reporting experience and end of period persistency assumptions that are consistent with those used to measure the corresponding liabilities.
The Company amortizes DAC for short-duration contracts, which is primarily comprised of commissions and certain underwriting expenses, in proportion to actual and future earned premium over the applicable contract term.

5052

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue (continued)
Unearned Revenue
Information regarding the Company’s UREV primarily related to universal life and variable universal life products by segment included in other policy-related balances was as follows:
U.S.MetLife HoldingsTotal
(In millions)
Balance at January 1, 2023$18 $227 $245 
Deferrals10 
Amortization(1)(5)(6)
Balance at March 31, 2023$18 $231 $249 
U.S.MetLife HoldingsTotalSix Months
Ended
June 30, 2023
(In millions)U.S.MetLife HoldingsTotal
Balance at January 1, 2022$21 $195 $216 
(In millions)
Balance, beginning of periodBalance, beginning of period$18 $227 $245 
DeferralsDeferrals— 12 12 Deferrals20 21 
AmortizationAmortization(1)(4)(5)Amortization(2)(9)(11)
Balance at March 31, 2022$20 $203 $223 
Balance, end of periodBalance, end of period$17 $238 $255 
Six Months
Ended
June 30, 2022
U.S.MetLife HoldingsTotal
(In millions)
Balance, beginning of periodBalance, beginning of period$21 $195 $216 
DeferralsDeferrals— 23 23 
AmortizationAmortization(2)(7)(9)
Balance, end of periodBalance, end of period$19 $211 $230 
Significant Methodologies and Assumptions
UREV is amortized similarly to DAC and VOBA, see “— DAC and VOBA.”
53

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
8. Closed Block
On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving Metropolitan Life Insurance Company’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, Metropolitan Life Insurance Company established a closed block for the benefit of holders of certain individual life insurance policies of Metropolitan Life Insurance Company. Assets have been allocated to the closed block in an amount that has been determined to produce cash flows which, together with anticipated revenues from the policies included in the closed block, are reasonably expected to be sufficient to support obligations and liabilities relating to these policies, including, but not limited to, provisions for the payment of claims and certain expenses and taxes, and to provide for the continuation of policyholder dividend scales in effect for 1999, if the experience underlying such dividend scales continues, and for appropriate adjustments in such scales if the experience changes. At least annually, the Company compares actual and projected experience against the experience assumed in the then-current dividend scales. Dividend scales are adjusted periodically to give effect to changes in experience.
The closed block assets, the cash flows generated by the closed block assets and the anticipated revenues from the policies in the closed block will benefit only the holders of the policies in the closed block. To the extent that, over time, cash flows from the assets allocated to the closed block and claims and other experience related to the closed block are, in the aggregate, more or less favorable than what was assumed when the closed block was established, total dividends paid to closed block policyholders in the future may be greater than or less than the total dividends that would have been paid to these policyholders if the policyholder dividend scales in effect for 1999 had been continued. Any cash flows in excess of amounts assumed will be available for distribution over time to closed block policyholders and will not be available to stockholders. If the closed block has insufficient funds to make guaranteed policy benefit payments, such payments will be made from assets outside of the closed block. The closed block will continue in effect as long as any policy in the closed block remains in-force. The expected life of the closed block is over 100 years from the Demutualization Date.
51

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
8. Closed Block (continued)
The Company uses the same accounting principles to account for the participating policies included in the closed block as it used prior to the Demutualization Date. However, the Company establishes a policyholder dividend obligation for earnings that will be paid to policyholders as additional dividends as described below. The excess of closed block liabilities over closed block assets at the Demutualization Date (adjusted to eliminate the impact of related amounts in AOCI) represents the estimated maximum future earnings from the closed block expected to result from operations, attributed net of income tax, to the closed block. Earnings of the closed block are recognized in income over the period the policies and contracts in the closed block remain in-force.
If, over the period the closed block remains in existence, the actual cumulative earnings of the closed block are greater than the expected cumulative earnings of the closed block, the Company will pay the excess to closed block policyholders as additional policyholder dividends unless offset by future unfavorable experience of the closed block and, accordingly, will recognize only the expected cumulative earnings in income with the excess recorded as a policyholder dividend obligation. If over such period, the actual cumulative earnings of the closed block are less than the expected cumulative earnings of the closed block, the Company will recognize only the actual earnings in income. However, the Company may change policyholder dividend scales in the future, which would be intended to increase future actual earnings until the actual cumulative earnings equal the expected cumulative earnings.
At least annually, management performs a premium deficiency test using best estimate assumptions to determine whether the projected future earnings of the closed block are sufficient to support the payment of future closed block contractual benefits. The most recent deficiency test demonstrated that the projected future earnings of the closed block are sufficient to support the payment of future closed block contractual benefits.
Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon policy count within the closed block.
Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item.
5254

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
8. Closed Block (continued)
Information regarding the closed block liabilities and assets designated to the closed block was as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
Closed Block LiabilitiesClosed Block LiabilitiesClosed Block Liabilities
Future policy benefitsFuture policy benefits$36,898 $37,222 Future policy benefits$36,650 $37,222 
Other policy-related balancesOther policy-related balances274 273 Other policy-related balances281 273 
Policyholder dividends payablePolicyholder dividends payable177 181 Policyholder dividends payable178 181 
Current income tax payableCurrent income tax payable— 
Other liabilitiesOther liabilities504 455 Other liabilities592 455 
Total closed block liabilitiesTotal closed block liabilities37,853 38,131 Total closed block liabilities37,710 38,131 
Assets Designated to the Closed BlockAssets Designated to the Closed BlockAssets Designated to the Closed Block
Investments:Investments:Investments:
Fixed maturity securities available-for-sale, at estimated fair valueFixed maturity securities available-for-sale, at estimated fair value20,033 19,648 Fixed maturity securities available-for-sale, at estimated fair value19,697 19,648 
Mortgage loansMortgage loans6,488 6,564 Mortgage loans6,269 6,564 
Policy loansPolicy loans4,044 4,084 Policy loans4,014 4,084 
Real estate and real estate joint venturesReal estate and real estate joint ventures647 635 Real estate and real estate joint ventures655 635 
Other invested assetsOther invested assets666 705 Other invested assets604 705 
Total investmentsTotal investments31,878 31,636 Total investments31,239 31,636 
Cash and cash equivalentsCash and cash equivalents477 437 Cash and cash equivalents656 437 
Accrued investment incomeAccrued investment income376 375 Accrued investment income369 375 
Premiums, reinsurance and other receivablesPremiums, reinsurance and other receivables70 52 Premiums, reinsurance and other receivables114 52 
Current income tax recoverableCurrent income tax recoverable79 88 Current income tax recoverable— 88 
Deferred income tax assetDeferred income tax asset311 423 Deferred income tax asset394 423 
Total assets designated to the closed blockTotal assets designated to the closed block33,191 33,011 Total assets designated to the closed block32,772 33,011 
Excess of closed block liabilities over assets designated to the closed blockExcess of closed block liabilities over assets designated to the closed block4,662 5,120 Excess of closed block liabilities over assets designated to the closed block4,938 5,120 
AOCI:AOCI:AOCI:
Unrealized investment gains (losses), net of income taxUnrealized investment gains (losses), net of income tax(924)(1,357)Unrealized investment gains (losses), net of income tax(1,176)(1,357)
Unrealized gains (losses) on derivatives, net of income taxUnrealized gains (losses) on derivatives, net of income tax253 262 Unrealized gains (losses) on derivatives, net of income tax212 262 
Total amounts included in AOCITotal amounts included in AOCI(671)(1,095)Total amounts included in AOCI(964)(1,095)
Maximum future earnings to be recognized from closed block assets and liabilitiesMaximum future earnings to be recognized from closed block assets and liabilities$3,991 $4,025 Maximum future earnings to be recognized from closed block assets and liabilities$3,974 $4,025 
Information regarding the closed block policyholder dividend obligation was as follows:
ThreeSix Months
Ended
March 31,June 30, 2023
Year 
 Ended 
 December 31, 2022
(In millions)
Balance, beginning of period$— $1,682 
Change in unrealized investment and derivative gains (losses)— (1,682)
Balance, end of period$— $— 
5355

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
8. Closed Block (continued)
Information regarding the closed block revenues and expenses was as follows:
Three Months
Ended
March 31,
Three Months
Ended
June 30,
Six Months
Ended
June 30,
202320222023202220232022
(In millions)(In millions)
RevenuesRevenuesRevenues
PremiumsPremiums$235 $275 Premiums$226 $274 $461 $549 
Net investment incomeNet investment income338 361 Net investment income341 352 679 713 
Net investment gains (losses)Net investment gains (losses)(32)Net investment gains (losses)(16)(48)
Net derivative gains (losses)Net derivative gains (losses)(2)Net derivative gains (losses)11 
Total revenuesTotal revenues575 607 Total revenues577 618 1,152 1,225 
ExpensesExpensesExpenses
Policyholder benefits and claimsPolicyholder benefits and claims413 483 Policyholder benefits and claims445 462 858 945 
Policyholder dividendsPolicyholder dividends97 134 Policyholder dividends89 128 186 262 
Other expensesOther expenses22 23 Other expenses22 23 44 46 
Total expensesTotal expenses532 640 Total expenses556 613 1,088 1,253 
Revenues, net of expenses before provision for income tax expense (benefit)Revenues, net of expenses before provision for income tax expense (benefit)43 (33)Revenues, net of expenses before provision for income tax expense (benefit)21 64 (28)
Provision for income tax expense (benefit)Provision for income tax expense (benefit)(7)Provision for income tax expense (benefit)13 (6)
Revenues, net of expenses and provision for income tax expense (benefit)Revenues, net of expenses and provision for income tax expense (benefit)$34 $(26)Revenues, net of expenses and provision for income tax expense (benefit)$17 $$51 $(22)
Metropolitan Life Insurance Company charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. Metropolitan Life Insurance Company also charges the closed block for expenses of maintaining the policies included in the closed block.
5456

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments
Fixed Maturity Securities Available-for-Sale
Fixed Maturity Securities Available-for-Sale by Sector
The following table presents fixed maturity securities available-for-sale (“AFS”) by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.”
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Amortized
Cost
Gross UnrealizedEstimated
Fair
Value
Amortized
Cost
Gross UnrealizedEstimated
Fair
Value
Amortized
Cost
Gross UnrealizedEstimated
Fair
Value
Amortized
Cost
Gross UnrealizedEstimated
Fair
Value
SectorSectorAllowance for
Credit Loss
GainsLossesAllowance for
Credit Loss
GainsLossesSectorAllowance for
Credit Loss
GainsLossesAllowance for
Credit Loss
GainsLosses
(In millions)(In millions)
U.S. corporateU.S. corporate$56,356 $(57)$1,031 $3,834 $53,496 $55,280 $(28)$649 $4,811 $51,090 U.S. corporate$56,350 $(63)$734 $3,983 $53,038 $55,280 $(28)$649 $4,811 $51,090 
Foreign corporateForeign corporate28,581 (3)323 3,830 25,071 28,328 (3)206 4,538 23,993 Foreign corporate28,111 (2)309 3,827 24,591 28,328 (3)206 4,538 23,993 
U.S. government and agencyU.S. government and agency24,180 — 365 1,732 22,813 24,409 — 333 2,384 22,358 U.S. government and agency23,817 — 220 2,106 21,931 24,409 — 333 2,384 22,358 
RMBSRMBS22,008 — 201 2,062 20,147 21,539 — 177 2,383 19,333 RMBS21,948 — 161 2,224 19,885 21,539 — 177 2,383 19,333 
ABS & CLOABS & CLO12,682 — 22 683 12,021 12,639 — 812 11,836 ABS & CLO12,719 — 13 667 12,065 12,639 — 812 11,836 
MunicipalsMunicipals7,863 — 422 506 7,779 7,880 — 256 672 7,464 Municipals7,772 — 355 475 7,652 7,880 — 256 672 7,464 
CMBSCMBS6,712 (7)605 6,107 6,691 (15)640 6,043 CMBS6,938 (7)643 6,292 6,691 (15)640 6,043 
Foreign governmentForeign government3,713 (68)160 279 3,526 3,711 (68)140 324 3,459 Foreign government3,811 (70)155 278 3,618 3,711 (68)140 324 3,459 
Total fixed maturity securities AFSTotal fixed maturity securities AFS$162,095 $(135)$2,531 $13,531 $150,960 $160,477 $(114)$1,777 $16,564 $145,576 Total fixed maturity securities AFS$161,466 $(142)$1,951 $14,203 $149,072 $160,477 $(114)$1,777 $16,564 $145,576 
The Company held non-income producing fixed maturity securities AFS with an estimated fair value of $84$97 million and $71 million at March 31,June 30, 2023 and December 31, 2022, respectively, with unrealized gains (losses) of ($23)31) million and ($1) million at March 31,June 30, 2023 and December 31, 2022, respectively.
Maturities of Fixed Maturity Securities AFS
The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at March 31,June 30, 2023:
Due in One
Year or Less
Due After
 One Year
Through
Five Years
Due After
Five Years
Through Ten
Years
Due After
Ten Years
Structured
Products
Total Fixed
Maturity
Securities
AFS
Due in One
Year or Less
Due After
 One Year
Through
Five Years
Due After
Five Years
Through Ten
Years
Due After
Ten Years
Structured
Products
Total Fixed
Maturity
Securities
AFS
(In millions)(In millions)
Amortized cost, net of ACLAmortized cost, net of ACL$3,317 $25,762 $28,441 $63,045 $41,395 $161,960 Amortized cost, net of ACL$3,476 $25,564 $28,563 $62,123 $41,598 $161,324 
Estimated fair valueEstimated fair value$3,214 $24,774 $26,849 $57,848 $38,275 $150,960 Estimated fair value$3,428 $24,421 $26,845 $56,136 $38,242 $149,072 
Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity.
5557

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector
The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position.
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Less than 12 MonthsEqual to or Greater
than 12 Months
Less than 12 MonthsEqual to or Greater
than 12 Months
Less than 12 MonthsEqual to or Greater
than 12 Months
Less than 12 MonthsEqual to or Greater
than 12 Months
Sector & Credit QualitySector & Credit QualityEstimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Sector & Credit QualityEstimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
(Dollars in millions)(Dollars in millions)
U.S. corporateU.S. corporate$23,203 $1,587 $12,221 $2,218 $34,358 $3,953 $3,383 $856 U.S. corporate$12,855 $520 $21,607 $3,435 $34,358 $3,953 $3,383 $856 
Foreign corporateForeign corporate9,697 1,110 10,551 2,720 16,834 3,350 3,977 1,188 Foreign corporate3,084 157 15,837 3,670 16,834 3,350 3,977 1,188 
U.S. government and agencyU.S. government and agency10,775 779 5,042 953 13,489 1,895 2,756 489 U.S. government and agency9,806 535 7,132 1,571 13,489 1,895 2,756 489 
RMBSRMBS7,145 442 8,969 1,620 11,622 1,280 4,585 1,103 RMBS6,179 289 10,761 1,935 11,622 1,280 4,585 1,103 
ABS & CLOABS & CLO2,640 81 7,907 602 7,725 499 3,009 313 ABS & CLO1,607 45 8,867 622 7,725 499 3,009 313 
MunicipalsMunicipals1,790 146 1,218 360 3,526 616 133 56 Municipals1,089 40 1,759 435 3,526 616 133 56 
CMBSCMBS2,593 137 3,047 467 4,376 426 1,254 213 CMBS1,450 64 4,144 576 4,376 426 1,254 213 
Foreign governmentForeign government1,098 70 781 208 1,803 209 306 115 Foreign government811 30 1,227 247 1,803 209 306 115 
Total fixed maturity securities AFSTotal fixed maturity securities AFS$58,941 $4,352 $49,736 $9,148 $93,733 $12,228 $19,403 $4,333 Total fixed maturity securities AFS$36,881 $1,680 $71,334 $12,491 $93,733 $12,228 $19,403 $4,333 
Investment gradeInvestment grade$55,769 $4,215 $45,957 $8,514 $88,059 $11,710 $17,470 $3,897 Investment grade$35,008 $1,614 $66,674 $11,852 $88,059 $11,710 $17,470 $3,897 
Below investment gradeBelow investment grade3,172 137 3,779 634 5,674 518 1,933 436 Below investment grade1,873 66 4,660 639 5,674 518 1,933 436 
Total fixed maturity securities AFSTotal fixed maturity securities AFS$58,941 $4,352 $49,736 $9,148 $93,733 $12,228 $19,403 $4,333 Total fixed maturity securities AFS$36,881 $1,680 $71,334 $12,491 $93,733 $12,228 $19,403 $4,333 
Total number of securities in an
unrealized loss position
Total number of securities in an
unrealized loss position
6,3275,85810,6882,110Total number of securities in an
unrealized loss position
4,7777,75210,6882,110
Evaluation of Fixed Maturity Securities AFS for Credit Loss
Evaluation and Measurement Methodologies
Management considers a wide range of factors about the security issuer and uses its best judgment in evaluating the cause of the decline in the estimated fair value of the security and in assessing the prospects for near-term recovery. Inherent in management’s evaluation of the security are assumptions and estimates about the operations of the issuer and its future earnings potential. Considerations used in the credit loss evaluation process include, but are not limited to: (i) the extent to which the estimated fair value has been below amortized cost, (ii) adverse conditions specifically related to a security, an industry sector or sub-sector, or an economically depressed geographic area, adverse change in the financial condition of the issuer of the security, changes in technology, discontinuance of a segment of the business that may affect future earnings, and changes in the quality of credit enhancement, (iii) payment structure of the security and likelihood of the issuer being able to make payments, (iv) failure of the issuer to make scheduled interest and principal payments, (v) whether the issuer, or series of issuers or an industry has suffered a catastrophic loss or has exhausted natural resources, (vi) whether the Company has the intent to sell or will more likely than not be required to sell, including transfers in connection with reinsurance transactions, a particular security before the decline in estimated fair value below amortized cost recovers, (vii) with respect to Structured Products, changes in forecasted cash flows after considering the changes in the financial condition of the underlying loan obligors and quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying assets backing a particular security, and the payment priority within the tranche structure of the security, (viii) changes in the rating of the security by a rating agency, and (ix) other subjective factors, including concentrations and information obtained from regulators.
The methodology and significant inputs used to determine the amount of credit loss are as follows:
The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security at the time of purchase for fixed-rate securities and the spot rate at the date of evaluation of credit loss for floating-rate securities.
5658

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall credit loss evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s single best estimate, the most likely outcome in a range of possible outcomes, after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security; the likelihood that the issuer can service the interest and principal payments; the quality and amount of any credit enhancements; the security’s position within the capital structure of the issuer; possible corporate restructurings or asset sales by the issuer; any private and public sector programs to restructure foreign government securities and municipals; and changes to the rating of the security or the issuer by rating agencies.
Additional considerations are made when assessing the unique features that apply to certain Structured Products including, but not limited to: the quality of underlying collateral, historical performance of the underlying loan obligors, historical rent and vacancy levels, changes in the financial condition of the underlying loan obligors, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, changes in the quality of credit enhancement and the payment priority within the tranche structure of the security.
With respect to securities that have attributes of debt and equity (“perpetual hybrid securities”), consideration is given in the credit loss analysis as to whether there has been any deterioration in the credit of the issuer and the likelihood of recovery in value of the securities that are in a severe unrealized loss position. Consideration is also given as to whether any perpetual hybrid securities with an unrealized loss, regardless of credit rating, have deferred any dividend payments.
In periods subsequent to the recognition of an initial ACL on a security, the Company reassesses credit loss quarterly. Subsequent increases or decreases in the expected cash flow from the security result in corresponding decreases or increases in the ACL which are recognized in earnings and reported within net investment gains (losses); however, the previously recorded ACL is not reduced to an amount below zero. Full or partial write-offs are deducted from the ACL in the period the security, or a portion thereof, is considered uncollectible. Recoveries of amounts previously written off are recorded to the ACL in the period received. When the Company has the intent-to-sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost, any ACL is written off and the amortized cost is written down to estimated fair value through a charge within net investment gains (losses), which becomes the new amortized cost of the security.
Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position
Gross unrealized losses on securities without an ACL decreased $3.1$2.4 billion for the threesix months ended March 31,June 30, 2023 to $13.5$14.2 billion primarily due to decreases in interest rates, andimpairments in connection with a pending reinsurance transaction, to a lesser extent the impactstrengthening of strengthening foreign currencies on certain non-functional currency denominated fixed maturity securities partially offset by wideningand narrowing credit spreads.
Gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater were $9.1$12.5 billion at March 31,June 30, 2023, or 68%88% of the total gross unrealized losses on securities without an ACL.
Investment Grade Fixed Maturity Securities AFS
Of the $9.1$12.5 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $8.5$11.9 billion, or 93%95%, were related to 5,2287,025 investment grade securities. Unrealized losses on investment grade securities are principally related to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase.
5759

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Below Investment Grade Fixed Maturity Securities AFS
Of the $9.1$12.5 billion of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater, $634$639 million, or 7%5%, were related to 630727 below investment grade securities. Unrealized losses on below investment grade securities are principally related to foreign corporate and U.S. corporate securities (primarily consumer, transportation consumer and communications). These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty, as well as with respect to fixed-rate securities, rising interest rates since purchase. Management evaluates U.S. corporate and foreign corporate securities based on several factors such as expected cash flows, financial condition and near-term and long-term prospects of the issuers.
Current Period Evaluation
At March 31,June 30, 2023, with respect to securities in an unrealized loss position without an ACL, the Company did not intend to sell these securities, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Based on the Company’s current evaluation of its securities in an unrealized loss position without an ACL, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at March 31,June 30, 2023.
Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation.
Rollforward of Allowance for Credit Loss for Fixed Maturity Securities AFS By Sector
The rollforward of ACL for fixed maturity securities AFS by sector is as follows:
U.S.
 Corporate
Foreign CorporateCMBSForeign
Government
TotalU.S.
 Corporate
Foreign CorporateCMBSForeign
Government
Total
Three Months Ended March 31, 2023(In millions)
Three Months Ended June 30, 2023Three Months Ended June 30, 2023(In millions)
Balance, at beginning of periodBalance, at beginning of period$28 $$15 $68 $114 Balance, at beginning of period$57 $$$68 $135 
ACL not previously recordedACL not previously recorded31 — — — 31 ACL not previously recorded— — — — — 
Changes for securities with previously recorded ACLChanges for securities with previously recorded ACL— — — Changes for securities with previously recorded ACL(1)— 
Securities sold or exchangedSecurities sold or exchanged(2)— (10)— (12)Securities sold or exchanged— — — — — 
Write-offsWrite-offs— — — — — Write-offs— — — — — 
Balance, at end of periodBalance, at end of period$57 $$$68 $135 Balance, at end of period$63 $$$70 $142 
Three Months Ended March 31, 2022
Three Months Ended June 30, 2022Three Months Ended June 30, 2022
Balance, at beginning of periodBalance, at beginning of period$30 $10 $13 $— $53 Balance, at beginning of period$13 $25 $13 $104 $155 
ACL not previously recordedACL not previously recorded13 11 — 104 128 ACL not previously recorded— — — — — 
Changes for securities with previously recorded ACLChanges for securities with previously recorded ACL— — — Changes for securities with previously recorded ACL14 (1)— (7)
Securities sold or exchangedSecurities sold or exchanged(8)— — — (8)Securities sold or exchanged— (17)— (20)(37)
Write-offsWrite-offs(22)— — — (22)Write-offs— — — — — 
Balance, at end of periodBalance, at end of period$13 $25 $13 $104 $155 Balance, at end of period$27 $$13 $77 $124 
5860

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
U.S.
 Corporate
Foreign CorporateCMBSForeign
Government
Total
Six Months Ended June 30, 2023(In millions)
Balance, at beginning of period$28 $$15 $68 $114 
ACL not previously recorded31 — — — 31 
Changes for securities with previously recorded ACL(1)
Securities sold or exchanged(2)— (10)— (12)
Write-offs— — — — — 
Balance, at end of period$63 $$$70 $142 
Six Months Ended June 30, 2022
Balance, at beginning of period$30 $10 $13 $— $53 
ACL not previously recorded13 11 — 104 128 
Changes for securities with previously recorded ACL14 — (7)10 
Securities sold or exchanged(8)(17)— (20)(45)
Write-offs(22)— — — (22)
Balance, at end of period$27 $$13 $77 $124 
Mortgage Loans
Mortgage Loans by Portfolio Segment
Mortgage loans are summarized as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Portfolio SegmentPortfolio SegmentCarrying
Value
% of
Total
Carrying
Value
% of
Total
Portfolio SegmentCarrying
Value
% of
Total
Carrying
Value
% of
Total
(Dollars in millions)(Dollars in millions)
Commercial(1)Commercial(1)$38,262 59.7 %$37,196 59.4 %Commercial(1)$37,910 59.4 %$37,196 59.4 %
AgriculturalAgricultural15,848 24.8 15,869 25.4 Agricultural16,035 25.1 15,869 25.4 
ResidentialResidential10,530 16.4 9,953 15.9 Residential10,391 16.3 9,953 15.9 
Total amortized costTotal amortized cost64,640 100.9 63,018 100.7 Total amortized cost64,336 100.8 63,018 100.7 
Allowance for credit lossAllowance for credit loss(587)(0.9)(448)(0.7)Allowance for credit loss(525)(0.8)(448)(0.7)
Total mortgage loans, net$64,053 100.0 %$62,570 100.0 %
Total mortgage loansTotal mortgage loans$63,811 100.0 %$62,570 100.0 %
__________________
(1)Includes commercial mortgage loans to be disposed of in connection with a pending reinsurance transaction, which are carried at the lower of amortized cost or estimated fair value of $117 million, net of the estimated fair value adjustment of $23 million, as of June 30, 2023. See Note 1.
The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($739)727) million and ($717) million at March 31,June 30, 2023 and December 31, 2022, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at March 31,June 30, 2023 was $185$192 million, $124$141 million and $79$78 million, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at December 31, 2022 was $171 million, $147 million and $70 million, respectively.
Purchases of mortgage loans, from unaffiliated parties, consisting primarily of residential mortgage loans, were $757$100 million and $533$857 million for the three months and six months ended March 31,June 30, 2023, respectively, and $596 million and $1.1 billion for the three months and six months ended June 30, 2022, respectively. See
61

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
During the second quarter of 2023, the Company assigned mortgage loans with a previously recorded amortized cost of $5.3 billion to its affiliated mortgage origination company, which is wholly-owned by MetLife. In connection with the assignment, this affiliate contemporaneously assumed the Company’s rights and obligations associated with the assigned mortgage loans. In exchange, the Company received $5.3 billion of mortgage secured loans from this affiliate, secured by the same mortgage loans assigned. As of June 30, 2023, the Company’s aggregate participation interest in affiliated mortgage secured loans included in commercial and agricultural mortgage loans was $13.0 billion. In addition, see “— Related Party Investment Transactions” for information regarding transfers of mortgage loans from affiliates.
Rollforward of Allowance for Credit Loss for Mortgage Loans by Portfolio Segment
The rollforward of ACL for mortgage loans, by portfolio segment, is as follows:
Three Months Ended March 31,Six Months Ended June 30,
2023202220232022
CommercialAgriculturalResidentialTotalCommercialAgriculturalResidentialTotalCommercialAgriculturalResidentialTotalCommercialAgriculturalResidentialTotal
(In millions)(In millions)
Balance, beginning of periodBalance, beginning of period$174 $105 $169 $448 $260 $79 $197 $536 Balance, beginning of period$174 $105 $169 $448 $260 $79 $197 $536 
Provision (release)Provision (release)79 49 18 146 (11)11 (25)(25)Provision (release)37 48 90 (13)36 (38)(15)
Charge-offs, net of recoveriesCharge-offs, net of recoveries— (7)— (7)— — (1)(1)Charge-offs, net of recoveries— (13)— (13)(82)(22)(1)(105)
Balance, end of periodBalance, end of period$253 $147 $187 $587 $249 $90 $171 $510 Balance, end of period$211 $140 $174 $525 $165 $93 $158 $416 
59

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Allowance for Credit Loss Methodology
The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Mortgage loans to be disposed of in a reinsurance transaction are carried at the lower of amortized cost or estimated fair value.
62

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Commercial and Agricultural Mortgage Loan Portfolio Segments
Commercial and agricultural mortgage loan ACL are calculated in a similar manner. Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans.
60

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans.
For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio.
For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated.
63

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Commitments to lend: After loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that are not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly.
Residential Mortgage Loan Portfolio Segment
The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year.
For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss.
61

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Modifications to Borrowers Experiencing Financial Difficulty
The Company may modify mortgage loans to borrowers. Each mortgage loan modification is evaluated to determine whether the borrower was experiencing financial difficulties. Disclosed below are those modifications where the borrower was determined to be experiencing financial difficulties and the mortgage loans were modified by any of the following means, principal forgiveness, interest rate reduction, other-than-insignificant payment delay or term extension. The amount, timing and extent of modifications granted are considered in determining any ACL recorded.
Commercial mortgage loans:
For the three months ended March 31,June 30, 2023, the Company granted an additional 3-month12-month term extension on a previously restructured loan with an amortized cost of $31 million. This$149 million and further extended the term of the loan modified loan representsin the first quarter of 2023 by an additional three months. These modified loans represent less than 1% of the portfolio segment.
Residential mortgage loans:
For the threesix months ended March 31,June 30, 2023, the Company granted term extensions on loans with an amortized cost of $3 million, term extensions and other-than-insignificant payment delays on loans with an amortized cost$180 million. These modifications added a weighted-average of $4 million and term extensions, other-than-insignificant payment delays and interest rate reductions on loans with an amortized costless than one year to the life of $3 million.the modified loans. These modified loans represent less than 1% of the portfolio segment. These loan modifications added a weighted-average of 11.1 years to the life of the modified loans, allowed for the capitalization or deferral of balances due and reduced the weighted-average interest rate of the modified loans from 5.9% to 4.2%.
All mortgage loans that were modified to borrowers experiencing financial difficulties during the three months ended March 31, 2023, are current.
Credit Quality of Mortgage Loans by Portfolio Segment
The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at March 31, 2023:
Credit Quality Indicator20232022202120202019PriorRevolving
Loans
Total% of
Total
(Dollars in millions)
LTV ratios:
Less than 65%$831 $3,292 $3,200 $2,135 $2,968 $13,873 $2,885 $29,184 76.3 %
65% to 75%— 1,548 1,002 738 1,204 2,276 — 6,768 17.7 
76% to 80%— 310 57 83 168 545 — 1,163 3.0 
Greater than 80%— 82 — 18 250 797 — 1,147 3.0 
Total$831 $5,232 $4,259 $2,974 $4,590 $17,491 $2,885 $38,262 100.0 %
DSCR:
> 1.20x$354 $4,482 $3,820 $2,696 $4,198 $15,694 $2,385 $33,629 87.9 %
1.00x - 1.20x477 516 259 52 178 971 204 2,657 6.9 
<1.00x— 234 180 226 214 826 296 1,976 5.2 
Total$831 $5,232 $4,259 $2,974 $4,590 $17,491 $2,885 $38,262 100.0 %
The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at March 31, 2023:
6264

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Credit Quality Indicator20232022202120202019PriorRevolving
Loans
Total% of
Total
(Dollars in millions)
LTV ratios:
Less than 65%$357 $1,987 $1,500 $1,885 $1,581 $5,970 $1,108 $14,388 90.8 %
65% to 75%87 228 293 24 565 40 1,242 7.8 
76% to 80%— — — — — 11 — 11 0.1 
Greater than 80%— — — 14 133 51 207 1.3 
Total$362 $2,074 $1,728 $2,192 $1,738 $6,597 $1,157 $15,848 100.0 %
Residential mortgage loans:
For the three months ended June 30, 2023, the Company granted term extensions on loans with an amortized cost of $2 million, other-than-insignificant payment delays on loans with an amortized cost of $5 million, term extensions and other-than-insignificant payment delays on loans with an amortized cost of $5 million and term extensions, other-than-insignificant payment delays and interest rate reductions on loans with an amortized cost of $1 million. These modified loans represent less than 1% of the portfolio segment. These loan modifications added a weighted-average of eight years to the life of the modified loans, allowed for the capitalization or deferral of balances due and reduced the weighted average interest rate of the modified loans from 5.7% to 4.2%.
For the six months ended June 30, 2023, the Company granted term extensions on loans with an amortized cost of $5 million, other-than-insignificant payment delays on loans with an amortized cost of $5 million, term extensions and other-than-insignificant payment delays on loans with an amortized cost of $9 million and term extensions, other-than-insignificant payment delays and interest rate reductions on loans with an amortized cost of $4 million. These modified loans represent less than 1% of the portfolio segment. These loan modifications added a weighted-average of nine years to the life of the modified loans, allowed for the capitalization or deferral of balances due and reduced the weighted-average interest rate of the modified loans from 5.8% to 4.2%.
For both the three months and six months ended June 30, 2023, the Company did not have a significant amount of mortgage loans that were modified to borrowers experiencing financial difficulty that are not considered current.
Credit Quality of Mortgage Loans by Portfolio Segment
The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2023:
Credit Quality Indicator20232022202120202019PriorRevolving
Loans
Total% of
Total
(Dollars in millions)
LTV ratios:
Less than 65%$1,096 $2,844 $2,430 $1,250 $2,040 $9,524 $2,927 $22,111 58.3 %
65% to 75%124 1,813 792 951 1,163 3,692 — 8,535 22.5 
76% to 80%— 523 321 91 872 1,117 — 2,924 7.7 
Greater than 80%92 618 666 536 2,422 — 4,340 11.5 
Total$1,226 $5,272 $4,161 $2,958 $4,611 $16,755 $2,927 $37,910 100.0 %
DSCR:
> 1.20x$817 $4,285 $3,938 $2,479 $3,980 $14,307 $1,687 $31,493 83.1 %
1.00x 1.20x409 224 186 18 353 1,320 944 3,454 9.1 
<1.00x— 763 37 461 278 1,128 296 2,963 7.8 
Total$1,226 $5,272 $4,161 $2,958 $4,611 $16,755 $2,927 $37,910 100.0 %
The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2023:
Credit Quality Indicator20232022202120202019PriorRevolving
Loans
Total% of
Total
(Dollars in millions)
LTV ratios:
Less than 65%$590 $1,987 $1,471 $1,973 $1,556 $5,829 $1,146 $14,552 90.7 %
65% to 75%21 91 228 209 24 563 131 1,267 7.9 
76% to 80%— — — — — 11 — 11 0.1 
Greater than 80%17 — — — 133 49 205 1.3 
Total$628 $2,078 $1,699 $2,182 $1,713 $6,452 $1,283 $16,035 100.0 %
65

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at March 31,June 30, 2023:
Credit Quality IndicatorCredit Quality Indicator20232022202120202019PriorRevolving
Loans
Total% of
Total
Credit Quality Indicator20232022202120202019PriorRevolving
Loans
Total% of
Total
(Dollars in millions)(Dollars in millions)
Performance indicators:Performance indicators:Performance indicators:
PerformingPerforming$177 $1,968 $812 $153 $595 $6,423 $— $10,128 96.2 %Performing$196 $1,954 $828 $147 $591 $6,300 $— $10,016 96.4 %
Nonperforming (1)Nonperforming (1)— 14 37 336 — 402 3.8 Nonperforming (1)— 14 10 34 310 — 375 3.6 
TotalTotal$177 $1,982 $821 $159 $632 $6,759 $— $10,530 100.0 %Total$196 $1,968 $838 $154 $625 $6,610 $— $10,391 100.0 %
__________________
(1)Includes residential mortgage loans in process of foreclosure of $150 million and $143 million at both March 31,June 30, 2023 and December 31, 2022.2022, respectively.
LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. The amortized cost of commercial and agricultural mortgage loans with an LTV ratio in excess of 100% was $655$746 million, or 1% of total commercial and agricultural mortgage loans, at March 31,June 30, 2023.
Past Due and Nonaccrual Mortgage Loans
The Company has a high quality, well performing mortgage loan portfolio, with 99% of all mortgage loans classified as performing at both March 31,June 30, 2023 and December 31, 2022. The Company defines delinquency consistent with industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows:
Past DuePast Due
and Still Accruing Interest
NonaccrualPast DuePast Due
and Still Accruing Interest
Nonaccrual
Portfolio SegmentPortfolio SegmentMarch 31, 2023December 31, 2022March 31, 2023December 31, 2022March 31, 2023December 31, 2022Portfolio SegmentJune 30, 2023December 31, 2022June 30, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
CommercialCommercial$22 $— $— $— $170 $158 Commercial$42 $— $— $— $192 $158 
AgriculturalAgricultural96 120 — 18 260 131 Agricultural98 120 22 18 235 131 
ResidentialResidential402 428 — — 404 429 Residential375 428 — — 376 429 
TotalTotal$520 $548 $— $18 $834 $718 Total$515 $548 $22 $18 $803 $718 
The amortized cost for nonaccrual commercial, agricultural and residential mortgage loans at beginning of year 2022 was $146 million, $225 million and $418 million, respectively. The amortized cost for nonaccrual commercial mortgage loans without an ACL was $149 million at June 30, 2023. There were no nonaccrual commercial mortgage loans without an ACL at December 31, 2022. The amortized cost for nonaccrual agricultural mortgage loans with nowithout an ACL was $77$61 million and $7 million at March 31,June 30, 2023 and December 31, 2022, respectively. There were no nonaccrual commercial or residential mortgage loans without an ACL at either March 31,June 30, 2023 orand December 31, 2022.
6366

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Real Estate and Real Estate Joint Ventures
The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method real estate joint ventures. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated:
March 31, 2023December 31, 2022Three Months 
 Ended 
 March 31,
June 30, 2023December 31, 2022Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
20232022December 31, 20222023202220232022
Income TypeIncome TypeCarrying ValueIncomeIncome TypeCarrying ValueIncome
(In millions)(In millions)
Wholly-owned real estate:Wholly-owned real estate:Wholly-owned real estate:
Leased real estateLeased real estate$1,612 $1,618 $42 $54 Leased real estate$1,610 $1,618 $41 $50 $83 $104 
Other real estateOther real estate489 487 46 30 Other real estate490 487 83 66 129 96 
Real estate joint venturesReal estate joint ventures6,391 6,311 (36)110 Real estate joint ventures6,393 6,311 (7)122 (43)232 
Total real estate and real estate joint venturesTotal real estate and real estate joint ventures$8,492 $8,416 $52 $194 Total real estate and real estate joint ventures$8,493 $8,416 $117 $238 $169 $432 
The carrying value of wholly-owned real estate acquired through foreclosure was $184$185 million and $179 million at March 31,June 30, 2023 and December 31, 2022, respectively. Depreciation expense on real estate investments was $20$22 million for both the three months ended March 31,June 30, 2023 and 2022, and $42 million for both thesix months ended June 30, 2023 and 2022. Real estate investments were net of accumulated depreciation of $586$608 million and $566 million at March 31,June 30, 2023 and December 31, 2022, respectively.
Leases
Leased Real Estate Investments - Operating Leases
The Company, as lessor, leases investment real estate, principally commercial real estate for office, apartment and retail use, through a variety of operating lease arrangements, which typically include tenant reimbursement for property operating costs and options to renew or extend the lease. In some circumstances, leases may include an option for the lessee to purchase the property. In addition, certain leases of retail space may stipulate that a portion of the income earned is contingent upon the level of the tenants’ revenues. The Company has elected a practical expedient of not separating non-lease components related to reimbursement of property operating costs from associated lease components. These property operating costs have the same timing and pattern of transfer as the related lease component, because they are incurred over the same period of time as the operating lease. Therefore, the combined component is accounted for as a single operating lease. Risk is managed through lessee credit analysis, property type diversification, and geographic diversification.
See Note 7 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report for a summary of leased real estate investments and income earned, by property type.
Leveraged and Direct Financing Leases
The Company has diversified leveraged and direct financing lease portfolios. Its leveraged leases principally include rail cars, commercial real estate and renewable energy generation facilities, and its direct financing leases principally include renewable energy generation facilities. These assets are leased through a variety of lease arrangements, which may include options to renew or extend the lease and options for the lessee to purchase the property. Residual values are estimated using available third-party data at inception of the lease. Risk is managed through lessee credit analysis, asset allocation, geographic diversification, and ongoing reviews of estimated residual values, using available third-party data. Generally, estimated residual values are not guaranteed by the lessee or a third party.
Lease receivables are generally due in periodic installments. The payment periods for leveraged leases generally range from one to nine years, but in certain circumstances can be over nine years, while the payment periods for direct financing leases generally range from one to 11 years.
6467

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
The Company records an allowance for expected lifetime credit loss in earnings within investment gains (losses) in an amount that represents the portion of the investment in leases that the Company does not expect to collect, resulting in the investment in leases being presented at the net amount expected to be collected. In determining the ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling leases that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of the lease, and (iii) considering past events and current and forecasted economic conditions. Leases with dissimilar risk characteristics are evaluated individually for credit loss. Expected lifetime credit loss on leveraged and direct financing lease receivables is estimated using a probability of default and loss given default model, where the probability of default incorporates third party credit ratings of the lessee and the related historical default data. The Company also assesses the non-guaranteed residual values for recoverability by comparison to the current estimated fair value of the leased asset and considers other relevant market information such as independent third-party forecasts, consulting, asset brokerage and investment banking reports and data, comparable market transactions, and factors such as the competitive dynamics impacting specific industries, technological change and obsolescence, government and regulatory rules, tax policy, potential environmental liabilities and litigation.
The investment in leveraged and direct financing leases, net of ACL, was $725$724 million and $123$122 million, respectively, at March 31,June 30, 2023 and $731 million and $127 million, respectively, at December 31, 2022. The ACL for leveraged and direct financing leases was $14$12 million and $19 million at March 31,June 30, 2023 and December 31, 2022, respectively.
Other Invested Assets
See Note 1 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report for further information about Other Invested Assets, which includes securities accounted for under the FVO and equity securities.
FVO Securities and Equity Securities
The following table presents FVO Securities and equity securities by security type. Common stock includes common stock and certain mutual funds. FVO Securities includes fixed maturity and equity securities to support asset and liability management strategies for certain insurance products and investments in certain separate accounts.
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
CostNet Unrealized Gains (Losses) (1)Estimated Fair ValueCostNet Unrealized Gains (Losses) (1)Estimated Fair ValueCostNet Unrealized Gains (Losses) (1)Estimated Fair ValueCostNet Unrealized Gains (Losses) (1)Estimated Fair Value
Security TypeSecurity TypeSecurity Type
(In millions)(In millions)
FVO SecuritiesFVO Securities$657 $235 $892 $673 $171 $844 FVO Securities$643 $294 $937 $673 $171 $844 
Equity securitiesEquity securitiesEquity securities
Common stockCommon stock$121 $45 $166 $119 $47 $166 Common stock$121 $47 $168 $119 $47 $166 
Non-redeemable preferred stockNon-redeemable preferred stock62 (3)59 77 (3)74 Non-redeemable preferred stock49 50 77 (3)74 
Total equity securitiesTotal equity securities$183 $42 $225 $196 $44 $240 Total equity securities$170 $48 $218 $196 $44 $240 
__________________
(1)Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI.
Cash Equivalents
Cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was $3.32.1 billion and $6.6 billion, principally at estimated fair value, at March 31,June 30, 2023 and December 31, 2022, respectively.
Concentrations of Credit Risk
There were no investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at both March 31,June 30, 2023 and December 31, 2022.
6568

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Securities Lending Transactions and Repurchase Agreements
Securities, Collateral and Reinvestment Portfolio
A summary of these transactions and agreements accounted for as secured borrowings were as follows:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Securities (1)Securities (1)Securities (1)Securities (1)
Agreement TypeAgreement TypeEstimated Fair ValueCash Collateral Received from Counterparties (2)Reinvestment Portfolio at Estimated
Fair Value
Estimated Fair ValueCash Collateral Received from Counterparties (2)Reinvestment Portfolio at Estimated
Fair Value
Agreement TypeEstimated Fair ValueCash Collateral Received from Counterparties (2)Reinvestment Portfolio at Estimated
Fair Value
Estimated Fair ValueCash Collateral Received from Counterparties (2)Reinvestment Portfolio at Estimated
Fair Value
(In millions)(In millions)
Securities lendingSecurities lending$6,442 $6,521 $6,372 $6,601 $6,773 $6,625 Securities lending$6,047 $6,148 $5,998 $6,601 $6,773 $6,625 
Repurchase agreementsRepurchase agreements$3,209 $3,125 $3,054 $3,176 $3,125 $3,057 Repurchase agreements$3,176 $3,100 $3,024 $3,176 $3,125 $3,057 
__________________
(1)These securities were included within fixed maturity securities AFS and cash equivalents at March 31, 2023 and within fixed maturity securities AFS and short-term investments at both June 30, 2023 and December 31, 2022.
(2)The liability for cash collateral is included within payables for collateral under securities loaned and other transactions.
Contractual Maturities
Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Remaining MaturitiesRemaining MaturitiesRemaining MaturitiesRemaining Maturities
Security TypeSecurity TypeOpen (1)1 Month
or Less
Over 1
 Month to 6
Months
Over 6 
Months
 to 1 Year
TotalOpen (1)1 Month
or Less
Over 1
Month to 6
Months
Over 6 Months to 1 YearTotalSecurity TypeOpen (1)1 Month
or Less
Over 1
 Month to 6
Months
Over 6 
Months
 to 1 Year
TotalOpen (1)1 Month
or Less
Over 1
Month to 6
Months
Over 6 Months to 1 YearTotal
(In millions)(In millions)
Cash collateral liability by security type:Cash collateral liability by security type:Cash collateral liability by security type:
Securities lending:Securities lending:Securities lending:
U.S. government and agencyU.S. government and agency$1,122 $2,414 $2,985 $— $6,521 $935 $4,233 $1,605 $— $6,773 U.S. government and agency$976 $2,450 $2,722 $— $6,148 $935 $4,233 $1,605 $— $6,773 
Repurchase agreements:Repurchase agreements:Repurchase agreements:
U.S. government and agencyU.S. government and agency$— $3,125 $— $— $3,125 $— $3,125 $— $— $3,125 U.S. government and agency$— $3,100 $— $— $3,100 $— $3,125 $— $— $3,125 
__________________
(1)The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.
If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell investments to meet the return obligation, it may have difficulty selling such collateral that is invested in a timely manner, be forced to sell investments in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both.
The securities lending and repurchase agreements reinvestment portfolios consist principally of high quality, liquid, publicly-traded fixed maturity securities AFS, short-term investments, cash equivalents or cash. If the securities or the reinvestment portfolio become less liquid, liquidity resources within the general account are available to meet any potential cash demands when securities are put back by the counterparty.
Invested Assets on Deposit and Pledged as Collateral
Invested assets on deposit and pledged as collateral are presented below at estimated fair value for all asset classes,
6669

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
except mortgage loans, which are presented at carrying value, and were as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
Invested assets on deposit (regulatory deposits)Invested assets on deposit (regulatory deposits)$101 $98 Invested assets on deposit (regulatory deposits)$102 $98 
Invested assets pledged as collateral (1)Invested assets pledged as collateral (1)22,097 20,612 Invested assets pledged as collateral (1)21,723 20,612 
Total invested assets on deposit and pledged as collateralTotal invested assets on deposit and pledged as collateral$22,198 $20,710 Total invested assets on deposit and pledged as collateral$21,825 $20,710 
__________________
(1)The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements, secured debt (see Notes 3 and 11 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report) and derivative transactions (see Note 10).
See “— Securities Lending Transactions and Repurchase Agreements” for information regarding securities supporting securities lending transactions and repurchase agreements, and Note 8 for information regarding investments designated to the closed block.block and Note 1 for investments to be disposed of in a pending reinsurance transaction. In addition, the Company’s investment in Federal Home Loan Bank of New York common stock, included within other invested assets, which is considered restricted until redeemed by the issuer, was $668 million and $659 million, at redemption value, at March 31,June 30, 2023 and December 31, 2022, respectively.
Variable Interest Entities
The Company has invested in legal entities that are VIEs. In certain instances, the Company holds both the power to direct the most significant activities of the entity, as well as an economic interest in the entity and, as such, is deemed to be the primary beneficiary or consolidator of the entity. The determination of the VIE’s primary beneficiary requires an evaluation of the contractual and implied rights and obligations associated with each party’s relationship with or involvement in the entity.
Consolidated VIEs
Creditors or beneficial interest holders of VIEs where the Company is the primary beneficiary have no recourse to the general credit of the Company, as the Company’s obligation to the VIEs is limited to the amount of its committed investment.
The following table presents the total assets and total liabilities relating to investment-related VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at:
March 31, 2023December 31, 2022
Asset TypeTotal
Assets
Total
Liabilities
Total
Assets
Total
Liabilities
(In millions)
Real estate joint ventures$1,380 $— $1,357 $— 
Mortgage loan joint ventures150 — 147 — 
Investment funds (primarily other invested assets)98 — 98 — 
Renewable energy partnership (primarily other invested assets)72 — 76 — 
Total$1,700 $— $1,678 $— 
__________________
June 30, 2023December 31, 2022
Asset TypeTotal
Assets
Total
Liabilities
Total
Assets
Total
Liabilities
(In millions)
Real estate joint ventures$1,329 $— $1,357 $— 
Mortgage loan joint ventures159 — 147 — 
Investment funds (primarily other invested assets)100 98 — 
Renewable energy partnership (primarily other invested assets)68 — 76 — 
Total$1,656 $$1,678 $— 
6770

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Unconsolidated VIEs
The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Asset TypeAsset TypeCarrying
Amount
Maximum
Exposure
to Loss (1)
Carrying
Amount
Maximum
Exposure
to Loss (1)
Asset TypeCarrying
Amount
Maximum
Exposure
to Loss (1)
Carrying
Amount
Maximum
Exposure
to Loss (1)
(In millions)(In millions)
Fixed maturity securities AFS (2)Fixed maturity securities AFS (2)$37,055 $37,055 $35,813 $35,813 Fixed maturity securities AFS (2)$37,047 $37,047 $35,813 $35,813 
Other limited partnership interestsOther limited partnership interests7,285 9,686 7,299 9,716 Other limited partnership interests7,391 9,647 7,299 9,716 
Other invested assetsOther invested assets1,339 1,499 1,342 1,509 Other invested assets1,331 1,432 1,342 1,509 
Real estate joint venturesReal estate joint ventures114 117 86 88 Real estate joint ventures128 291 86 88 
TotalTotal$45,793 $48,357 $44,540 $47,126 Total$45,897 $48,417 $44,540 $47,126 
__________________
(1)The maximum exposure to loss relating to fixed maturity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests (“OLPI”) and real estate joint ventures (“REJV”) is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee.
(2)For variable interests in Structured Products included within fixed maturity securities AFS, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.
As described in Note 16, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to investees designated as VIEs for either the threesix months ended March 31,June 30, 2023 or 2022.
6871

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Net Investment Income
The composition of net investment income by asset type was as follows:
Three Months 
 Ended 
 March 31,
Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
Asset TypeAsset Type20232022Asset Type2023202220232022
(In millions)(In millions)
Fixed maturity securities AFSFixed maturity securities AFS$1,846 $1,501 Fixed maturity securities AFS$1,897 $1,543 $3,743 $3,044 
Equity securitiesEquity securitiesEquity securities
Mortgage loansMortgage loans790 613 Mortgage loans829 605 1,619 1,218 
Policy loansPolicy loans73 72 Policy loans75 72 148 144 
Real estate and real estate joint ventures52 194 
Other limited partnership interests533 
Real estate and REJVReal estate and REJV117 238 169 432 
OLPIOLPI91 64 92 597 
Cash, cash equivalents and short-term investmentsCash, cash equivalents and short-term investments84 Cash, cash equivalents and short-term investments89 11 173 15 
FVO SecuritiesFVO Securities50 (29)FVO Securities46 (113)96 (142)
Operating joint ventureOperating joint venture14 16 Operating joint venture26 21 42 
OtherOther79 69 Other46 185 125 254 
Subtotal investment incomeSubtotal investment income2,990 2,974 Subtotal investment income3,201 2,632 6,191 5,606 
Less: Investment expensesLess: Investment expenses305 148 Less: Investment expenses328 190 633 338 
Net investment incomeNet investment income$2,685 $2,826 Net investment income$2,873 $2,442 $5,558 $5,268 
Net Investment Income (“NII”) InformationNet Investment Income (“NII”) InformationNet Investment Income (“NII”) Information
Net realized and unrealized gains (losses) recognized in NII:Net realized and unrealized gains (losses) recognized in NII:Net realized and unrealized gains (losses) recognized in NII:
Net realized gains (losses) from sales and disposalsNet realized gains (losses) from sales and disposals$— $— Net realized gains (losses) from sales and disposals$— $(4)$— $(4)
Net unrealized gains (losses) from changes in estimated fair value (primarily FVO Securities and real estate joint ventures)58 18 
Net unrealized gains (losses) from changes in estimated fair value (primarily FVO Securities and REJV)Net unrealized gains (losses) from changes in estimated fair value (primarily FVO Securities and REJV)76 (75)134 (57)
Net realized and unrealized gains (losses) recognized in NIINet realized and unrealized gains (losses) recognized in NII$58 $18 Net realized and unrealized gains (losses) recognized in NII$76 $(79)$134 $(61)
Changes in estimated fair value subsequent to purchase of FVO Securities still held at the end of the respective periods and recognized in NIIChanges in estimated fair value subsequent to purchase of FVO Securities still held at the end of the respective periods and recognized in NII$47 $(32)Changes in estimated fair value subsequent to purchase of FVO Securities still held at the end of the respective periods and recognized in NII$45 $(114)$92 $(147)
Equity method investments NII (primarily real estate joint ventures, other limited partnership interests, tax credit and renewable energy partnerships and an operating joint venture)$(38)$617 
Equity method investments NII (primarily REJV, OLPI, tax credit and renewable energy partnerships and an operating joint venture)Equity method investments NII (primarily REJV, OLPI, tax credit and renewable energy partnerships and an operating joint venture)$65 $188 $27 $805 
6972

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Net Investment Gains (Losses)
Net Investment Gains (Losses) by Asset Type and Transaction Type
The composition of net investment gains (losses) by asset type and transaction type was as follows:
Three Months 
 Ended 
 March 31,
Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
Asset TypeAsset Type20232022Asset Type2023202220232022
(In millions)(In millions)
Fixed maturity securities AFS(1)Fixed maturity securities AFS(1)$52 $(302)Fixed maturity securities AFS(1)$(746)$(356)$(694)$(658)
Equity securitiesEquity securities(5)Equity securities
Mortgage loans(1)Mortgage loans(1)(149)23 Mortgage loans(1)33 (13)(116)10 
Real estate and real estate joint ventures (excluding changes in estimated fair value)
Other limited partnership interests (excluding changes in estimated fair value)
Real estate and REJV (excluding changes in estimated fair value)Real estate and REJV (excluding changes in estimated fair value)62 159 64 163 
OLPI (excluding changes in estimated fair value)OLPI (excluding changes in estimated fair value)
Other gains (losses)Other gains (losses)17 Other gains (losses)49 14 66 
SubtotalSubtotal(87)(252)Subtotal(634)(158)(721)(410)
Change in estimated fair value of other limited partnership interests and real estate joint ventures(5)
Change in estimated fair value of OLPI and REJVChange in estimated fair value of OLPI and REJV— (4)
Non-investment portfolio gains (losses)Non-investment portfolio gains (losses)(10)20 Non-investment portfolio gains (losses)(26)75 (36)95 
SubtotalSubtotal(15)26 Subtotal(25)75 (40)101 
Net investment gains (losses)Net investment gains (losses)$(102)$(226)Net investment gains (losses)$(659)$(83)$(761)$(309)
Transaction TypeTransaction TypeTransaction Type
Realized gains (losses) on investments sold or disposedRealized gains (losses) on investments sold or disposed$83 $(148)Realized gains (losses) on investments sold or disposed$(3)$(183)$80 $(331)
Impairment (losses)(1)Impairment (losses)(1)(6)(33)Impairment (losses)(1)(684)— (690)(33)
Recognized gains (losses):Recognized gains (losses):Recognized gains (losses):
Change in allowance for credit loss recognized in earningsChange in allowance for credit loss recognized in earnings(162)(80)Change in allowance for credit loss recognized in earnings47 29 (115)(51)
Unrealized net gains (losses) recognized in earningsUnrealized net gains (losses) recognized in earnings(7)15 Unrealized net gains (losses) recognized in earnings(4)— 11 
Total recognized gains (losses)Total recognized gains (losses)(92)(246)Total recognized gains (losses)54 25 (115)(40)
Non-investment portfolio gains (losses)Non-investment portfolio gains (losses)(10)20 Non-investment portfolio gains (losses)(26)75 (36)95 
Net investment gains (losses)Net investment gains (losses)$(102)$(226)Net investment gains (losses)$(659)$(83)$(761)$(309)
Net Investment Gains (Losses) (“NIGL”) InformationNet Investment Gains (Losses) (“NIGL”) InformationNet Investment Gains (Losses) (“NIGL”) Information
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in NIGLChanges in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in NIGL$(3)$Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in NIGL$$(1)$$
Other gains (losses) include:Other gains (losses) include:
Gains (losses) on disposed investments which were previously in a qualified cash flow hedge relationshipGains (losses) on disposed investments which were previously in a qualified cash flow hedge relationship$(27)$52 $(25)$70 
Foreign currency gains (losses)Foreign currency gains (losses)$(15)$12 Foreign currency gains (losses)$(36)$54 $(51)$66 
Net Realized Investment Gains (Losses) From Sales and Disposals of Investments:Net Realized Investment Gains (Losses) From Sales and Disposals of Investments:Net Realized Investment Gains (Losses) From Sales and Disposals of Investments:
Recognized in NIGLRecognized in NIGL$83 $(148)Recognized in NIGL$(3)$(183)$80 $(331)
Recognized in NIIRecognized in NII— — Recognized in NII— (4)— (4)
Net realized investment gains (losses) from sales and disposals of investmentsNet realized investment gains (losses) from sales and disposals of investments$83 $(148)Net realized investment gains (losses) from sales and disposals of investments$(3)$(187)$80 $(335)
__________________
(1) Includes ($654) million and ($23) million of impairments for fixed maturity securities AFS and the lower of amortized cost or estimated fair value adjustments for mortgage loans, respectively, during the three months ended June 30, 2023, for investments to be disposed of in a pending reinsurance transaction. See Note 1.
7073

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Investments (continued)
Fixed Maturity Securities AFS and Equity Securities – Composition of Net Investment Gains (Losses)
The composition of net investment gains (losses) for these securities is as follows:
Three Months 
 Ended 
 March 31,
Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
Fixed Maturity Securities AFSFixed Maturity Securities AFS20232022Fixed Maturity Securities AFS2023202220232022
(In millions)(In millions)
ProceedsProceeds$8,422 $7,489 Proceeds$3,291 $12,499 $11,713 $19,988 
Gross investment gainsGross investment gains$239 $25 Gross investment gains$27 $45 $266 $70 
Gross investment (losses)Gross investment (losses)(160)(191)Gross investment (losses)(102)(432)(262)(623)
Realized gains (losses) on sales and disposalsRealized gains (losses) on sales and disposals79 (166)Realized gains (losses) on sales and disposals(75)(387)(553)
Net credit loss (provision) release (change in ACL recognized in earnings)Net credit loss (provision) release (change in ACL recognized in earnings)(21)(103)Net credit loss (provision) release (change in ACL recognized in earnings)(10)31 (31)(72)
Impairment (losses)Impairment (losses)(6)(33)Impairment (losses)(661)— (667)(33)
Net credit loss (provision) release and impairment (losses)Net credit loss (provision) release and impairment (losses)(27)(136)Net credit loss (provision) release and impairment (losses)(671)31 (698)(105)
Net investment gains (losses)Net investment gains (losses)$52 $(302)Net investment gains (losses)$(746)$(356)$(694)$(658)
Equity SecuritiesEquity SecuritiesEquity Securities
Realized gains (losses) on sales and disposalsRealized gains (losses) on sales and disposals$(2)$(7)Realized gains (losses) on sales and disposals$— $$(2)$(4)
Unrealized net gains (losses) recognized in earningsUnrealized net gains (losses) recognized in earnings(3)10 Unrealized net gains (losses) recognized in earnings(2)
Net investment gains (losses)Net investment gains (losses)$(5)$Net investment gains (losses)$$$$
Related Party Investment Transactions
The Company transfers invested assets primarily consisting of fixed maturity securities AFS, mortgage loans and real estate and real estate joint ventures to and from affiliates. Invested assets transferred were as follows:
Three Months 
 Ended 
 March 31,
Three Months
Ended
June 30,
Six Months
Ended
June 30,
202320222023202220232022
(In millions)(In millions)
Estimated fair value of invested assets transferred to affiliatesEstimated fair value of invested assets transferred to affiliates$— $189 Estimated fair value of invested assets transferred to affiliates$$— $$189 
Amortized cost of invested assets transferred to affiliatesAmortized cost of invested assets transferred to affiliates$— $191 Amortized cost of invested assets transferred to affiliates$$— $$191 
Net investment gains (losses) recognized on transfersNet investment gains (losses) recognized on transfers$— $(2)Net investment gains (losses) recognized on transfers$— $— $— $(2)
Estimated fair value of invested assets transferred from affiliatesEstimated fair value of invested assets transferred from affiliates$515 $257 Estimated fair value of invested assets transferred from affiliates$645 $$1,160 $266 
Recurring related party investments and related net investment income were as follows at and for the periods ended:
March 31, 2023December 31, 2022Three Months 
 Ended 
 March 31,
June 30, 2023December 31, 2022Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
20232022December 31, 20222023202220232022
Investment Type/
Balance Sheet Category
Investment Type/
Balance Sheet Category
Related PartyCarrying ValueNet Investment IncomeInvestment Type/
Balance Sheet Category
Related PartyCarrying ValueNet Investment Income
(In millions)(In millions)
Affiliated investments (1)Affiliated investments (1)MetLife, Inc.$1,197 $1,207 $$Affiliated investments (1)MetLife, Inc.$1,102 $1,207 $$$10 $10 
Affiliated investments (2)Affiliated investments (2)American Life Insurance Company100 100 — — Affiliated investments (2)American Life Insurance Company— 100 
Other invested assetsOther invested assets$1,297 $1,307 $$Other invested assets$1,102 $1,307 $$$11 $11 
________________
(1)Represents an investment in affiliated senior unsecured notes which have maturity dates from July 2023 to December 2031 and bear interest, payable semi-annually, at rates per annum ranging from 1.60% to 1.85%. In July 2023, ¥37.3 billion (the equivalent of $258 million) of 1.60% affiliated senior unsecured notes matured and were refinanced with ¥37.3 billion 2.16% affiliated senior unsecured notes due July 2030. See Note 7 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report for further information.
(2)Represents an affiliated surplus note which matureswas prepaid in June 2023. The surplus note had an original maturity date in June 2025 and bearsbore interest, payable semi-annually, at a rate per annum of 1.88%.
The Company incurred investment advisory charges from an affiliate of $68$69 million and $137 million for each of the three months and six months ended March 31,June 30, 2023, respectively, and 2022.$68 million and $136 million for the three months and six months ended June 30, 2022, respectively.
See “— Variable Interest Entities” for information on investments in affiliated real estate joint ventures and affiliated mortgage loan joint ventures.
See “— Related Party Reinsurance Transactions” in Note 17 for information about affiliated funds withheld.
10. Derivatives
Accounting for Derivatives
See Note 1 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report for a description of the Company’s accounting policies for derivatives and Note 11 for information about the fair value hierarchy for derivatives.
Derivative Strategies
Types of Derivative Instruments and Derivative Strategies
The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Commonly used derivative instruments include, but are not limited to:    
Interest rate derivatives: swaps, total return swaps, caps, floors, futures, swaptions, forwards and synthetic GICs;
Foreign currency exchange rate derivatives: swaps and forwards;
Credit derivatives: purchased or written single name or index credit default swaps, and forwards; and
Equity derivatives: index options, variance swaps, exchange-traded futures and total return swaps.        
For detailed information on these contracts and the related strategies, see Note 8 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report.
7174

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
Primary Risks Managed by Derivatives
The following table presents the primary underlying risk exposure, gross notional amount, and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Primary Underlying Risk Exposure
Gross
Notional
Amount
Estimated Fair Value
Gross
Notional
Amount
Estimated Fair ValuePrimary Underlying Risk Exposure
Gross
Notional
Amount
Estimated Fair Value
Gross
Notional
Amount
Estimated Fair Value
AssetsLiabilitiesAssetsLiabilitiesAssetsLiabilitiesAssetsLiabilities
(In millions)(In millions)
Derivatives Designated as Hedging Instruments:Derivatives Designated as Hedging Instruments:Derivatives Designated as Hedging Instruments:
Fair value hedges:Fair value hedges:Fair value hedges:
Interest rate swapsInterest rate swapsInterest rate$4,036 $1,394 $384 $4,036 $1,353 $443 Interest rate swapsInterest rate$3,973 $1,310 $472 $4,036 $1,353 $443 
Foreign currency swapsForeign currency swapsForeign currency exchange rate565 59 — 565 74 — Foreign currency swapsForeign currency exchange rate1,459 65 — 565 74 — 
SubtotalSubtotal4,601 1,453 384 4,601 1,427 443 Subtotal5,432 1,375 472 4,601 1,427 443 
Cash flow hedges:Cash flow hedges:Cash flow hedges:
Interest rate swapsInterest rate swapsInterest rate3,739 42 189 3,739 239 Interest rate swapsInterest rate3,739 10 218 3,739 239 
Interest rate forwardsInterest rate forwardsInterest rate1,932 — 284 2,227 — 404 Interest rate forwardsInterest rate1,687 — 292 2,227 — 404 
Foreign currency swapsForeign currency swapsForeign currency exchange rate29,402 2,404 1,040 29,290 2,453 1,364 Foreign currency swapsForeign currency exchange rate29,766 2,392 907 29,290 2,453 1,364 
SubtotalSubtotal35,073 2,446 1,513 35,256 2,460 2,007 Subtotal35,192 2,402 1,417 35,256 2,460 2,007 
Total qualifying hedgesTotal qualifying hedges39,674 3,899 1,897 39,857 3,887 2,450 Total qualifying hedges40,624 3,777 1,889 39,857 3,887 2,450 
Derivatives Not Designated or Not Qualifying as Hedging Instruments:Derivatives Not Designated or Not Qualifying as Hedging Instruments:Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate swapsInterest rate swapsInterest rate14,602 1,640 607 15,358 1,579 704 Interest rate swapsInterest rate14,627 1,479 689 15,358 1,579 704 
Interest rate floorsInterest rate floorsInterest rate21,495 128 — 23,371 114 — Interest rate floorsInterest rate18,246 50 — 23,371 114 — 
Interest rate capsInterest rate capsInterest rate41,290 698 — 46,666 903 — Interest rate capsInterest rate41,040 749 — 46,666 903 — 
Interest rate futuresInterest rate futuresInterest rate265 — 414 — Interest rate futuresInterest rate58 — — 414 — 
Interest rate optionsInterest rate optionsInterest rate39,806 393 — 39,712 434 36 Interest rate optionsInterest rate38,636 275 39,712 434 36 
Synthetic GICsSynthetic GICsInterest rate10,525 — — 13,044 — — Synthetic GICsInterest rate10,629 — — 13,044 — — 
Foreign currency swapsForeign currency swapsForeign currency exchange rate4,612 621 12 4,739 720 Foreign currency swapsForeign currency exchange rate4,555 583 25 4,739 720 
Foreign currency forwardsForeign currency forwardsForeign currency exchange rate1,398 15 17 1,328 16 25 Foreign currency forwardsForeign currency exchange rate1,118 1,328 16 25 
Credit default swaps — purchasedCredit default swaps — purchasedCredit804 11 843 16 — Credit default swaps — purchasedCredit804 843 16 — 
Credit default swaps — writtenCredit default swaps — writtenCredit10,335 112 18 9,074 113 26 Credit default swaps — writtenCredit10,910 161 12 9,074 113 26 
Equity futuresEquity futuresEquity market1,110 16 1,063 — Equity futuresEquity market1,214 13 1,063 — 
Equity index optionsEquity index optionsEquity market15,756 499 177 14,143 585 179 Equity index optionsEquity market17,069 396 197 14,143 585 179 
Equity variance swapsEquity variance swapsEquity market90 — 90 — Equity variance swapsEquity market90 — 90 — 
Equity total return swapsEquity total return swapsEquity market1,980 26 24 1,922 23 103 Equity total return swapsEquity market1,980 — 88 1,922 23 103 
Total non-designated or nonqualifying derivativesTotal non-designated or nonqualifying derivatives164,068 4,150 872 171,767 4,509 1,079 Total non-designated or nonqualifying derivatives160,976 3,715 1,044 171,767 4,509 1,079 
TotalTotal$203,742 $8,049 $2,769 $211,624 $8,396 $3,529 Total$201,600 $7,492 $2,933 $211,624 $8,396 $3,529 
Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship at both March 31,June 30, 2023 and December 31, 2022. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge MRBs that do not qualify for hedge accounting because the changes in estimated fair value of the MRBs are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged.
7275

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, nonqualifying hedging relationships and embedded derivatives:
Three Months Ended March 31, 2023Three Months Ended June 30, 2023
Net
Investment
Income
Net
Investment
Gains
(Losses)
Net
Derivative
Gains
(Losses)
Policyholder
Benefits and
Claims
Interest Credited to Policyholder Account BalancesOCINet
Investment
Income
Net
Investment
Gains
(Losses)
Net
Derivative
Gains
(Losses)
Policyholder
Benefits and
Claims
Interest Credited to Policyholder Account BalancesOther Comprehensive Income (Loss)
(In millions)(In millions)
Gain (Loss) on Fair Value Hedges:Gain (Loss) on Fair Value Hedges:Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:Interest rate derivatives:Interest rate derivatives:
Derivatives designated as hedging instruments (1)Derivatives designated as hedging instruments (1)$(1)$— $— $126 $32 N/ADerivatives designated as hedging instruments (1)$— $— $— $(135)$(32)N/A
Hedged itemsHedged items— — (126)(32)N/AHedged items(1)— — 121 31 N/A
Foreign currency exchange rate derivatives:Foreign currency exchange rate derivatives:Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)Derivatives designated as hedging instruments (1)(16)— — — — N/ADerivatives designated as hedging instruments (1)(6)— — — 13 N/A
Hedged itemsHedged items16 — — — — N/AHedged items— — — (11)N/A
SubtotalSubtotal— — — — — N/ASubtotal(2)— — (14)N/A
Gain (Loss) on Cash Flow Hedges:Gain (Loss) on Cash Flow Hedges:Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)Interest rate derivatives: (1)Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIAmount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A$200 Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A$(156)
Amount of gains (losses) reclassified from AOCI into incomeAmount of gains (losses) reclassified from AOCI into income14 — — — (16)Amount of gains (losses) reclassified from AOCI into income13 55 — — — (68)
Foreign currency exchange rate derivatives: (1)Foreign currency exchange rate derivatives: (1)Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCIAmount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A(41)Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A56 
Amount of gains (losses) reclassified from AOCI into incomeAmount of gains (losses) reclassified from AOCI into income129 — — — (130)Amount of gains (losses) reclassified from AOCI into income310 — — — (311)
Foreign currency transaction gains (losses) on hedged itemsForeign currency transaction gains (losses) on hedged items— (124)— — — — Foreign currency transaction gains (losses) on hedged items— (293)— — — — 
Credit derivatives: (1)Credit derivatives: (1)
Amount of gains (losses) deferred in AOCIAmount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A(1)
Amount of gains (losses) reclassified from AOCI into incomeAmount of gains (losses) reclassified from AOCI into income— — — — — — 
SubtotalSubtotal15 — — — 13 Subtotal14 72 — — — (480)
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)Interest rate derivatives (1)— — (61)— — N/AInterest rate derivatives (1)— — (336)— — N/A
Foreign currency exchange rate derivatives (1)Foreign currency exchange rate derivatives (1)— — (95)— — N/AForeign currency exchange rate derivatives (1)— — (44)— — N/A
Credit derivatives — purchased (1)Credit derivatives — purchased (1)— — (9)— — N/ACredit derivatives — purchased (1)— — (8)— — N/A
Credit derivatives — written (1)Credit derivatives — written (1)— — — — N/ACredit derivatives — written (1)— — 60 — — N/A
Equity derivatives (1)Equity derivatives (1)(6)— (403)— — N/AEquity derivatives (1)(36)— (348)— — N/A
Foreign currency transaction gains (losses) on hedged itemsForeign currency transaction gains (losses) on hedged items— — 32 — — N/AForeign currency transaction gains (losses) on hedged items— — 39 — — N/A
SubtotalSubtotal(6)— (530)— — N/ASubtotal(36)— (637)— — N/A
Earned income on derivativesEarned income on derivatives43 — 245 (33)— Earned income on derivatives39 — 189 (34)— 
Synthetic GICsSynthetic GICsN/AN/AN/AN/AN/ASynthetic GICsN/AN/AN/AN/AN/A
Embedded derivativesEmbedded derivativesN/AN/A(280)— N/AN/AEmbedded derivativesN/AN/A212 — N/AN/A
TotalTotal$52 $$(560)$$(33)$13 Total$15 $72 $(232)$(11)$(33)$(480)
7376

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
Three Months Ended March 31, 2022Three Months Ended June 30, 2022
Net Investment IncomeNet Investment Gains (Losses)Net Derivative Gains (Losses)Policyholder Benefits and ClaimsInterest Credited to Policyholder Account BalancesOCINet Investment IncomeNet Investment Gains (Losses)Net Derivative Gains (Losses)Policyholder Benefits and ClaimsInterest Credited to Policyholder Account BalancesOther Comprehensive Income (Loss)
(In millions)(In millions)
Gain (Loss) on Fair Value Hedges:Gain (Loss) on Fair Value Hedges:Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:Interest rate derivatives:Interest rate derivatives:
Derivatives designated as hedging instruments (1)Derivatives designated as hedging instruments (1)$$— $— $(373)$(76)N/ADerivatives designated as hedging instruments (1)$$— $— $(323)$(82)N/A
Hedged itemsHedged items(4)— — 357 75 N/AHedged items(4)— — 306 78 N/A
Foreign currency exchange rate derivatives:Foreign currency exchange rate derivatives:Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)Derivatives designated as hedging instruments (1)31 — — — — N/ADerivatives designated as hedging instruments (1)59 — — — — N/A
Hedged itemsHedged items(29)— — — — N/AHedged items(58)— — — — N/A
SubtotalSubtotal— — (16)(1)N/ASubtotal(1)— — (17)(4)N/A
Gain (Loss) on Cash Flow Hedges:Gain (Loss) on Cash Flow Hedges:Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)Interest rate derivatives: (1)Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIAmount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A$(542)Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A$(568)
Amount of gains (losses) reclassified from AOCI into incomeAmount of gains (losses) reclassified from AOCI into income15 18 — — — (33)Amount of gains (losses) reclassified from AOCI into income16 53 — — — (69)
Foreign currency exchange rate derivatives: (1)Foreign currency exchange rate derivatives: (1)Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCIAmount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A152 Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A472 
Amount of gains (losses) reclassified from AOCI into incomeAmount of gains (losses) reclassified from AOCI into income(77)— — — 75 Amount of gains (losses) reclassified from AOCI into income— (555)— — — 555 
Foreign currency transaction gains (losses) on hedged itemsForeign currency transaction gains (losses) on hedged items— 72 — — — — Foreign currency transaction gains (losses) on hedged items— 547 — — — — 
Credit derivatives: (1)Credit derivatives: (1)
Amount of gains (losses) deferred in AOCIAmount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A— 
Amount of gains (losses) reclassified from AOCI into incomeAmount of gains (losses) reclassified from AOCI into income— — — — — — 
SubtotalSubtotal17 13 — — — (348)Subtotal16 45 — — — 390 
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)Interest rate derivatives (1)— (731)— — N/AInterest rate derivatives (1)— (872)— — N/A
Foreign currency exchange rate derivatives (1)Foreign currency exchange rate derivatives (1)— 123 — — N/AForeign currency exchange rate derivatives (1)— 386 — — N/A
Credit derivatives — purchased (1)Credit derivatives — purchased (1)— — 31 — — N/ACredit derivatives — purchased (1)— — 27 — — N/A
Credit derivatives — written (1)Credit derivatives — written (1)— — (36)— — N/ACredit derivatives — written (1)— — (154)— — N/A
Equity derivatives (1)Equity derivatives (1)(7)— 182 — — N/AEquity derivatives (1)36 — 637 — — N/A
Foreign currency transaction gains (losses) on hedged itemsForeign currency transaction gains (losses) on hedged items— — (63)— — N/AForeign currency transaction gains (losses) on hedged items— — (179)— — N/A
SubtotalSubtotal(5)— (494)— — N/ASubtotal39 — (155)— — N/A
Earned income on derivativesEarned income on derivatives85 — 137 41 (26)— Earned income on derivatives140 — 126 35 (29)— 
Synthetic GICsSynthetic GICsN/AN/A— N/AN/AN/ASynthetic GICsN/AN/A— N/AN/AN/A
Embedded derivativesEmbedded derivativesN/AN/A478 — N/AN/AEmbedded derivativesN/AN/A615 — N/AN/A
TotalTotal$99 $13 $121 $25 $(27)$(348)Total$194 $45 $586 $18 $(33)$390 
77

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
Six Months Ended June 30, 2023
Net
Investment
Income
Net
Investment
Gains
(Losses)
Net
Derivative
Gains
(Losses)
Policyholder
Benefits and
Claims
Interest Credited to Policyholder Account BalancesOCI
(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)$(1)$— $— $(9)$— N/A
Hedged items— — — (5)(1)N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)(22)— — — 13 N/A
Hedged items21 — — — (11)N/A
Subtotal(2)— — (14)N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A$44 
Amount of gains (losses) reclassified from AOCI into income27 57 — — — (84)
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A15 
Amount of gains (losses) reclassified from AOCI into income439 — — — (441)
Foreign currency transaction gains (losses) on hedged items— (417)— — — — 
Credit derivatives (1):
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A(1)
Amount of gains (losses) reclassified from AOCI into income— — — — — — 
Subtotal29 79 — — — (467)
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)— — (397)— — N/A
Foreign currency exchange rate derivatives (1)— — (139)— — N/A
Credit derivatives — purchased (1)— — (17)— — N/A
Credit derivatives — written (1)— — 66 — — N/A
Equity derivatives (1)(42)— (751)— — N/A
Foreign currency transaction gains (losses) on hedged items— — 71 — — N/A
Subtotal(42)— (1,167)— — N/A
Earned income on derivatives82 — 434 (67)— 
Synthetic GICsN/AN/AN/AN/AN/A
Embedded derivativesN/AN/A(68)— N/AN/A
Total$67 $79 $(792)$(6)$(66)$(467)
78

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
Six Months Ended June 30, 2022
Net Investment IncomeNet Investment Gains (Losses)Net Derivative Gains (Losses)Policyholder Benefits and ClaimsInterest Credited to Policyholder Account BalancesOCI
(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)$$— $— $(696)$(158)N/A
Hedged items(8)— — 663 153 N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)90 — — — — N/A
Hedged items(87)— — — — N/A
Subtotal— — (33)(5)N/A
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A$(1,110)
Amount of gains (losses) reclassified from AOCI into income31 71 — — — (102)
Foreign currency exchange rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A624 
Amount of gains (losses) reclassified from AOCI into income(632)— — — 630 
Foreign currency transaction gains (losses) on hedged items— 619 — — — — 
Credit derivatives (1):
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A— 
Amount of gains (losses) reclassified from AOCI into income— — — — — — 
Subtotal33 58 — — — 42 
Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate derivatives (1)— (1,603)— — N/A
Foreign currency exchange rate derivatives (1)— 509 — — N/A
Credit derivatives — purchased (1)— — 58 — — N/A
Credit derivatives — written (1)— — (190)— — N/A
Equity derivatives (1)29 — 819 — — N/A
Foreign currency transaction gains (losses) on hedged items— — (242)— — N/A
Subtotal34 — (649)— — N/A
Earned income on derivatives225 — 263 76 (55)— 
Synthetic GICsN/AN/A— N/AN/AN/A
Embedded derivativesN/AN/A1,093 — N/AN/A
Total$293 $58 $707 $43 $(60)$42 
__________________
(1)Excludes earned income on derivatives.
Fair Value Hedges
The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities and (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities.
The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges:
7479

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
Balance Sheet Line ItemCarrying Amount of the
Hedged
Assets/(Liabilities)
Cumulative Amount
of Fair Value Hedging Adjustments
Included in the Carrying Amount of Hedged
Assets/(Liabilities) (1)
March 31, 2023December 31, 2022March 31, 2023December 31, 2022
(In millions)
Fixed maturity securities AFS$253 $247 $$
Mortgage loans$342 $319 $(16)$(18)
Future policy benefits$(2,982)$(2,816)$78 $200 
Policyholder account balances$(1,807)$(1,735)$22 $80 
The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges:
Balance Sheet Line ItemCarrying Amount of the
Hedged
Assets/(Liabilities)
Cumulative Amount
of Fair Value Hedging Adjustments
Included in the Carrying Amount of Hedged
Assets/(Liabilities) (1)
June 30, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)
Fixed maturity securities AFS$164 $247 $$
Mortgage loans$322 $319 $(20)$(18)
Future policy benefits$(2,901)$(2,816)$204 $200 
Policyholder account balances$(1,817)$(1,735)$43 $80 
__________________
(1)Includes ($130)124) million and ($136) million of hedging adjustments on discontinued hedging relationships at March 31,June 30, 2023 and December 31, 2022, respectively.
All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.
Cash Flow Hedges
The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments.
In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were $1$19 million and $0$20 million for the three months and six months ended March 31,June 30, 2023, respectively, and 2022, respectively.$4 million for both the three months and six months ended June 30, 2022.
At both March 31,June 30, 2023 and December 31, 2022, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed six years.
At both March 31,June 30, 2023 and December 31, 2022, the balance in AOCI associated with cash flow hedges was $1.5 billion and $2.0 billion.billion, respectively.
All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.
At March 31,June 30, 2023, the Company expected to reclassify $115$150 million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months.
Credit Derivatives
In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the interim condensed consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps.
7580

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Rating Agency Designation of Referenced
Credit Obligations (1)
Rating Agency Designation of Referenced
Credit Obligations (1)
Estimated
Fair Value
of Credit
Default
Swaps
Maximum
Amount of
Future
Payments under
Credit Default
Swaps
Weighted
Average
Years to
Maturity (2)
Estimated
Fair Value
of Credit
Default
Swaps
Maximum
Amount of
Future
Payments under
Credit Default
Swaps
Weighted
Average
Years to
Maturity (2)
Rating Agency Designation of Referenced
Credit Obligations (1)
Estimated
Fair Value
of Credit
Default
Swaps
Maximum
Amount of
Future
Payments under
Credit Default
Swaps
Weighted
Average
Years to
Maturity (2)
Estimated
Fair Value
of Credit
Default
Swaps
Maximum
Amount of
Future
Payments under
Credit Default
Swaps
Weighted
Average
Years to
Maturity (2)
(Dollars in millions)(Dollars in millions)
Aaa/Aa/AAaa/Aa/AAaa/Aa/A
Single name credit default swaps (3)Single name credit default swaps (3)$— $10 1.2$$10 1.5Single name credit default swaps (3)$— $10 1.0$$10 1.5
Credit default swaps referencing indicesCredit default swaps referencing indices82 4,251 3.279 4,251 3.4Credit default swaps referencing indices84 4,351 2.979 4,251 3.4
SubtotalSubtotal82 4,261 3.280 4,261 3.4Subtotal84 4,361 2.980 4,261 3.4
BaaBaaBaa
Single name credit default swaps (3)Single name credit default swaps (3)40 2.2— 40 2.5Single name credit default swaps (3)40 2.0— 40 2.5
Credit default swaps referencing indicesCredit default swaps referencing indices15 5,859 5.913 4,598 5.9Credit default swaps referencing indices66 6,359 5.213 4,598 5.9
SubtotalSubtotal16 5,899 5.813 4,638 5.8Subtotal67 6,399 5.213 4,638 5.8
BaBaBa
Single name credit default swaps (3)Single name credit default swaps (3)45 0.445 0.7Single name credit default swaps (3)— 20 0.545 0.7
Credit default swaps referencing indicesCredit default swaps referencing indices25 3.725 4.0Credit default swaps referencing indices25 3.525 4.0
SubtotalSubtotal70 1.670 1.9Subtotal45 2.170 1.9
BBB
Credit default swaps referencing indicesCredit default swaps referencing indices75 5.275 4.5Credit default swaps referencing indices75 5.075 4.5
SubtotalSubtotal75 5.275 4.5Subtotal75 5.075 4.5
CaaCaaCaa
Credit default swaps referencing indicesCredit default swaps referencing indices(8)30 3.2(10)30 3.5Credit default swaps referencing indices(7)30 3.0(10)30 3.5
SubtotalSubtotal(8)30 3.2(10)30 3.5Subtotal(7)30 3.0(10)30 3.5
TotalTotal$94 $10,335 4.7$87 $9,074 4.6Total$149 $10,910 4.2$87 $9,074 4.6
__________________
(1)The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used.
(2)The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts.
(3)Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals.
Credit Risk on Freestanding Derivatives
The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements.
7681

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s over-the-counter bilateral (“OTC-bilateral”), contracts between two counterparties, derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians.
The Company’s over-the-counter cleared (“OTC-cleared”) derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives.
See Note 11 for a description of the impact of credit risk on the valuation of derivatives.
The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
Derivatives Subject to a Master Netting Arrangement or a Similar ArrangementDerivatives Subject to a Master Netting Arrangement or a Similar ArrangementAssetsLiabilitiesAssetsLiabilitiesDerivatives Subject to a Master Netting Arrangement or a Similar ArrangementAssetsLiabilitiesAssetsLiabilities
(In millions)(In millions)
Gross estimated fair value of derivatives:Gross estimated fair value of derivatives:Gross estimated fair value of derivatives:
OTC-bilateral (1)OTC-bilateral (1)$8,095 $2,784 $8,456 $3,499 OTC-bilateral (1)$7,530 $2,975 $8,456 $3,499 
OTC-cleared (1)OTC-cleared (1)74 57 29 OTC-cleared (1)88 57 29 
Exchange-tradedExchange-traded16 Exchange-traded13 
Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1)Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1)8,172 2,808 8,515 3,529 Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1)7,620 2,997 8,515 3,529 
Gross amounts not offset on the interim condensed consolidated balance sheets:Gross amounts not offset on the interim condensed consolidated balance sheets:Gross amounts not offset on the interim condensed consolidated balance sheets:
Gross estimated fair value of derivatives: (2)Gross estimated fair value of derivatives: (2)Gross estimated fair value of derivatives: (2)
OTC-bilateralOTC-bilateral(2,640)(2,640)(3,317)(3,317)OTC-bilateral(2,685)(2,685)(3,317)(3,317)
OTC-clearedOTC-cleared(14)(14)OTC-cleared(6)(6)(14)(14)
Exchange-tradedExchange-traded(2)(2)— — Exchange-traded(2)(2)— — 
Cash collateral: (3), (4)Cash collateral: (3), (4)Cash collateral: (3), (4)
OTC-bilateralOTC-bilateral(3,576)— (4,044)— OTC-bilateral(3,140)— (4,044)— 
OTC-clearedOTC-cleared(16)— (18)(1)OTC-cleared(63)— (18)(1)
Securities collateral: (5)Securities collateral: (5)Securities collateral: (5)
OTC-bilateralOTC-bilateral(1,842)(144)(1,078)(182)OTC-bilateral(1,637)(290)(1,078)(182)
OTC-clearedOTC-cleared— (14)— (14)OTC-cleared— (3)— (14)
Exchange-tradedExchange-traded— (14)— (1)Exchange-traded— (11)— (1)
Net amount after application of master netting agreements and collateralNet amount after application of master netting agreements and collateral$102 $— $44 $— Net amount after application of master netting agreements and collateral$87 $— $44 $— 
__________________
(1)At March 31,June 30, 2023 and December 31, 2022, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $123$128 million and $119 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $39$64 million and $0, respectively.
7782

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
(2)Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals.
(3)Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the centralized clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet.
(4)The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At March 31,June 30, 2023 and December 31, 2022, the Company received excess cash collateral of $204$244 million and $210 million, respectively, and provided excess cash collateral of $0 and $1 million, respectively.
(5)Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at March 31,June 30, 2023, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At March 31,June 30, 2023 and December 31, 2022, the Company received excess securities collateral with an estimated fair value of $305$377 million and $366 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At March 31,June 30, 2023 and December 31, 2022, the Company provided excess securities collateral with an estimated fair value of $991$944 million and $934 million, respectively, for its OTC-bilateral derivatives, $502$488 million and $442 million, respectively, for its OTC-cleared derivatives, and $60$55 million and $96 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.
The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. All of the Company’s netting agreements for derivatives contain provisions that require both Metropolitan Life Insurance Company and the counterparty to maintain a specific investment grade financial strength or credit rating from each of Moody’s and S&P. If a party’s financial strength or credit rating were to fall below that specific investment grade financial strength or credit rating, that party would be in violation of these provisions, and the other party to the derivatives could terminate the transactions and demand immediate settlement and payment based on such party’s reasonable valuation of the derivatives.
The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged.
Derivatives Subject to Financial
Strength-Contingent Provisions
Derivatives Subject to Financial
Strength-Contingent Provisions
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
Estimated fair value of derivatives in a net liability position (1)Estimated fair value of derivatives in a net liability position (1)$144 $182 Estimated fair value of derivatives in a net liability position (1)$290 $182 
Estimated fair value of collateral provided:Estimated fair value of collateral provided:Estimated fair value of collateral provided:
Fixed maturity securities AFSFixed maturity securities AFS$216 $221 Fixed maturity securities AFS$553 $221 
__________________
(1)After taking into consideration the existence of netting agreements.
7883

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Derivatives (continued)
Embedded Derivatives
The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives.
The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at:
Balance Sheet LocationMarch 31, 2023December 31, 2022
(In millions)
Embedded derivatives within asset host contracts:
Assumed on affiliated reinsuranceOther invested assets$42 $149 
Funds withheld on affiliated reinsuranceOther invested assets49 — 
Total$91 $149 
Embedded derivatives within liability host contracts:
Assumed on affiliated reinsuranceOther liabilities53— 
Funds withheld on affiliated reinsuranceOther liabilities(280)(450)
Fixed annuities with equity indexed returnsPolicyholder account balances150 141 
Total$(77)$(309)

Balance Sheet LocationJune 30, 2023December 31, 2022
(In millions)
Embedded derivatives within asset host contracts:
Assumed on affiliated reinsuranceOther invested assets$171 $149 
Funds withheld on affiliated reinsuranceOther invested assets(9)— 
Total$162 $149 
Embedded derivatives within liability host contracts:
Funds withheld on affiliated reinsuranceOther liabilities(371)(450)
Fixed annuities with equity indexed returnsPolicyholder account balances155 141 
Total$(216)$(309)
7984

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value
Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts.
Recurring Fair Value Measurements
The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at:
March 31, 2023June 30, 2023
Fair Value HierarchyFair Value Hierarchy
Level 1Level 2Level 3
Total 
Estimated
Fair Value
Level 1Level 2Level 3
Total 
Estimated
Fair Value
(In millions)(In millions)
AssetsAssetsAssets
Fixed maturity securities AFS:Fixed maturity securities AFS:Fixed maturity securities AFS:
U.S. corporateU.S. corporate$— $44,957 $8,539 $53,496 U.S. corporate$— $44,499 $8,539 $53,038 
Foreign corporateForeign corporate— 17,893 7,178 25,071 Foreign corporate— 17,114 7,477 24,591 
U.S. government and agencyU.S. government and agency9,397 13,416 — 22,813 U.S. government and agency8,561 13,370 — 21,931 
RMBSRMBS18,656 1,487 20,147 RMBS18,422 1,459 19,885 
ABS & CLOABS & CLO— 10,309 1,712 12,021 ABS & CLO— 10,413 1,652 12,065 
MunicipalsMunicipals— 7,779 — 7,779 Municipals— 7,648 7,652 
CMBSCMBS— 5,805 302 6,107 CMBS— 5,994 298 6,292 
Foreign governmentForeign government— 3,511 15 3,526 Foreign government— 3,601 17 3,618 
Total fixed maturity securities AFSTotal fixed maturity securities AFS9,401 122,326 19,233 150,960 Total fixed maturity securities AFS8,565 121,061 19,446 149,072 
Short-term investmentsShort-term investments1,872 117 57 2,046 Short-term investments3,305 134 17 3,456 
Other investmentsOther investments258 199 1,052 1,509 Other investments258 191 1,115 1,564 
Derivative assets: (1)Derivative assets: (1)Derivative assets: (1)
Interest rateInterest rate4,295 — 4,296 Interest rate— 3,873 — 3,873 
Foreign currency exchange rateForeign currency exchange rate— 3,099 — 3,099 Foreign currency exchange rate— 3,049 — 3,049 
CreditCredit— 116 123 Credit— 161 168 
Equity marketEquity market522 531 Equity market393 402 
Total derivative assetsTotal derivative assets8,032 14 8,049 Total derivative assets7,476 14 7,492 
Embedded derivatives within asset host contracts (4)Embedded derivatives within asset host contracts (4)— — 91 91 Embedded derivatives within asset host contracts (4)— — 162 162 
Market risk benefitsMarket risk benefits— — 124 124 Market risk benefits— — 163 163 
Separate account assets (2)Separate account assets (2)15,248 72,108 1,001 88,357 Separate account assets (2)14,036 69,819 1,055 84,910 
Total assets (3)Total assets (3)$26,782 $202,782 $21,572 $251,136 Total assets (3)$26,166 $198,681 $21,972 $246,819 
LiabilitiesLiabilitiesLiabilities
Derivative liabilities: (1)Derivative liabilities: (1)Derivative liabilities: (1)
Interest rateInterest rate$— $1,180 $284 $1,464 Interest rate$— $1,388 $292 $1,680 
Foreign currency exchange rateForeign currency exchange rate— 1,069 — 1,069 Foreign currency exchange rate— 938 — 938 
CreditCredit— 18 19 Credit— 17 — 17 
Equity marketEquity market16 201 — 217 Equity market13 285 — 298 
Total derivative liabilitiesTotal derivative liabilities16 2,468 285 2,769 Total derivative liabilities13 2,628 292 2,933 
Embedded derivatives within liability host contracts (4)Embedded derivatives within liability host contracts (4)— — (77)(77)Embedded derivatives within liability host contracts (4)— — (216)(216)
Market risk benefitsMarket risk benefits— — 3,432 3,432 Market risk benefits— — 2,942 2,942 
Separate account liabilities (2)Separate account liabilities (2)12 15 Separate account liabilities (2)11 
Total liabilitiesTotal liabilities$28 $2,470 $3,641 $6,139 Total liabilities$20 $2,631 $3,019 $5,670 
8085

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
December 31, 2022
Fair Value Hierarchy
Level 1Level 2Level 3
Total
Estimated
Fair Value
(In millions)
Assets
Fixed maturity securities AFS:
U.S. corporate$— $43,147 $7,943 $51,090 
Foreign corporate— 17,203 6,790 23,993 
U.S. government and agency9,126 13,232 — 22,358 
RMBS17,804 1,525 19,333 
ABS & CLO— 10,329 1,507 11,836 
Municipals— 7,464 — 7,464 
CMBS— 5,702 341 6,043 
Foreign government— 3,444 15 3,459 
Total fixed maturity securities AFS9,130 118,325 18,121 145,576 
Short-term investments2,677 35 47 2,759 
Other investments246 212 1,022 1,480 
Derivative assets: (1)
Interest rate— 4,390 — 4,390 
Foreign currency exchange rate— 3,263 — 3,263 
Credit— 47 82 129 
Equity market605 614 
Total derivative assets8,305 89 8,396 
Embedded derivatives within asset host contracts (4)— — 149 149 
Market risk benefits— — 174 174 
Separate account assets (2)16,206 72,022 1,013 89,241 
Total assets (3)$28,261 $198,899 $20,615 $247,775 
Liabilities
Derivative liabilities: (1)
Interest rate$$1,421 $405 $1,827 
Foreign currency exchange rate— 1,394 — 1,394 
Credit— 11 15 26 
Equity market— 282 — 282 
Total derivative liabilities3,108 420 3,529 
Embedded derivatives within liability host contracts (4)— — (309)(309)
Market risk benefits— — 3,270 3,270 
Separate account liabilities (2)15 18 41 
Total liabilities$$3,123 $3,399 $6,531 
__________________
(1)Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables.
(2)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities.
8186

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
(3)Total assets included in the fair value hierarchy exclude other limited partnership interests that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. At March 31,both June 30, 2023 and December 31, 2022, the estimated fair value of such investments was $59 million and $61 million, respectively.million.
(4)Embedded derivatives within asset host contracts are presented within other invested assets on the interim condensed consolidated balance sheets. Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the interim condensed consolidated balance sheets.
The following describes the valuation methodologies used to measure assets and liabilities at fair value.
Investments
Securities, Short-term Investments and Other Investments
When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings and valuation of these securities does not involve management’s judgment.
When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based, in large part, on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments.
The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein.
The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g., cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs.
8287

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
Instrument
Level 2
Observable Inputs
Level 3
Unobservable Inputs
Fixed maturity securities AFS
U.S. corporate and Foreign corporate securities
Valuation Approaches: Principally the market and income approaches.Valuation Approaches: Principally the market approach.
Key Inputs:Key Inputs:
quoted prices in markets that are not activeilliquidity premium
benchmark yields; spreads off benchmark yields; new issuances; issuer ratingsdelta spread adjustments to reflect specific credit-related issues
trades of identical or comparable securities; durationcredit spreads
privately-placed securities are valued using the additional key inputs:
quoted prices in markets that are not active for identical or similar
securities that are less liquid and based on lower levels of trading
activity than securities classified in Level 2
market yield curve; call provisions
observable prices and spreads for similar public or private securities that
incorporate the credit quality and industry sector of the issuer

independent non-binding broker quotations
delta spread adjustments to reflect specific credit-related issues
U.S. government and agency securities, Municipals and Foreign government securities
Valuation Approaches: Principally the market approach.Valuation Approaches: Principally the market approach.
Key Inputs:Key Inputs:
quoted prices in markets that are not activeindependent non-binding broker quotations
benchmark U.S. Treasury yield or other yields
quoted prices in markets that are not active for identical or similar
securities that are less liquid and based on lower levels of trading
activity than securities classified in Level 2
the spread off the U.S. Treasury yield curve for the identical security
issuer ratings and issuer spreads; broker-dealer quotationscredit spreads
comparable securities that are actively traded
Structured Products
Valuation Approaches: Principally the market and income approaches.Valuation Approaches: Principally the market and income approaches.
Key Inputs:Key Inputs:
quoted prices in markets that are not activecredit spreads
spreads for actively traded securities; spreads off benchmark yields
quoted prices in markets that are not active for identical or similar
securities that are less liquid and based on lower levels of trading
activity than securities classified in Level 2
expected prepayment speeds and volumes
current and forecasted loss severity; ratings; geographic regionindependent non-binding broker quotations
weighted average coupon and weighted average maturitycredit ratings
average delinquency rates; DSCR
credit ratings
issuance-specific information, including, but not limited to:
collateral type; structure of the security; vintage of the loans
payment terms of the underlying assets
payment priority within the tranche; deal performance
8388

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
Instrument
Level 2
Observable Inputs
Level 3
Unobservable Inputs
Short-term investments and Other investments
Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above; while certain other investments are similar to equity securities. The valuation approaches and observable inputs used in their valuation are also similar to those described above. Other investments contain equity securities valued using quoted prices in markets that are not considered active.Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above, while certain other investments are similar to equity securities. The valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments contain equity securities that use key unobservable inputs such as credit ratings; issuance structures, in addition to those described above for fixed maturities AFS. Other investments also include certain real estate joint ventures and use the valuation approach and key inputs as described for other limited partnership interests below.
Separate account assets and Separate account liabilities (1)
Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly
Key Input:N/A
quoted prices or reported NAV provided by the fund managers
Other limited partnership interests
N/AValued giving consideration to the underlying holdings
of the partnerships and adjusting, if appropriate.
Key Inputs:
liquidity; bid/ask spreads; performance record of the fund manager
other relevant variables that may impact the exit value of the particular
partnership interest
__________________
(1)Estimated fair value equals carrying value, based on the value of the underlying assets, including: mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, other limited partnership interests, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.”
Derivatives
The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.
The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. With respect to certain OTC-bilateral and OTC-cleared derivatives, management may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives.
8489

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income.
The credit risk of both the counterparty and the Company is considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period.
Freestanding Derivatives
Level 2 Valuation Approaches and Key Inputs:
This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3.
Level 3 Valuation Approaches and Key Inputs:
These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data.
Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows:
InstrumentInterest RateForeign Currency
Exchange Rate
CreditEquity Market
Inputs common to Level 2 and Level 3 by instrument typeswap yield curvesswap yield curvesswap yield curvesswap yield curves
basis curvesbasis curvescredit curvesspot equity index levels
interest rate volatility (1)currency spot ratesrecovery ratesdividend yield curves
cross currency basis curvesequity volatility (1)
Level 3swap yield curves (2)swap yield curves (2)swap yield curves (2)dividend yield curves (2)
basis curves (2)basis curves (2)credit curves (2)equity volatility (1), (2)
repurchase ratescross currency basis curves (2)credit spreadscorrelation between model inputs (1)
interest rate volatility (1), (2)currency correlationrepurchase rates
independent non-binding
broker quotations
__________________
(1)Option-based only.
(2)Extrapolation beyond the observable limits of the curve(s).
8590

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
Embedded Derivatives
Embedded derivatives principally include equity-indexed annuity contracts and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income.
The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance and experience refund related to certain assumed reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the reinsurance liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of guarantees related to reinsurance is determined based on multiple stochastic scenarios and includes a nonperformance risk adjustment. The estimated fair value of these embedded derivatives is included, along with their underlying host contracts, in other liabilities and other invested assets on the interim condensed consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income.
The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk.
Market Risk Benefits
See Note 5 for information on the Company’s valuation approaches and key inputs for MRBs.
Transfers between Levels
Overall, transfers between levels occur when there are changes in the observability of inputs and market activity.
Transfers into or out of Level 3:
Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.
8691

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at:
March 31, 2023December 31, 2022Impact of
Increase in Input
on Estimated
Fair Value (2)
June 30, 2023December 31, 2022Impact of
Increase in Input
on Estimated
Fair Value (2)
Valuation
Techniques
Significant
Unobservable Inputs
RangeWeighted
Average (1)
RangeWeighted
Average (1)
Valuation
Techniques
Significant
Unobservable Inputs
RangeWeighted
Average (1)
RangeWeighted
Average (1)
Fixed maturity securities AFS (3)Fixed maturity securities AFS (3)Fixed maturity securities AFS (3)
U.S. corporate and foreign corporateU.S. corporate and foreign corporateMatrix pricingOffered quotes (4)12-13092-12689IncreaseU.S. corporate and foreign corporateMatrix pricingOffered quotes (4)17-12891-12689Increase
Market pricingQuoted prices (4)18-1109220-10792IncreaseMarket pricingQuoted prices (4)5-1049220-10792Increase
RMBSRMBSMarket pricingQuoted prices (4)-10893-10693Increase (5)RMBSMarket pricingQuoted prices (4)-10993-10693Increase (5)
ABS & CLOABS & CLOMarket pricingQuoted prices (4)74-1029374-10191Increase (5)ABS & CLOMarket pricingQuoted prices (4)75-1019274-10191Increase (5)
DerivativesDerivativesDerivatives
Interest rateInterest ratePresent value techniquesSwap yield (6)329-360343372-392381Increase (7)Interest ratePresent value techniquesSwap yield (6)360-380371372-392381Increase (7)
CreditCreditPresent value techniquesCredit spreads (8)-84-138101Decrease (7)CreditPresent value techniquesCredit spreads (8)-84-138101Decrease (7)
Consensus pricingOffered quotes (9)Consensus pricingOffered quotes (9)
Market Risk BenefitsMarket Risk BenefitsMarket Risk Benefits
Direct and assumed guaranteed minimum benefitsDirect and assumed guaranteed minimum benefitsOption pricing techniquesMortality rates:Direct and assumed guaranteed minimum benefitsOption pricing techniquesMortality rates:
Ages 0 - 400.01%-0.13%0.05%0.01%-0.08%0.05%(10)Ages 0 - 400.01%-0.13%0.05%0.01%-0.08%0.05%(10)
Ages 41 - 600.05%-0.67%0.20%0.05%-0.43%0.20%(10)Ages 41 - 600.05%-0.67%0.20%0.05%-0.43%0.20%(10)
Ages 61 - 1150.34%-100%1.44%0.34%-100%1.44%(10)Ages 61 - 1150.34%-100%1.44%0.34%-100%1.44%(10)
Lapse rates:Lapse rates:
Durations 1 - 100.50%-32.80%8.96%0.50%-37.50%8.96%Decrease (11)Durations 1 - 100.50%-32.80%8.96%0.50%-37.50%8.96%Decrease (11)
Durations 11 - 200.70%-18.20%6.52%0.70%-35.75%6.52%Decrease (11)Durations 11 - 200.70%-18.20%6.52%0.70%-35.75%6.52%Decrease (11)
Durations 21 - 1160.75%-10%2.89%1.60%-35.75%2.89%Decrease (11)Durations 21 - 1160.75%-10%2.89%1.60%-35.75%2.89%Decrease (11)
Utilization rates0.20%-22%0.38%0.20%-22%0.38%Increase (12)Utilization rates0.20%-22%0.38%0.20%-22%0.38%Increase (12)
Withdrawal rates0.25%-7%4.02%0.25%-10%4.02%(13)Withdrawal rates0.25%-7%4.02%0.25%-10%4.02%(13)
Long-term equity volatilities16.46%-22.01%18.49%16.46%-22.01%18.49%Increase (14)Long-term equity volatilities16.46%-22.01%18.49%16.46%-22.01%18.49%Increase (14)
Nonperformance risk spread0.45%-0.85%0.75%0.34%-0.74%0.75%Decrease (15)Nonperformance risk spread0.44%-0.84%0.75%0.34%-0.74%0.75%Decrease (15)
__________________
(1)The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for MRBs is determined based on a combination of account values and experience data.
(2)The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions.
(3)Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations.
(4)Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par.
(5)Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates.
(6)Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.
8792

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
(7)Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions.
(8)Represents the risk quoted in basis points of a credit default event on the underlying instrument. Credit derivatives with significant unobservable inputs are primarily comprised of written credit default swaps.
(9)At both March 31,June 30, 2023 and December 31, 2022, independent non-binding broker quotations were used in the determination of 1% or less of the total net derivative estimated fair value.
(10)Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates result in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates result in a decrease (increase) in the estimated fair value of MRBs.
(11)Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.
(12)The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.
(13)The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRB. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value.
(14)Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.
(15)Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs.
All other classes of securities classified within Level 3, including those within Other investments, Separate account assets, and Embedded derivatives within funds withheld related to certain ceded reinsurance, use the same valuation techniques and significant unobservable inputs as previously described for Level 3 securities. Generally, all other classes of assets and liabilities classified within Level 3 that are not included above use the same valuation techniques and significant unobservable inputs as previously described for Level 3. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table. The valuation techniques and significant unobservable inputs used in the fair value measurement for the more significant assets measured at estimated fair value on a nonrecurring basis and determined using significant unobservable inputs (Level 3) are summarized in “— Nonrecurring Fair Value Measurements.”
8893

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
The following tables summarize the change of all assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3):
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Fixed Maturity Securities AFS Fixed Maturity Securities AFS
Corporate (6)Structured
Products
Foreign
Government
Short-term
Investments
Corporate (6)Structured
Products
MunicipalsForeign
Government
Short-term
Investments
(In millions) (In millions)
Three Months Ended March 31, 2023
Three Months Ended June 30, 2023Three Months Ended June 30, 2023
Balance, beginning of periodBalance, beginning of period$14,733 $3,373 $15 $47 Balance, beginning of period$15,717 $3,501 $— $15 $57 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(5)— — Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(11)— (1)— 
Total realized/unrealized gains (losses) included in
AOCI
Total realized/unrealized gains (losses) included in
AOCI
376 20 (1)Total realized/unrealized gains (losses) included in AOCI(101)(20)— (1)
Purchases (3)Purchases (3)1,355 189 52 Purchases (3)808 67 — 
Sales (3)Sales (3)(463)(100)(1)(43)Sales (3)(393)(86)— — (44)
Issuances (3)Issuances (3)— — — — Issuances (3)— — — — — 
Settlements (3)Settlements (3)— — — — Settlements (3)— — — — — 
Transfers into Level 3 (4)Transfers into Level 3 (4)161 70 — — Transfers into Level 3 (4)125 34 — — — 
Transfers out of Level 3 (4)Transfers out of Level 3 (4)(447)(46)— — Transfers out of Level 3 (4)(129)(94)— — — 
Balance, end of periodBalance, end of period$15,717 $3,501 $15 $57 Balance, end of period$16,016 $3,409 $$17 $17 
Three Months Ended March 31, 2022
Three Months Ended June 30, 2022Three Months Ended June 30, 2022
Balance, beginning of periodBalance, beginning of period$14,935 $4,600 $12 $Balance, beginning of period$13,940 $4,566 $— $13 $— 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(15)12 — — Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(11)12 — — 
Total realized/unrealized gains (losses) included in
AOCI
Total realized/unrealized gains (losses) included in
AOCI
(1,114)(160)(1)— Total realized/unrealized gains (losses) included in AOCI(1,496)(142)— — 
Purchases (3)Purchases (3)528 473 — Purchases (3)945 321 — — — 
Sales (3)Sales (3)(382)(187)— (2)Sales (3)(211)(394)— (1)— 
Issuances (3)Issuances (3)— — — — Issuances (3)— — — — — 
Settlements (3)Settlements (3)— — — — Settlements (3)— — — — — 
Transfers into Level 3 (4)Transfers into Level 3 (4)307 102 — — Transfers into Level 3 (4)137 79 — 100 
Transfers out of Level 3 (4)Transfers out of Level 3 (4)(319)(274)— — Transfers out of Level 3 (4)(300)(352)— (2)— 
Balance, end of periodBalance, end of period$13,940 $4,566 $13 $— Balance, end of period$13,004 $4,090 $— $21 $100 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at March 31, 2023 (5)
$$(1)$— $— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at March 31, 2022 (5)
$(15)$12 $— $— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at March 31, 2023 (5)
$374 $17 $(1)$— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at March 31, 2022 (5)
$(1,120)$(160)$(1)$— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2023 (5)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2023 (5)
$(10)$$— $(1)$— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2022 (5)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2022 (5)
$(11)$12 $— $$— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2023 (5)
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2023 (5)
$(110)$(21)$— $$(1)
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2022 (5)
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2022 (5)
$(1,495)$(139)$— $$— 
8994

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Residential
Mortgage
Loans - FVO
Other
 Investments
Net
Derivatives (7)
Net Embedded
Derivatives (8)
Separate
Accounts (9) 
Residential
Mortgage
Loans - FVO
Other
Investments
Net
Derivatives (7)
Net Embedded
Derivatives (8)
Separate
Accounts (9) 
(In millions) (In millions)
Three Months Ended March 31, 2023
Three Months Ended June 30, 2023Three Months Ended June 30, 2023
Balance, beginning of periodBalance, beginning of period$— $1,022 $(331)$458 $995 Balance, beginning of period$— $1,052 $(271)$168 $1,000 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)Total realized/unrealized gains (losses) included in net income (loss) (1), (2)— 28 — (280)(9)Total realized/unrealized gains (losses) included in net income (loss) (1), (2)— 63 (12)212 (10)
Total realized/unrealized gains (losses) included in
AOCI
Total realized/unrealized gains (losses) included in
AOCI
— — 66 — — Total realized/unrealized gains (losses) included in AOCI— — (39)— — 
Purchases (3)Purchases (3)— — — 101 Purchases (3)— — — — 72 
Sales (3)Sales (3)— — — — (93)Sales (3)— — — — (20)
Issuances (3)Issuances (3)— — — — — Issuances (3)— — — — — 
Settlements (3)Settlements (3)— — 55 (10)Settlements (3)— — 44 (2)— 
Transfers into Level 3 (4)Transfers into Level 3 (4)— — — — Transfers into Level 3 (4)— — — — 12 
Transfers out of Level 3 (4)Transfers out of Level 3 (4)— — (61)— — Transfers out of Level 3 (4)— — — — — 
Balance, end of periodBalance, end of period$— $1,052 $(271)$168 $1,000 Balance, end of period$— $1,115 $(278)$378 $1,054 
Three Months Ended March 31, 2022
Three Months Ended June 30, 2022Three Months Ended June 30, 2022
Balance, beginning of periodBalance, beginning of period$127 $894 $86 $(1,236)$1,958 Balance, beginning of period$119 $1,123 $29 $(722)$1,931 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(3)44 67 478 Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(5)(64)(88)615 11 
Total realized/unrealized gains (losses) included in
AOCI
Total realized/unrealized gains (losses) included in
AOCI
— — (212)— — Total realized/unrealized gains (losses) included in AOCI— — (207)— — 
Purchases (3)Purchases (3)— 188 88 — 288 Purchases (3)— 10 145 — 35 
Sales (3)Sales (3)— (1)— — (316)Sales (3)— (8)— — (949)
Issuances (3)Issuances (3)— — (2)— Issuances (3)— — — — (5)
Settlements (3)Settlements (3)(5)— 36 (2)Settlements (3)(5)— 18 26 
Transfers into Level 3 (4)Transfers into Level 3 (4)— — — — Transfers into Level 3 (4)— — — — — 
Transfers out of Level 3 (4)Transfers out of Level 3 (4)— (2)— — (4)Transfers out of Level 3 (4)— (100)— — — 
Balance, end of periodBalance, end of period$119 $1,123 $29 $(722)$1,931 Balance, end of period$109 $961 $(103)$(81)$1,029 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at March 31, 2023 (5)
$— $29 $$(280)$— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at March 31, 2022 (5)
$(4)$45 $66 $478 $— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at March 31, 2023 (5)
$— $— $62 $— $— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at March 31, 2022 (5)
$— $— $(207)$— $— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2023 (5)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2023 (5)
$— $64 $$212 $— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2022 (5)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2022 (5)
$(5)$(64)$(87)$615 $— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2023 (5)
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2023 (5)
$— $— $(48)$— $— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2022 (5)
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2022 (5)
$— $— $(199)$— $— 
95

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
 Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
 Fixed Maturity Securities AFS
 Corporate (6)Structured
Products
MunicipalsForeign
Government
Short-term
Investments
 (In millions)
Six Months Ended June 30, 2023
Balance, beginning of period$14,733 $3,373 $— $15 $47 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(18)— (1)— 
Total realized/unrealized gains (losses) included in 
AOCI
285 — — — 
Purchases (3)2,015 153 17 
Sales (3)(848)(175)— (1)(47)
Issuances (3)— — — — — 
Settlements (3)— — — — — 
Transfers into Level 3 (4)280 103 — — — 
Transfers out of Level 3 (4)(431)(46)— — — 
Balance, end of period$16,016 $3,409 $$17 $17 
Six Months Ended June 30, 2022
Balance, beginning of period$14,935 $4,600 $— $12 $
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(26)23 — (42)— 
Total realized/unrealized gains (losses) included in 
AOCI
(2,613)(305)— — 
Purchases (3)1,347 429 — — 100 
Sales (3)(575)(563)— (2)(2)
Issuances (3)— — — — — 
Settlements (3)— — — — — 
Transfers into Level 3 (4)223 148 — 46 — 
Transfers out of Level 3 (4)(287)(242)— — — 
Balance, end of period$13,004 $4,090 $— $21 $100 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2023 (5)
$(17)$$— $(1)$— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2022 (5)
$(26)$23 $— $(42)$— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2023 (5)
$272 $(4)$— $$(1)
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2022 (5)
$(2,618)$(300)$— $$— 
96

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
 Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
 Residential
Mortgage
Loans - FVO
Other
 Investments
Net
Derivatives (7)
Net Embedded
Derivatives (8)
Separate
Accounts (9) 
 (In millions)
Six Months Ended June 30, 2023
Balance, beginning of period$— $1,022 $(331)$458 $995 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)— 91 (27)(68)(18)
Total realized/unrealized gains (losses) included in 
AOCI
— — 43 — — 
Purchases (3)— — — 170 
Sales (3)— — — — (109)
Issuances (3)— — — — — 
Settlements (3)— — 98 (12)
Transfers into Level 3 (4)— — — — 15 
Transfers out of Level 3 (4)— — (61)— — 
Balance, end of period$— $1,115 $(278)$378 $1,054 
Six Months Ended June 30, 2022
Balance, beginning of period$127 $894 $86 $(1,236)$1,958 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(9)(19)(22)1,093 17 
Total realized/unrealized gains (losses) included in 
AOCI
— — (418)— — 
Purchases (3)— 195 233 — 104 
Sales (3)— (10)— — (1,046)
Issuances (3)— — (2)— (5)
Settlements (3)(9)— 20 62 
Transfers into Level 3 (4)— — — 
Transfers out of Level 3 (4)— (102)— — (4)
Balance, end of period$109 $961 $(103)$(81)$1,029 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2023 (5)
$— $93 $$(68)$— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held
at June 30, 2022 (5)
$(9)$(22)$(21)$1,093 $— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2023 (5)
$— $— $$— $— 
Changes in unrealized gains (losses) included in AOCI for the instruments still held
at June 30, 2022 (5)
$— $— $(394)$— $— 
__________________
(1)Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses), while changes in estimated fair value of residential mortgage loans — FVO are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).
(2)Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward.
(3)Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements.
(4)Items transferred into and then out of Level 3 in the same period are excluded from the rollforward.
9097

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
(5)Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).
(6)Comprised of U.S. and foreign corporate securities.
(7)Freestanding derivative assets and liabilities are presented net for purposes of the rollforward.
(8)Embedded derivative assets and liabilities are presented net for purposes of the rollforward.
(9)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss). Separate account assets and liabilities are presented net for the purposes of the rollforward.
Nonrecurring Fair Value Measurements
The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment), using significant unobservable inputs (Level 3).
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(in millions)(in millions)
Carrying value after measurement
Mortgage loans (1)Mortgage loans (1)$266 $222 Mortgage loans (1)$278 $222 
Three Months 
 Ended 
 March 31,
Three Months
Ended
June 30,
Six Months
Ended
June 30,
202320222023202220232022
(in millions)(in millions)
Realized gains (losses) net:
Mortgage loans (1)Mortgage loans (1)$(66)$Mortgage loans (1)$(31)$(24)$(105)$(15)
__________________
(1)Estimated fair values for impaired mortgage loans are based on estimated fair value of the underlying collateral.collateral or discounted cash flows. See Note 9.
Fair Value of Financial Instruments Carried at Other Than Fair Value
The following tables provide fair value information for financial instruments that are carried on the balance sheet at amounts other than fair value. These tables exclude the following financial instruments: cash and cash equivalents, accrued investment income, payables for collateral under securities loaned and other transactions, short-term debt and those short-term investments that are not securities, such as time deposits, and therefore are not included in the three-level hierarchy table disclosed in the “— Recurring Fair Value Measurements” section. The Company believes that due to the short-term nature of these excluded assets, which are primarily classified in Level 2, the estimated fair value approximates carrying value. All remaining balance sheet amounts excluded from the tables below are not considered financial instruments subject to this disclosure.
9198

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Fair Value (continued)
The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at:
March 31, 2023June 30, 2023
Fair Value HierarchyFair Value Hierarchy
Carrying
Value
Level 1Level 2Level 3Total
Estimated
Fair Value
Carrying
Value
Level 1Level 2Level 3Total
Estimated
Fair Value
(In millions)(In millions)
AssetsAssetsAssets
Mortgage loans (1)Mortgage loans (1)$64,053 $— $— $61,025 $61,025 Mortgage loans (1)$63,811 $— $— $60,000 $60,000 
Policy loansPolicy loans$5,701 $— $— $6,177 $6,177 Policy loans$5,692 $— $— $6,107 $6,107 
Other invested assetsOther invested assets$1,977 $— $1,997 $— $1,997 Other invested assets$1,782 $— $1,806 $— $1,806 
Premiums, reinsurance and other receivablesPremiums, reinsurance and other receivables$12,126 $— $549 $11,837 $12,386 Premiums, reinsurance and other receivables$11,967 $— $487 $11,729 $12,216 
Other assets$821 $— $791 $29 $820 
LiabilitiesLiabilitiesLiabilities
Policyholder account balancesPolicyholder account balances$87,664 $— $— $85,569 $85,569 Policyholder account balances$87,765 $— $— $84,948 $84,948 
Long-term debtLong-term debt$1,886 $— $1,942 $— $1,942 Long-term debt$1,885 $— $1,934 $— $1,934 
Other liabilitiesOther liabilities$12,278 $— $545 $11,706 $12,251 Other liabilities$12,125 $— $518 $11,583 $12,101 
Separate account liabilitiesSeparate account liabilities$36,167 $— $36,167 $— $36,167 Separate account liabilities$31,904 $— $31,904 $— $31,904 

December 31, 2022December 31, 2022
Fair Value HierarchyFair Value Hierarchy
Carrying
Value
Level 1Level 2Level 3Total
Estimated
Fair Value
Carrying
Value
Level 1Level 2Level 3Total
Estimated
Fair Value
(In millions)(In millions)
AssetsAssetsAssets
Mortgage loans (1)Mortgage loans (1)$62,570 $— $— $58,858 $58,858 Mortgage loans (1)$62,570 $— $— $58,858 $58,858 
Policy loansPolicy loans$5,729 $— $— $6,143 $6,143 Policy loans$5,729 $— $— $6,143 $6,143 
Other invested assetsOther invested assets$1,978 $— $1,979 $— $1,979 Other invested assets$1,978 $— $1,979 $— $1,979 
Premiums, reinsurance and other
receivables
Premiums, reinsurance and other
receivables
$12,036 $— $454 $11,826 $12,280 
Premiums, reinsurance and other
receivables
$12,036 $— $454 $11,826 $12,280 
Other assets$— $— $— $— $— 
LiabilitiesLiabilitiesLiabilities
Policyholder account balancesPolicyholder account balances$85,957 $— $— $83,594 $83,594 Policyholder account balances$85,957 $— $— $83,594 $83,594 
Long-term debtLong-term debt$1,676 $— $1,758 $— $1,758 Long-term debt$1,676 $— $1,758 $— $1,758 
Other liabilitiesOther liabilities$12,546 $— $671 $11,842 $12,513 Other liabilities$12,546 $— $671 $11,842 $12,513 
Separate account liabilitiesSeparate account liabilities$38,391 $— $38,391 $— $38,391 Separate account liabilities$38,391 $— $38,391 $— $38,391 
_________________
(1)Includes mortgage loans measured at estimated fair value on a nonrecurring basis.
9299

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
12. Long-term Debt
Other Notes
In March 2023, Missouri Reinsurance, Inc., a wholly-owned subsidiary of the Company, borrowed funds from MetLife, Inc. under a term loan agreement, interest on which is payable semi-annually. The terms of the promissory notes are as follows:
$80 million 5.34% fixed rate due March 2028;
$80 million 5.68% fixed rate due March 2033; and
$50 million 6.05% fixed rate due March 2038.
Credit Facility
See Note 18 for information on the $3.0 billion unsecured revolving credit facility (the “Credit Facility”) maintained byIn May 2023, MetLife, Inc. and MetLife Funding, Inc., a wholly-owned subsidiary of Metropolitan Life Insurance Company, (“MetLife Funding”amended and restated their $3.0 billion unsecured revolving credit facility (as amended and restated, the “Credit Facility”). The facility may be used for general corporate purposes, to support the borrowers’ commercial paper programs and for the issuance of letters of credit. All borrowings under the Credit Facility must be repaid by May 8, 2028, except that letters of credit outstanding on that date may remain outstanding until no later than May 8, 2029.
13. Equity
Accumulated Other Comprehensive Income (Loss)
Information regarding changes in the balances of each component of AOCI attributable to Metropolitan Life Insurance Company was as follows:
Three Months 
 Ended 
 June 30, 2023
Unrealized
Investment Gains
(Losses), Net of
Related Offsets
Deferred
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
 (In millions)
Balance, beginning of period$(8,167)$1,568 $(106)$149 $(139)$(137)$(6,832)
OCI before reclassifications(2,114)(101)1,051 (73)17 — (1,220)
Deferred income tax benefit (expense)452 21 (219)16 (5)— 265 
AOCI before reclassifications, net of income tax(9,829)1,488 726 92 (127)(137)(7,787)
Amounts reclassified from AOCI829 (379)— — — 453 
Deferred income tax benefit (expense)(167)79 — — — (1)(89)
Amounts reclassified from AOCI, net of income tax662 (300)— — — 364 
Balance, end of period$(9,167)$1,188 $726 $92 $(127)$(135)$(7,423)
93
100

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Equity (continued)
Three Months
Ended
March 31, 2023
Three Months 
 Ended 
 June 30, 2022
Unrealized
Investment Gains
(Losses), Net of
Related Offsets
Unrealized
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
TotalUnrealized
Investment Gains
(Losses), Net of
Related Offsets
Deferred
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions) (In millions)
Balance, beginning of periodBalance, beginning of period$(11,161)$1,557 $1,529 $80 $(187)$(138)$(8,320)Balance, beginning of period$4,172 $1,597 $(8,611)$182 $(57)$(387)$(3,104)
OCI before reclassificationsOCI before reclassifications3,812 159 (2,068)88 60 (1)2,050 OCI before reclassifications(12,827)(96)8,565 (8)(34)— (4,400)
Deferred income tax benefit (expense)Deferred income tax benefit (expense)(798)(33)433 (19)(12)— (429)Deferred income tax benefit (expense)2,697 20 (1,799)— 925 
AOCI before reclassifications, net of income taxAOCI before reclassifications, net of income tax(8,147)1,683 (106)149 (139)(139)(6,699)AOCI before reclassifications, net of income tax(5,958)1,521 (1,845)176 (86)(387)(6,579)
Amounts reclassified from AOCIAmounts reclassified from AOCI(25)(146)— — — (169)Amounts reclassified from AOCI403 486 — — — 10 899 
Deferred income tax benefit (expense)Deferred income tax benefit (expense)31 — — — — 36 Deferred income tax benefit (expense)(85)(102)— — — (2)(189)
Amounts reclassified from AOCI, net of income taxAmounts reclassified from AOCI, net of income tax(20)(115)— — — (133)Amounts reclassified from AOCI, net of income tax318 384 — — — 710 
Balance, end of periodBalance, end of period$(8,167)$1,568 $(106)$149 $(139)$(137)$(6,832)Balance, end of period$(5,640)$1,905 $(1,845)$176 $(86)$(379)$(5,869)

Three Months
Ended
March 31, 2022
Six Months
Ended
June 30, 2023
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
Unrealized
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
TotalUnrealized
Investment Gains
(Losses), Net of
Related Offsets
Deferred
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)(In millions)
Balance, beginning of periodBalance, beginning of period$12,799 $1,872 $(15,553)$267 $(45)$(395)$(1,055)Balance, beginning of period$(11,161)$1,557 $1,529 $80 $(187)$(138)$(8,320)
OCI before reclassificationsOCI before reclassifications(11,131)(390)8,787 (107)(16)— (2,857)OCI before reclassifications1,698 58 (1,017)15 77 (1)830 
Deferred income tax benefit (expense)Deferred income tax benefit (expense)2,333 82 (1,845)22 — 596 Deferred income tax benefit (expense)(346)(12)214 (3)(17)— (164)
AOCI before reclassifications, net of income taxAOCI before reclassifications, net of income tax4,001 1,564 (8,611)182 (57)(395)(3,316)AOCI before reclassifications, net of income tax(9,809)1,603 726 92 (127)(139)(7,654)
Amounts reclassified from AOCIAmounts reclassified from AOCI216 42 — — — 10 268 Amounts reclassified from AOCI804 (525)— — — 284 
Deferred income tax benefit (expense)Deferred income tax benefit (expense)(45)(9)— — — (2)(56)Deferred income tax benefit (expense)(162)110 — — — (1)(53)
Amounts reclassified from AOCI, net of income taxAmounts reclassified from AOCI, net of income tax171 33 — — — 212 Amounts reclassified from AOCI, net of income tax642 (415)— — — 231 
Balance, end of periodBalance, end of period$4,172 $1,597 $(8,611)$182 $(57)$(387)$(3,104)Balance, end of period$(9,167)$1,188 $726 $92 $(127)$(135)$(7,423)

Six Months
Ended
June 30, 2022
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
Deferred
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)
Balance, beginning of period$12,799 $1,872 $(15,553)$267 $(45)$(395)$(1,055)
OCI before reclassifications(23,958)(486)17,352 (115)(50)— (7,257)
Deferred income tax benefit (expense)5,030 102 (3,644)24 — 1,521 
AOCI before reclassifications, net of income tax(6,129)1,488 (1,845)176 (86)(395)(6,791)
Amounts reclassified from AOCI619 528 — — — 20 1,167 
Deferred income tax benefit (expense)(130)(111)— — — (4)(245)
Amounts reclassified from AOCI, net of income tax489 417 — — — 16 922 
Balance, end of period$(5,640)$1,905 $(1,845)$176 $(86)$(379)$(5,869)
For information on offsets to investments related to policyholder liabilities, see “— Net Unrealized Investment Gains (Losses).”
94101

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Equity (continued)
Information regarding amounts reclassified out of each component of AOCI was as follows:
Three Months
Ended
March 31,
Three Months
Ended
June 30,
Six Months
Ended
June 30,
202320222023202220232022
AOCI ComponentsAOCI ComponentsAmounts Reclassified from AOCIConsolidated Statements of
Operations and
Comprehensive Income (Loss)
Locations
AOCI ComponentsAmounts Reclassified from AOCIConsolidated Statements of
Operations and
Comprehensive Income (Loss)
Locations
(In millions)(In millions)
Net unrealized investment gains (losses):Net unrealized investment gains (losses):Net unrealized investment gains (losses):
Net unrealized investment gains (losses)Net unrealized investment gains (losses)$41 $(213)Net investment gains (losses)Net unrealized investment gains (losses)$(828)$(388)$(787)$(601)Net investment gains (losses)
Net unrealized investment gains (losses)Net unrealized investment gains (losses)Net investment incomeNet unrealized investment gains (losses)Net investment income
Net unrealized investment gains (losses)Net unrealized investment gains (losses)(18)(5)Net derivative gains (losses)Net unrealized investment gains (losses)(2)(16)(20)(21)Net derivative gains (losses)
Net unrealized investment gains (losses), before income taxNet unrealized investment gains (losses), before income tax25 (216)Net unrealized investment gains (losses), before income tax(829)(403)(804)(619)
Income tax (expense) benefitIncome tax (expense) benefit(5)45 Income tax (expense) benefit167 85 162 130 
Net unrealized investment gains (losses), net of income taxNet unrealized investment gains (losses), net of income tax20 (171)Net unrealized investment gains (losses), net of income tax(662)(318)(642)(489)
Unrealized gains (losses) on derivatives - cash flow hedges:
Deferred gains (losses) on derivatives - cash flow hedges:Deferred gains (losses) on derivatives - cash flow hedges:
Interest rate derivativesInterest rate derivatives14 15 Net investment incomeInterest rate derivatives13 16 27 31 Net investment income
Interest rate derivativesInterest rate derivatives18 Net investment gains (losses)Interest rate derivatives55 53 57 71 Net investment gains (losses)
Foreign currency exchange rate derivativesForeign currency exchange rate derivativesNet investment incomeForeign currency exchange rate derivatives— Net investment income
Foreign currency exchange rate derivativesForeign currency exchange rate derivatives129 (77)Net investment gains (losses)Foreign currency exchange rate derivatives310 (555)439 (632)Net investment gains (losses)
Gains (losses) on cash flow hedges, before income taxGains (losses) on cash flow hedges, before income tax146 (42)Gains (losses) on cash flow hedges, before income tax379 (486)525 (528)
Income tax (expense) benefitIncome tax (expense) benefit(31)Income tax (expense) benefit(79)102 (110)111 
Gains (losses) on cash flow hedges, net of income taxGains (losses) on cash flow hedges, net of income tax115 (33)Gains (losses) on cash flow hedges, net of income tax300 (384)415 (417)
Defined benefit plans adjustment: (1)Defined benefit plans adjustment: (1)Defined benefit plans adjustment: (1)
Amortization of net actuarial gains (losses)Amortization of net actuarial gains (losses)(3)(10)Amortization of net actuarial gains (losses)(3)(11)(6)(21)
Amortization of prior service (costs) creditAmortization of prior service (costs) credit— Amortization of prior service (costs) credit— 
Amortization of defined benefit plan items, before income taxAmortization of defined benefit plan items, before income tax(2)(10)Amortization of defined benefit plan items, before income tax(3)(10)(5)(20)
Income tax (expense) benefitIncome tax (expense) benefit— Income tax (expense) benefit
Amortization of defined benefit plan items, net of income taxAmortization of defined benefit plan items, net of income tax(2)(8)Amortization of defined benefit plan items, net of income tax(2)(8)(4)(16)
Total reclassifications, net of income taxTotal reclassifications, net of income tax$133 $(212)Total reclassifications, net of income tax$(364)$(710)$(231)$(922)
__________________
(1)These AOCI components are included in the computation of net periodic benefit costs.
95102

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Equity (continued)
Net Unrealized Investment Gains (Losses)
Unrealized investment gains (losses) on fixed maturity securities AFS, derivatives and other investments and the effect on policyholder liabilities that would result from the realization of the unrealized gains (losses), are included in net unrealized investment gains (losses) in AOCI.
The components of net unrealized investment gains (losses), included in AOCI, were as follows:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
(In millions)(In millions)
Fixed maturity securities AFSFixed maturity securities AFS$(10,961)$(14,741)Fixed maturity securities AFS$(12,215)$(14,741)
DerivativesDerivatives1,984 1,971 Derivatives1,504 1,971 
OtherOther475 455 Other488 455 
SubtotalSubtotal(8,502)(12,315)Subtotal(10,223)(12,315)
Amounts allocated from:Amounts allocated from:Amounts allocated from:
Policyholder liabilitiesPolicyholder liabilities42 55 Policyholder liabilities(2)55 
Deferred income tax benefit (expense)Deferred income tax benefit (expense)1,861 2,656 Deferred income tax benefit (expense)2,246 2,656 
Net unrealized investment gains (losses)Net unrealized investment gains (losses)$(6,599)$(9,604)Net unrealized investment gains (losses)$(7,979)$(9,604)
14. Other Revenues and Other Expenses
Other Revenues
Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows:
Three Months
Ended
March 31,
Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
202320222023202220232022
(In millions)(In millions)
Prepaid legal plansPrepaid legal plans$115 $108 Prepaid legal plans$115 $106 $230 $214 
Recordkeeping and administrative services (1)Recordkeeping and administrative services (1)37 47 Recordkeeping and administrative services (1)37 42 74 89 
Administrative services-only contractsAdministrative services-only contracts61 55 Administrative services-only contracts62 57 123 112 
Other revenue from service contracts from customersOther revenue from service contracts from customers10 Other revenue from service contracts from customers11 21 14 
Total revenues from service contracts from customersTotal revenues from service contracts from customers223 217 Total revenues from service contracts from customers225 212 448 429 
Other (2)Other (2)192 194 Other (2)194 160 386 354 
Total other revenuesTotal other revenues$415 $411 Total other revenues$419 $372 $834 $783 
__________________
(1)Related to products and businesses no longer actively marketed by the Company.
(2)Primarily includes reinsurance ceded. See Note 17.
96103

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
14. Other Revenues and Other Expenses (continued)
Other Expenses
Information on other expenses was as follows:
Three Months
Ended
March 31,
Three Months 
 Ended 
 June 30,
Six Months
Ended
June 30,
202320222023202220232022
(In millions)(In millions)
General and administrative expenses (1)General and administrative expenses (1)$661 $639 General and administrative expenses (1)$677 $725 $1,338 $1,364 
Pension, postretirement and postemployment benefit costsPension, postretirement and postemployment benefit costs50 30 Pension, postretirement and postemployment benefit costs50 29 100 59 
Premium taxes, other taxes, and licenses & feesPremium taxes, other taxes, and licenses & fees93 80 Premium taxes, other taxes, and licenses & fees106 81 199 161 
Commissions and other variable expensesCommissions and other variable expenses714 482 Commissions and other variable expenses467 491 1,181 973 
Capitalization of DACCapitalization of DAC(77)(27)Capitalization of DAC(12)(34)(89)(61)
Amortization of DAC and VOBAAmortization of DAC and VOBA77 80 Amortization of DAC and VOBA74 76 151 156 
Interest expense on debtInterest expense on debt30 24 Interest expense on debt34 25 64 49 
Total other expensesTotal other expenses$1,548 $1,308 Total other expenses$1,396 $1,393 $2,944 $2,701 
__________________
(1)Includes ($30)27) million and $22($57) million for the three months and six months ended March 31,June 30, 2023, respectively, and $52 million and $74 million for the three months and six months endedJune 30, 2022, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.
Affiliated Expenses
See Note 17 for a discussion of affiliated expenses included in the table above.
15. Income Tax
For the three months and six months ended March 31,June 30, 2023, the effective tax rate on income (loss) before provision for income tax was 13% and (7%), respectively. The Company’s effective tax rate for the three months ended June 30, 2023 differed from the U.S. statutory rate primarily due to tax benefits from tax credits and non-taxable investment income. The Company’s effective tax rate for the six months ended June 30, 2023 reflected an income tax benefit despite having income before provision for income tax and differed from the U.S. statutory rate primarily due to tax benefits from tax credits, non-taxable investment income and the corporate tax deduction for stock compensation.
For the three months and six months ended June 30, 2022, the effective tax rate on income (loss) before provision for income tax was 53%19% and 18%, respectively. The Company’s effective tax rate for both the three months ended March 31, 2023June 30, 2022 differed from the U.S. statutory rate primarily due to tax benefits from tax credits and non-taxable investment income. The Company’s effective tax rate for the six months ended June 30, 2022 differed from the U.S. statutory rate primarily due to tax benefits from tax credits, the corporate tax deduction for stock compensation and non-taxable investment income.
16. Contingencies, Commitments and Guarantees
Contingencies
Litigation
The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s interim condensed consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor, broker-dealer, and taxpayer.
104

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
16. Contingencies, Commitments and Guarantees (continued)
The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the United States where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries.
97

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
16. Contingencies, Commitments and Guarantees (continued)
It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. In certain circumstances where liabilities have been established there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at March 31,June 30, 2023. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods.
Matters as to Which an Estimate Can Be Made
For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of March 31,June 30, 2023, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million.
Matters as to Which an Estimate Cannot Be Made
For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews.
Asbestos-Related Claims
Metropolitan Life Insurance Company is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. Metropolitan Life Insurance Company has never engaged in the business of manufacturing or selling asbestos-containing products, nor has Metropolitan Life Insurance Company issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of Metropolitan Life Insurance Company’s employees during the period from the 1920s through approximately the 1950s and allege that Metropolitan Life Insurance Company learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. Metropolitan Life Insurance Company believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against Metropolitan Life Insurance Company.
105

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
16. Contingencies, Commitments and Guarantees (continued)
Metropolitan Life Insurance Company’s defenses include that: (i) Metropolitan Life Insurance Company owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of Metropolitan Life Insurance Company; (iii) Metropolitan Life Insurance Company’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against Metropolitan Life Insurance Company, while other trial courts have denied Metropolitan Life Insurance Company’s motions. There can be no assurance that Metropolitan Life Insurance Company will receive favorable decisions on motions in the future. While most cases brought to date have settled, Metropolitan Life Insurance Company intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials.
98

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
16. Contingencies, Commitments and Guarantees (continued)
As reported in the 2022 Annual Report, Metropolitan Life Insurance Company received approximately 2,610 asbestos-related claims in 2022. For the threesix months ended March 31,June 30, 2023 and 2022, Metropolitan Life Insurance Company received approximately 5871,306 and 7211,319 new asbestos-related claims, respectively. See Note 16 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report for historical information concerning asbestos claims and Metropolitan Life Insurance Company’s update in its recorded liability at December 31, 2022. The number of asbestos cases that may be brought, the aggregate amount of any liability that Metropolitan Life Insurance Company may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year.
The ability of Metropolitan Life Insurance Company to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against Metropolitan Life Insurance Company when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts.
The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position.
The Company believes adequate provision has been made in its interim condensed consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. Metropolitan Life Insurance Company’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis.
Metropolitan Life Insurance Company reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, Metropolitan Life Insurance Company has updated its liability analysis for asbestos-related claims through March 31,June 30, 2023.
Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017)
Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the State of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., Metropolitan Life Insurance Company and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. The Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and Metropolitan Life Insurance Company’s motion to dismiss and remanded the case to the trial court where the Relator has filed an amended complaint. The Company intends to defend the action vigorously.
106

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
16. Contingencies, Commitments and Guarantees (continued)
Matters Related to Group Annuity Benefits
In 2018, the Company announced that it identified a material weakness in its internal control over financial reporting related to the practices and procedures for estimating reserves for certain group annuity benefits. Several regulators have made inquiries into this issue and it is possible that other jurisdictions may pursue similar investigations or inquiries. The Company could be exposed to lawsuits, and additional legal actions relating to this issue. These may result in payments, including damages, fines, penalties, interest and other amounts assessed or awarded by courts or regulatory authorities under applicable escheat, tax, securities, Employee Retirement Income Security Act of 1974, or other laws or regulations. The Company could incur significant costs in connection with these actions.
99

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
16. Contingencies, Commitments and Guarantees (continued)
Commitments
Mortgage Loan Commitments
The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $2.4$2.0 billion and $2.7 billion at March 31,June 30, 2023 and December 31, 2022, respectively.
Commitments to Fund Partnership Investments, Bank Credit Facilities and Private Corporate Bond Investments
The Company commits to fund partnership investments and to lend funds under bank credit facilities and private corporate bond investments. The amounts of these unfunded commitments were $4.5$5.0 billion and $4.8 billion at March 31,June 30, 2023 and December 31, 2022, respectively.
Guarantees
In the normal course of its business, the Company has provided certain indemnities and guarantees to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $239$232 million, with a cumulative maximum of $340$331 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities or guarantees.
In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future.
The Company’s recorded liabilities were $2 million at both March 31,June 30, 2023 and December 31, 2022, for indemnities and guarantees.
107

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
17. Related Party Transactions
Service Agreements
The Company has entered into various agreements with affiliates for services necessary to conduct its activities. Typical services provided under these agreements include personnel, policy administrative functions and distribution services. The bases for such charges are modified and adjusted by management when necessary or appropriate to reflect fairly and equitably the actual cost incurred by the Company and/or its affiliates. Expenses and fees incurred with affiliates related to these agreements, recorded in other expenses, were $715$737 million and $636 million$1.5 billion for the three months and six months ended March 31,June 30, 2023, respectively, and $649 million and $1.3 billion for the three months and six months ended June 30, 2022, respectively. Total revenues received from affiliates related to these agreements were $14$15 million and $12$29 million for the three months and six months ended March 31,June 30, 2023, respectively, and $11 million and $23 million for the three months and six months ended June 30, 2022, respectively.
The Company had net payables to affiliates, related to the items discussed above, of $92$96 million and $188 million at March 31,June 30, 2023 and December 31, 2022, respectively.
See Notes 9 and 12 for additional information on related party transactions.
100108

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
17. Related Party Transactions (continued)
Related Party Reinsurance Transactions
The Company has reinsurance agreements with certain of MetLife, Inc.’s subsidiaries, including MetLife Reinsurance Company of Charleston (“MRC”), MetLife Reinsurance Company of Vermont, Metropolitan Tower Life Insurance Company (“MTL”), and MetLife Insurance K.K., all of which are related parties.
Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated statements of operations and comprehensive income (loss) was as follows:
Three Months
Ended
March 31,
Three Months
Ended
June 30,
Six Months
Ended
June 30,
202320222023202220232022
(In millions)(In millions)
PremiumsPremiumsPremiums
Reinsurance assumedReinsurance assumed$(27)$Reinsurance assumed$$$(25)$
Reinsurance cededReinsurance ceded(84)(31)Reinsurance ceded(89)(37)(173)(68)
Net premiumsNet premiums$(111)$(30)Net premiums$(87)$(35)$(198)$(65)
Universal life and investment-type product policy feesUniversal life and investment-type product policy feesUniversal life and investment-type product policy fees
Reinsurance assumedReinsurance assumed$— $— Reinsurance assumed$$— $$— 
Reinsurance cededReinsurance ceded(2)(1)Reinsurance ceded(2)(1)(4)(2)
Net universal life and investment-type product policy feesNet universal life and investment-type product policy fees$(2)$(1)Net universal life and investment-type product policy fees$(1)$(1)$(3)$(2)
Other revenuesOther revenuesOther revenues
Reinsurance assumedReinsurance assumed$22 $24 Reinsurance assumed$24 $$46 $29 
Reinsurance cededReinsurance ceded115 123 Reinsurance ceded116 124 231 247 
Net other revenuesNet other revenues$137 $147 Net other revenues$140 $129 $277 $276 
Policyholder benefits and claimsPolicyholder benefits and claimsPolicyholder benefits and claims
Reinsurance assumedReinsurance assumed$(169)$11 Reinsurance assumed$18 $20 $(151)$31 
Reinsurance cededReinsurance ceded(77)(32)Reinsurance ceded(68)(42)(145)(74)
Net policyholder benefits and claimsNet policyholder benefits and claims$(246)$(21)Net policyholder benefits and claims$(50)$(22)$(296)$(43)
Policyholder liability remeasurement (gains) lossesPolicyholder liability remeasurement (gains) lossesPolicyholder liability remeasurement (gains) losses
Reinsurance assumedReinsurance assumed$(39)$(18)Reinsurance assumed$— $(15)$(39)$(33)
Reinsurance cededReinsurance ceded(5)(3)Reinsurance ceded— (1)(5)(4)
Net policyholder liability remeasurement (gains) lossesNet policyholder liability remeasurement (gains) losses$(44)$(21)Net policyholder liability remeasurement (gains) losses$— $(16)$(44)$(37)
Interest credited to policyholder account balancesInterest credited to policyholder account balancesInterest credited to policyholder account balances
Reinsurance assumedReinsurance assumed$73 $Reinsurance assumed$88 $12 $161 $21 
Reinsurance cededReinsurance ceded(3)(3)Reinsurance ceded(3)(3)(6)(6)
Net interest credited to policyholder account balancesNet interest credited to policyholder account balances$70 $Net interest credited to policyholder account balances$85 $$155 $15 
Other expensesOther expensesOther expenses
Reinsurance assumedReinsurance assumed$204 $Reinsurance assumed$11 $$215 $10 
Reinsurance cededReinsurance ceded63 86 Reinsurance ceded65 109 128 195 
Net other expensesNet other expenses$267 $95 Net other expenses$76 $110 $343 $205 
101109

Table of Contents
Metropolitan Life Insurance Company
(A Wholly-Owned Subsidiary of MetLife, Inc.)
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
17. Related Party Transactions (continued)
Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated balance sheets was as follows at:
March 31, 2023December 31, 2022June 30, 2023December 31, 2022
AssumedCededAssumedCededAssumedCededAssumedCeded
(In millions)(In millions)
AssetsAssetsAssets
Premiums, reinsurance and other receivablesPremiums, reinsurance and other receivables$743 $11,294 $723 $11,303 Premiums, reinsurance and other receivables$170 $11,261 $723 $11,303 
Deferred policy acquisition costs and value of business acquiredDeferred policy acquisition costs and value of business acquired168 (163)120 (164)Deferred policy acquisition costs and value of business acquired167 (162)120 (164)
Total assetsTotal assets$911 $11,131 $843 $11,139 Total assets$337 $11,099 $843 $11,139 
LiabilitiesLiabilitiesLiabilities
Future policy benefitsFuture policy benefits$2,322 $— $2,484 $— Future policy benefits$2,253 $— $2,484 $— 
Policyholder account balancesPolicyholder account balances8,817 — 6,216 — Policyholder account balances9,043 — 6,216 — 
Other policy-related balancesOther policy-related balances63 (26)61 (23)Other policy-related balances65 (29)61 (23)
Other liabilitiesOther liabilities926 10,466 910 10,380 Other liabilities857 10,288 910 10,380 
Total liabilitiesTotal liabilities$12,128 $10,440 $9,671 $10,357 Total liabilities$12,218 $10,259 $9,671 $10,357 
Effective April 1, 2021, the Company, through its wholly-owned subsidiary, Missouri Reinsurance, Inc., entered into an agreement to assume certain group annuity contracts issued in connection with a qualifying pension risk transfer on a modified coinsurance basis from MTL. The significant reinsurance effects to the Company were primarily increases in future policy benefits of $2.3$2.2 billion and $2.4 billion and other invested assets of $2.9 billion and $3.0 billion at March 31,June 30, 2023 and December 31, 2022, respectively, as well asrespectively. Also, the Company recorded policyholder benefits and claims of ($171) $14 million and $11($157) million and other expenses of $194 million$0 and $8$194 million for the three months and six months ended March 31,June 30, 2023, respectively. Additionally, policyholder benefits and claims of $19 million and $30 million and other expenses of $0 and $8 million were recorded for the three months and six months ended June 30, 2022, respectively. Also, as a result of this agreement, other invested assets increased by $3.0 billion at both March 31, 2023 and December 31, 2022.
The Company ceded two blocks of business to an affiliate on a 75% coinsurance with funds withheld basis. Certain contractual features of these agreements qualify as embedded derivatives, which are separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivatives related to the funds withheld associated with these reinsurance agreements are included within other liabilities and were ($22)$1 million and ($28) million at March 31,June 30, 2023 and December 31, 2022, respectively. Net derivative gains (losses) associated with these embedded derivatives were ($6)23) million and $25($29) million for the three months and six months ended March 31,June 30, 2023, respectively, and $22 million and $47 million for the three months and six months ended June 30, 2022, respectively.
Certain contractual features of the closed block agreement with MRC qualify as embedded derivatives, which are separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivative related to the funds withheld associated with this reinsurance agreement was included within other liabilities and was ($258)372) million and ($423) million at March 31,June 30, 2023 and December 31, 2022, respectively. Net derivative gains (losses) associated with the embedded derivative were ($165)$114 million and $613($51) million for the three months and six months ended March 31,June 30, 2023, respectively, and $504 million and $1.1 billion for the three months and six months ended June 30, 2022, respectively.
18. Subsequent Events
On May 8, 2023, the Credit Facility maintained by MetLife, Inc. and MetLife Funding was amended and restated to, among other things, extend the maturity date to May 2028. All borrowings under the amended and restated Credit Facility must be repaid by May 8, 2028 except that letters of credit outstanding upon termination may remain outstanding until no later than May 8, 2029.


102110

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Index to Management’s Discussion and Analysis of Financial Condition and Results of Operations
Page
103111

Table of Contents
Forward-Looking Statements and Other Financial Information
For purposes of this discussion, “MLIC,” the “Company,” “we,” “our” and “us” refer to Metropolitan Life Insurance Company, a New York corporation incorporated in 1868, and its subsidiaries. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”). Management’s narrative analysis of the Company’s results of operations is presented pursuant to General Instruction H(2)(a) of Form 10-Q. This narrative analysis should be read in conjunction with Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), the cautionary language regarding forward-looking statements included below, the “Risk Factors” set forth in Part II, Item 1A, and the additional risk factors referred to therein, “Quantitative and Qualitative Disclosures About Market Risk” and the Company’s interim condensed consolidated financial statements included elsewhere herein.
This narrative analysis may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. See “Note Regarding Forward-Looking Statements” for cautionary language regarding forward-looking statements.
This narrative analysis includes references to our performance measure, adjusted earnings, that is not based on accounting principles generally accepted in the United States of America (“GAAP”). See “— Non-GAAP and Other Financial Disclosures” for definitions and a discussion of this and other financial measures, and “— Results of Operations” for reconciliations of historical non-GAAP financial measures to the most directly comparable GAAP measures.
Business
Current Market Conditions
In the United States (“U.S.”), the Board of Governors of the Federal Reserve System and the Federal Open Market Committee took various actions in 2022 and in most of the beginningfirst half of 2023 to promote economic stability and combat inflation, including raising interest rates, although a heightened level of concern about an economic downturn in the U.S. remains, exacerbated by the recent banking turmoil. During inflationary periods with rising interest rates, the value of fixed income investments falls which could increase realized and unrealized losses, resulting in additional deferred tax assets that may not be realizable.
Regulatory Developments
The following discussion on regulatory developments should be read in conjunction with “Business — Regulation” in the 2022 Annual Report, as amended or supplemented here.
Insurance Regulation
U.S. Federal Initiatives
On April 21, 2023, the Financial Stability Oversight Council (“FSOC”) proposed certain changes to how FSOC would designate non-bank financial companies as systemically important financial institutions (“non-bank SIFIs”). The proposed changes include a revised approach to non-bank SIFI designation based on risk factors contained in a proposed analytic framework, including leverage, liquidity risk and maturity mismatch, interconnections, operational risks, complexity, or opacity, inadequate risk management, concentration, and destabilizing activities, regardless of whether those risks arise from activities, firms, or otherwise. The proposed changes also include eliminating any requirement that FSOC conduct a cost-benefit analysis and an assessment of the likelihood of a non-bank financial company’s material financial distress before designating the non-bank financial company as a non-bank SIFI. The FSOC’s proposed changes, if adopted, could have the effect of simplifying and shortening FSOC’s procedures for designating non-bank financial companies as non-bank SIFIs and thus subject a non-bank financial company so designated to additional supervision, examination, and regulation. Any such designation would create uncertainties for the non-bank financial company regarding the likelihood, frequency or impact of any formal or informal regulatory or supervisory actions or inquiries; the scope of applicable regulatory or supervisory requirements or restrictions and the related compliance measures and internal controls; and the permissibility of certain activities or transactions. It is difficult to predict whether or the extent to which FSOC’s proposed changes would be adopted as proposed or if any further change would be made and any potential impact thereof.
104112

Table of Contents
Surplus and Capital
Risk-Based Capital
In light of the rising interest rate environment, the National Association of Insurance Commissioners (“NAIC”) is focused on identifying aan interim solution that would be in place for year-end 2023 with regard to the treatment of an insurer’s negative interest maintenance reserve (“IMR”) balance, since this can impact how accurately the insurer’s surplus and financial strength are captured in its statutory financial statements due to lower surplus and risk-based capital (“RBC”) ratios. The NAIC has proposedis developing a new interpretation of statutory accounting guidance that would permit an insurer with ana company action level RBC ratio greater than 150% (or an authorized control level RBC ratio greater than 300%) to admit negative IMR of up to 5%a specified percentage of its general account capital and surplus, subject to certain restrictions and reporting obligations. Comments onThe NAIC intends to consider adoption of this interpretation in August 2023 at the proposal are due in June 2023.NAIC Summer National Meeting following a public comment period. As proposed, the interim approach, if adopted, would apply through 2025. The NAIC also intends to develop a long-term solution for this issue even if interest rates shift.
The NAIC has been evaluating the risks associated with certain insurers’ investments in leveraged loans and collateralized loan obligations (“CLOs”). The NAIC is considering a proposal to assign risk weights to CLOs based on its own modeling as opposed to credit ratings. Under this proposal, the NAIC Structured Securities Group would model CLO investments and evaluate tranche level losses across all debt and equity tranches under a series of calibrated and weighted collateral stress scenarios to assign NAIC designations that minimize RBC arbitrage. The NAIC’s goal is to ensure that the aggregate RBC factor for owning all tranches of a CLO is similar to that required for owning all of the underlying loan collateral, in order to reduce RBC arbitrage. This change would be implemented at year-end 2024 at the earliest. It is currently unclear whether this will apply to all CLOs or only in specified cases. It is possible that the NAIC may propose new regulations or changes to statutory accounting principles regarding CLOs.
Cybersecurity, Privacy and Data Protection Regulation
Cybersecurity
In July 2023, the U.S. Securities and Exchange Commission adopted the Risk Management, Strategy, Governance, and Incident Disclosure Final Rule (the “Cybersecurity Final Rule”) enhancing disclosure requirements for registered companies covering cybersecurity risk and management. The Cybersecurity Final Rule requires registrants to disclose material cybersecurity incidents on Form 8-K within four business days of a determination that a cybersecurity incident is material, and such materiality determination must be made without unreasonable delay. The rule also requires periodic disclosures of, among other things, details on the company’s processes to assess, identify, and manage cybersecurity risks, cybersecurity governance, and management’s role in overseeing such a compliance program, including the board of directors’ oversight of cybersecurity risks. Certain reporting requirements under the Cybersecurity Final Rule become effective as early as December 2023.
London Interbank Offered Rate
The Financial Conduct AuthorityIntercontinental Exchange (“FCA”ICE”), Benchmark Administration, the United Kingdom regulatoradministrator of the London Interbank Offered Rate (“LIBOR”), and the Intercontinental Exchange (“ICE”) Benchmark Administration, the administrator of LIBOR, have announced the cessation dates forceased the publication of all U.S. Dollar and non-U.S. Dollar LIBOR settings. The cessation datessettings at the end of many of these settings have occurred and the cessation date of the remaining U.S. Dollar LIBOR settings (overnight and one-, three-, six- and 12-month U.S. Dollar LIBOR) will occur on June 30, 2023. The FCA has announced thatHowever, the ICE Benchmark Administration will continue publication of one-, three- and six-month U.S. Dollar LIBOR settings on a “synthetic,” or non-representative, basis through the end of September 2024.
113

Table of Contents
Summary of Critical Accounting Estimates
The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. Effective January 1, 2023, the Company adopted a new accounting pronouncement related to targeted improvements to the accounting for long-duration contracts (“LDTI”) with a January 1, 2021 transition date (the “Transition Date”). The effects of adoption were therefore applied for years ended December 31, 2022 and 2021, as described in Note1 of the Notes to the Interim Condensed Consolidated Financial Statements. This summary of critical accounting estimates reflects this adoption. For a discussion of our significant accounting policies, see Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements. The most critical estimates include those used in determining:
(i)future policy benefit liabilities (“FPBs”), market risk benefits (“MRBs”) and the accounting for reinsurance;
(ii)estimated fair values of investments in the absence of quoted market values;
(iii)investment allowance for credit loss (“ACL”) and impairments;
(iv)estimated fair values of freestanding derivatives;
(v)measurement of employee benefit plan liabilities;
(vi)measurement of income taxes and the valuation of deferred tax assets; and
(vii)liabilities for litigation and regulatory matters.
105

Table of Contents
Due to the adoption of LDTI, the measurement model for deferred policy acquisition costs (“DAC”) and value of business acquired (“VOBA”) changed and the majority of the embedded derivatives met the criteria to be accounted for as MRBs; therefore, we no longer believe that DAC, VOBA and embedded derivatives are critical accounting estimates. LDTI impacted the recognition and measurement of FPBs, MRBs and reinsurance, along with the resulting impacts to deferred income taxes which are described in further detail below. The other critical accounting estimates above were not impacted by the adoption of LDTI and are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates” and Note 1 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report.
In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to our business and operations. Actual results could differ from these estimates.
Future Policy Benefit Liabilities
Generally, FPBs are payable over an extended period of time and calculated as the present value of future expected benefits and claim settlement expenses to be paid, reduced by the present value of future expected net premiums. Such liabilities are established based on methods and underlying assumptions in accordance with GAAP and applicable actuarial standards. Principal assumptions used in the establishment of FPBs for traditional long-duration non-participating products are expectations related to mortality, morbidity, termination, claim settlement expense, policy lapse, renewal, retirement, disability incidence, disability terminations, inflation, and other contingent events as appropriate to the respective product type and geographical area. These assumptions are updated at least annually to reflect our expected experience for future periods. If net premiums exceed gross premiums (i.e., expected benefits exceed expected gross premiums), the FPBs are increased, and a corresponding adjustment is recognized in net income.
Liabilities for unpaid claims are estimated based upon our historical experience and other actuarial assumptions that consider the effects of current developments, anticipated trends and risk management programs.
114

Table of Contents
Traditional non-participating long-duration and limited-payment contracts comprise the majority of MLIC’s FPBs, inclusive of deferred profit liabilities, as described in Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements. For such contracts, cash flow assumptions are incorporated into the calculation of the FPBs, and are used to project the amount and timing of expected future benefits and claim settlement expenses to be paid and the expected future premiums to be collected for a cohort. Beginning on the Transition Date, the liabilities for these products are updated retrospectively on a quarterly basis for actual experience and at least once a year for any changes in cash flow assumptions. The change in FPBs reflected in the statement of operations is calculated using a locked-in discount rate. For products issued prior to the Transition Date, the Company developed a cohort level locked-in discount rate that reflects the interest accretion rates that were locked in at inception of the underlying contracts (unless there was a historical premium deficiency event that resulted in updating the interest accretion rate prior to the Transition Date), or the acquisition date for contracts acquired through an assumed in-force reinsurance transaction or a business combination. As described in Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements, the upper-medium grade discount rate, which the Company generally interprets as a rate comparable to that of a U.S. corporate single A discount rate which reflects the duration characteristics of the liability, is used to discount the estimated cash flows and that discount rate is updated at each reporting period through other comprehensive income (loss) (“OCI”).
We measure market risk related to our market sensitive traditional long-duration non-participating and limited-payment contracts based on changes in interest rates utilizing a sensitivity analysis. The results of this sensitivity analysis are included in “Quantitative and Qualitative Disclosures About Market Risk — Management of Market Risk Exposures.” We have also assessed the sensitivities of hypothetical changes in significant assumptions to reported amounts related to our traditional long-duration non-participating and limited-payment contracts, for products including, but not limited to, those within the disaggregated rollforwards included in Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements, as reflected in the following tables:
106

Table of Contents
Traditional long-duration non-participating and limited-payment contracts
December 31, 2022
FPBs (1)Pre-tax
Net Income
OCI
Increase / (Decrease) (In millions)
Assumptions:
Mortality
Effect of an increase by 1%$(55)$68 $(13)
Effect of a decrease by 1%$57 $(70)$13 
Morbidity (2) 
Effect of an increase by 5%$359 $(394)$35 
Effect of a decrease by 5%$(144)$177 $(33)
Lapse (3) 
Effect of an increase by 10%$(99)$164 $(65)
Effect of a decrease by 10%$340 $(418)$78 
__________________
(1)FPBs are inclusive of deferred profit liabilities where applicable to the sensitivity.
(2)For products which are subject to morbidity risk, MLIC applied sensitivities to the incidence rate assumptions only.
(3)For MetLife Holdings long-term care products, the lapse impacts include mortality as both mortality and lapse result in termination of these contracts without any additional benefit payment.
See Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements for additional information, including the significant inputs, judgments, valuation methods and assumptions used in the establishment of FPBs, as well as the effect of changes in such factors on the measurement of our FPBs during the year.
115

Table of Contents
Traditional participating contracts comprise a significant portion of MLIC’s FPBs, as described in Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements. For such contracts, original assumptions developed at the time of issue are locked-in and used in all future liability calculations provided the resulting liabilities are adequate to provide for future benefits and expenses (i.e., there is no premium deficiency). Therefore, liabilities for these products would not be impacted by changes in assumptions unless such change would result in an adverse impact that would trigger an establishment of a premium deficiency reserve. For these contracts, MLIC’s risk of adverse experience may be mitigated through adjustments to the dividend scales.
Liabilities for universal and variable universal life secondary and paid-up guarantees are determined by estimating the expected value of death benefits payable when the account balance is projected to be zero and recognizing those benefits ratably over the accumulation period based on total expected assessments. The assumptions used in estimating the secondary and paid-up guarantee liabilities are mortality, lapse, and premium payment pattern and persistency. In addition, the projected account balance and assessments used in this calculation are impacted by the earned rate on investments and the interest crediting rates, which are typically subject to guaranteed minimums. The assumptions of investment performance and volatility for variable products’ separate account funds are consistent with historical experience of the appropriate underlying equity index, such as the S&P Global Ratings (“S&P”) 500 Index. These assumptions are monitored and updated periodically based on market conditions and historical experience. For further information on additional insurance liabilities and the amounts included in the disaggregated rollforwards, see Note 3 of the Notes to the Interim Condensed Consolidated Financial Statements.
For all insurance assets and liabilities, MLIC holds capital and surplus to mitigate potential adverse experience development. The Company’s approaches for managing liquidity and capital are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources” included in the 2022 Annual Report.
107

Table of Contents
Market Risk Benefits
MRBs are contracts or contract features that guarantee benefits, such as guaranteed minimum benefits (referred to as “GMXBs”), in addition to an account balance which expose insurance companies to other than nominal capital market risk (equity price, interest rate, and/or foreign currency exchange risk) and protect the contractholder from the same risk. Certain contracts may have multiple contract features or guarantees that meet the definition of an MRB. Those benefits are aggregated and measured as a single compound MRB.
All identified MRBs are required to be measured at estimated fair value, which is determined based on the present value of projected future benefits minus the present value of projected future fees attributable to those benefit features. The projections of future benefits and future fees require capital market and actuarial assumptions, including expectations concerning policyholder behavior. A risk neutral valuation methodology is used under which the cash flows from the guarantees are projected under multiple capital market scenarios using observable risk-free rates. The valuation of these MRBs also includes an adjustment for our nonperformance risk and risk margins for non-capital market inputs. The nonperformance risk adjustment, which is captured as a spread over the risk-free rate in determining the discount rate to discount the cash flows of the liability, is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties in certain actuarial assumptions. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees.
Changes in the estimated fair value of MRBs are recognized in net income, except for fair value changes attributable to a change in nonperformance risk of the Company which is recorded within OCI.
The cost of MRBs may rise in volatile or declining equity markets or in a low interest rate environment. Market conditions including, but not limited to, changes in interest rates, equity indices, market volatility and foreign currency exchange rates, variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, may result in significant fluctuations in the estimated fair value of the guarantees that could materially affect net income, and changes in our nonperformance risk could materially affect OCI.
108116

Table of Contents
We measure market risk related to our MRBs based on changes in interest rates, foreign currency exchange rates and equity market prices utilizing a sensitivity analysis. The results of this sensitivity analysis are included in “Quantitative and Qualitative Disclosures About Market Risk — Management of Market Risk Exposures.” We have also assessed the sensitivities of hypothetical changes in significant assumptions to reported amounts related to our MRBs for products included within the disaggregated rollforwards in Note 5 of the Notes to the Interim Condensed Consolidated Financial Statements, as reflected in the following table:
December 31, 2022
MRBs
(Liabilities net of Assets)
Pre-tax
Net Income
OCI
Increase / (Decrease) (In millions)
Assumptions:
Mortality
Effect of an increase by 1%$$(1)$(1)
Effect of a decrease by 1%$(2)$$
Lapse
Effect of an increase by 10%$(29)$34 $(5)
Effect of a decrease by 10%$26 $(30)$
Nonperformance risk (1)
Effect of an increase by 50 bps$(265)N/A$265 
Effect of a decrease by 50 bps$291 N/A$(291)
__________________
(1)In the valuation of MRBs, the Company applies a nonperformance risk adjustment, which is captured as a spread over the risk-free rate in determining the discount rate to discount the cash flows of the liability, determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries compared to MetLife, Inc.
See Note 5 of the Notes to the Interim Condensed Consolidated Financial Statements for additional information, including the significant inputs, judgments, valuation methods and assumptions used in the establishment of the MRBs, as well as the effect of changes in such factors on the measurement of our MRBs during the year. Also, see Note 11 of the Notes to the Interim Condensed Consolidated Financial Statements for additional information on the fair value measurement of MRBs.
Reinsurance
Accounting for reinsurance generally presents the income statement effect of direct policies on a net-of-reinsurance basis by using assumptions and methodologies consistent with those used to project the future performance of the underlying direct business. Further, the potential impact of counterparty credit risks are considered when measuring the reinsurance recoverable. We periodically review actual and anticipated experience compared to the aforementioned assumptions used to establish assets and liabilities relating to ceded and assumed reinsurance and evaluate the financial strength of counterparties to our reinsurance agreements using criteria similar to that evaluated in our security impairment process. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates — Investment Allowance for Credit Loss and Impairments” included in the 2022 Annual Report. Additionally, for each of our reinsurance agreements, we determine whether the agreement provides indemnification against loss or liability relating to insurance risk, in accordance with applicable accounting standards. We review all contractual features, including those that may limit the amount of insurance risk to which the reinsurer is subject or features that delay the timely reimbursement of claims. If we determine that a reinsurance agreement does not expose the reinsurer to a reasonable possibility of a significant loss from insurance risk, we record the agreement using the deposit method of accounting. The reinsurance recoverables associated with the FPBs are not included in the sensitivities presented above as they are not considered significant in relation to the associated liabilities.
See Note 5 of the Notes to the Consolidated Financial Statements included in the 2022 Annual Report for additional information on our reinsurance programs.
109117

Table of Contents
Income Taxes and Valuation of Deferred Tax Assets
Our accounting for income taxes represents our best estimate of various events and transactions. Tax laws are often complex and may be subject to differing interpretations by the taxpayer and the relevant governmental taxing authorities. In establishing a provision for income tax expense, we must make judgments and interpretations about the application of inherently complex tax laws. We must also make estimates about when in the future certain items will affect taxable income in the various tax jurisdictions in which we conduct business.
The Company considers all available factors, both positive and negative, to determine whether, based on the weight of these factors, a partial or full valuation allowance for categories of deferred tax assets is required. The weight given to these factors is commensurate with the extent to which it can be objectively verified. Examples of factors considered in determining deferred tax asset realizability include past earnings history, projections of taxable income and tax planning strategies. Changes in tax laws and/or statutory tax rates in countries in which we operate could have an impact on our valuation of net deferred tax assets. Following the adoption of LDTI, if there were a 1% increase in the global effective income tax rate, the change would have resulted in an approximate $139 million increase in the net deferred income tax asset balance at December 31, 2022.
110

Table of Contents
Results of Operations
Overview
MLIC is a provider of insurance, annuities, employee benefits and asset management. MLIC is organized into two segments: U.S. and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other. See Note 2 of the Notes to the Interim Condensed Consolidated Financial Statements for further information on the Company’s segments and Corporate & Other.
Pending Reinsurance Transaction
In May 2023, the Company entered into a definitive agreement with a subsidiary of Global Atlantic Financial Group, a retirement and life insurance company, to reinsure approximately $13.0 billion of universal life, variable universal life, universal life with secondary guarantees, and fixed annuities which are reported in the MetLife Holdings segment. The transaction is expected to close in the second half of 2023 and is subject to regulatory approvals and satisfaction of other closing conditions. See Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements for further information.
Key Financial Highlights
Net loss attributable to MLIC of $89 million for the three months ended March 31, 2023, compared to net income attributable to MLIC of $1.9$378 million for the six months ended June 30, 2023, compared to $3.6 billion for the threesix months ended March 31,June 30, 2022.
Adjusted earnings of $795 million$1.6 billion for the threesix months ended March 31,June 30, 2023, compared to adjusted earnings of $984 million$1.8 billion for the threesix months ended March 31,June 30, 2022.
118

Table of Contents
Consolidated Results
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(In millions)(In millions)
RevenuesRevenuesRevenues
PremiumsPremiums$5,849 $5,906 Premiums$11,802 $11,570 
Universal life and investment-type product policy feesUniversal life and investment-type product policy fees430 479 Universal life and investment-type product policy fees852 946 
Net investment incomeNet investment income2,685 2,826 Net investment income5,558 5,268 
Other revenuesOther revenues415 411 Other revenues834 783 
Net investment gains (losses)Net investment gains (losses)(102)(226)Net investment gains (losses)(761)(309)
Net derivative gains (losses)Net derivative gains (losses)(560)121 Net derivative gains (losses)(792)707 
Total revenuesTotal revenues8,717 9,517 Total revenues17,493 18,965 
ExpensesExpensesExpenses
Policyholder benefits and claims and policyholder dividendsPolicyholder benefits and claims and policyholder dividends6,346 6,812 Policyholder benefits and claims and policyholder dividends12,898 12,975 
Policyholder liability remeasurement (gains) lossesPolicyholder liability remeasurement (gains) losses(57)(29)Policyholder liability remeasurement (gains) losses(40)(41)
Market risk benefits remeasurement (gains) lossesMarket risk benefits remeasurement (gains) losses244 (1,361)Market risk benefits remeasurement (gains) losses(426)(2,091)
Interest credited to policyholder account balancesInterest credited to policyholder account balances831 502 Interest credited to policyholder account balances1,724 1,067 
Amortization of DAC and VOBAAmortization of DAC and VOBA77 80 Amortization of DAC and VOBA151 156 
Interest expense on debtInterest expense on debt30 24 Interest expense on debt64 49 
Other expenses, net of capitalization of DACOther expenses, net of capitalization of DAC1,441 1,204 Other expenses, net of capitalization of DAC2,729 2,496 
Total expensesTotal expenses8,912 7,232 Total expenses17,100 14,611 
Income (loss) before provision for income taxIncome (loss) before provision for income tax(195)2,285 Income (loss) before provision for income tax393 4,354 
Provision for income tax expense (benefit)Provision for income tax expense (benefit)(104)403 Provision for income tax expense (benefit)(26)788 
Net income (loss)Net income (loss)(91)1,882 Net income (loss)419 3,566 
Less: Net income (loss) attributable to noncontrolling interestsLess: Net income (loss) attributable to noncontrolling interests(2)— Less: Net income (loss) attributable to noncontrolling interests41 
Net income (loss) attributable to Metropolitan Life Insurance CompanyNet income (loss) attributable to Metropolitan Life Insurance Company$(89)$1,882 Net income (loss) attributable to Metropolitan Life Insurance Company$378 $3,564 
ThreeSix Months Ended March 31,June 30, 2023 Compared with the ThreeSix Months Ended March 31,June 30, 2022
Net income (loss) attributable to MLIC - Decreased $2.0$3.2 billion primarily due to the following:
Net Investment Gains (Losses) - FavorableUnfavorable change of $124$452 million ($98357 million, net of income tax):
Higher losses on fixed maturity securities and mortgage loans, primarily due to current period impairments for investments to be disposed of in a pending reinsurance transaction
Foreign currency transaction losses
Prior period gains on sales of real estate investments
Partially offset by:
Lower losses on sales of fixed maturity securities
Lower provisions for credit loss on fixed maturity securities
Partially offset by:
Higher provisions for credit loss on mortgage loans
Foreign currency transaction losses in the current period versus gains in the prior period
111

Table of Contents
Net Derivative Gains (Losses) - Unfavorable change of $681 million$1.5 billion ($538 million,1.2 billion, net of income tax)(1):
Change in the value of the underlying assets - unfavorable impact to embedded derivatives related to funds withheld on a certain reinsurance agreement
Key equity indexes increased in the current period versus decreased in the prior period - unfavorable impact to equity options and total rate of return swaps (“TRRs”)
Change in the value of the underlying assets - unfavorable impact to embedded derivatives related to funds withheld on a certain reinsurance agreement
Partially offset by:
Long-term interest rates decreasedwere relatively unchanged in the current period versus increased significantly in the prior period - favorable impact to the estimated fair value of receive fixed interest rate swaps
119

Table of Contents
Market Risk Benefits Remeasurement Gains (Losses)(2) - Unfavorable change of $1.6$1.7 billion ($1.3 billion, net of income tax):
Long-term interest rates decreasedwere relatively unchanged in the current period versus increased significantly in the prior period
Partially offset by:
Key equity indexes increased in the current period versus decreased in the prior period
Adjusted Earnings(3) - Unfavorable change of $189$195 million. See “— Consolidated Results — Adjusted Earnings.”
Taxes - UnfavorableFavorable change in effective tax rate - 53%(7)% current period versus 18% prior period
Current period effective tax rate on lossincome before provision for income tax was 53%(7)%, which reflected an income tax benefit despite having income before provision for income tax, versus statutory rate of 21%:
Tax benefits from tax credits
Non-taxable investment income
Corporate tax deduction for stock compensation
Non-taxable investment income
Prior period effective tax rate on income before provision for income tax was 18% versus statutory rate of 21%:
Tax benefits from tax credits
Corporate tax deduction for stock compensation
Non-taxable investment income
__________________
(1) Includes amounts relating to investment hedge adjustments, which are also included in adjusted earnings.
(2) See Note 5 of the Notes to the Interim Condensed Consolidated Financial Statements for further information on the Company’s MRBs.
(3) As used in “— Consolidated Results — Adjusted Earnings” and as more fully described in “— Non-GAAP and Other Financial Disclosures,” we refer to adjusted earnings, which does not equate to net income (loss), as determined in accordance with GAAP, to analyze our performance, evaluate segment performance, and allocate resources. We believe that the presentation of adjusted earnings, as we measure it for management purposes, enhances the understanding of our performance by highlighting the results of operations and the underlying profitability drivers of the business. Adjusted earnings allows analysis of our performance and facilitates comparisons to industry results. Adjusted earnings should not be viewed as a substitute for net income (loss).
112120

Table of Contents
Reconciliation of net income (loss) to adjusted earnings and premiums, fees and other revenues to adjusted premiums, fees and other revenues
Three Months
Ended
March 31,
Six Months
Ended
June 30,
2023202220232022
(In millions)(In millions)
Net income (loss)Net income (loss)$(91)$1,882 Net income (loss)$419 $3,566 
Less: adjustments from net income (loss) to adjusted earnings:Less: adjustments from net income (loss) to adjusted earnings:Less: adjustments from net income (loss) to adjusted earnings:
Revenues:Revenues:Revenues:
Net investment gains (losses)(102)(226)Net investment gains (losses)(761)(309)
Net derivative gains (losses)(560)121 Net derivative gains (losses)(792)707 
Premiums— — Premiums— — 
Universal life and investment-type product policy fees— — Universal life and investment-type product policy fees— — 
Net investment income(201)(131)Net investment income(398)(250)
Other revenues(5)— Other revenues(8)— 
Expenses:Expenses:Expenses:
Policyholder benefits and claims and policyholder dividends(3)(9)Policyholder benefits and claims and policyholder dividends(6)(16)
Policyholder liability remeasurement (gains) losses— — Policyholder liability remeasurement (gains) losses— — 
Market risk benefits remeasurement (gains) losses(244)1,361 Market risk benefits remeasurement (gains) losses426 2,091 
Interest credited to policyholder account balances(1)22 Interest credited to policyholder account balances— 28 
Capitalization of DAC— — Capitalization of DAC— — 
Amortization of DAC and VOBA— — Amortization of DAC and VOBA— — 
Interest expense on debt— — Interest expense on debt— — 
Other expenses(5)— Other expenses49 (2)
Provision for income tax (expense) benefitProvision for income tax (expense) benefit235 (240)Provision for income tax (expense) benefit314 (473)
Adjusted earningsAdjusted earnings$795 $984 Adjusted earnings$1,595 $1,790 
Premiums, fees and other revenuesPremiums, fees and other revenues$6,694 $6,796 Premiums, fees and other revenues$13,488 $13,299 
Less: adjustments to premiums, fees and other revenuesLess: adjustments to premiums, fees and other revenues(5)— Less: adjustments to premiums, fees and other revenues(8)— 
Adjusted premiums, fees and other revenuesAdjusted premiums, fees and other revenues$6,699 $6,796 Adjusted premiums, fees and other revenues$13,496 $13,299 
113121

Table of Contents
Consolidated Results — Adjusted Earnings
Business Overview. Adjusted premiums, fees and other revenues for the threesix months ended March 31,June 30, 2023 decreased $97increased $197 million, or 1%, compared to the prior periodperiod. This was primarily due to a decreasegrowth in our MetLife HoldingsGroup Benefits business, as well as our Retirement and Income Solutions (“RIS”) business, both in our U.S. segment. The increase in our Group Benefits business was primarily due to growth from our core and voluntary products. The increase in premiums in our RIS business was driven by our post-retirement benefit, pension risk transfer and income annuities businesses. Changes in RIS premiums are generally offset by a corresponding change in policyholder benefits. In our MetLife Holdings segment, we anticipate an annual decline in adjusted premiums, fees and other revenues from expected business run-off. In addition, lower premiums in our Retirement and Income Solutions (“RIS”) business were partially offset by growth in our Group Benefits business, both in our U.S. segment. The decrease in premiums in RIS was mainly driven by our pension risk transfer business. Changes in RIS premiums are generally offset by a corresponding change in policyholder benefits. The increase in our Group Benefits business was primarily due to growth from our voluntary products and group term life, group disability and dental businesses, substantially offset by a decrease in premiums related to our participating life contracts, which can fluctuate with claims experience.
ThreeSix Months Ended March 31,June 30, 2023 Compared with the ThreeSix Months Ended March 31,June 30, 2022
Unless otherwise stated, all amounts discussed below are net of income tax.
Adjusted Earnings - Decreased $189$195 million primarily due to the following business drivers:
Market Factors - Decreased adjusted earnings by $431$441 million
Variable investment income decreased - lower returns on our private equity and real estate funds
Higher average interest crediting rates on investment-type and certain insurance products in our U.S. segment
PartiallyLargely offset by:
Recurring investment income increased - higher yields on fixed income securities and mortgage loans
Volume Growth - Increased adjusted earnings by $57$141 million:
Positive flows from pension risk transfer transactions and funding agreement issuances in our U.S. segment and higher average invested assets in Corporate & Other
Partially offset by:
Increase in interest credited expenses on long duration insurance products in our U.S. segment
Underwriting and Other Insurance Adjustments - Increased adjusted earnings by $269$271 million:
Favorable mortality - U.S. segment - decreases in both incidence and severity of COVID-19 claims in our Group Benefits business
Favorable mortality - life business in our MetLife Holdings segment
Lower dividend expense in our MetLife Holdings segment due to dividend scale reductions, as well as run-off in our closed block
Partially offset by:
Unfavorable morbidity - U.S. segment - Group Benefits - mainly due to higher dental utilization, partially offset by favorable results in our disability businesses
Expenses - Decreased adjusted earnings by $65$139 million:
Higher corporate-related expenses, partially offset by lower interest on uncertain tax positions, primarily in Corporate & Other
Higher direct expenses, including certain employee-related costs, exceeded the corresponding increase in premiums, fees and other revenues in our U.S. segment
Adopted Accounting Pronouncements
See Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements.
Future Adoption of Accounting Pronouncements
See Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements.
122

Table of Contents
Non-GAAP and Other Financial Disclosures
In this report, the Company presents certain measures of its performance that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for the Company and our investors of our performance by highlighting the results of operations and the underlying profitability drivers of our business.
114

Table of Contents
The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
Non-GAAP financial measures:Comparable GAAP financial measures:
(i)adjusted premiums, fees and other revenues(i)premiums, fees and other revenues
(ii)adjusted earnings(ii)net income (loss)
Reconciliations of these non-GAAP financial measures to the most directly comparable historical GAAP financial measures are included in “— Results of Operations.” Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are not accessible on a forward-looking basis because we believe it is not possible without unreasonable effort to provide other than a range of net investment gains and losses and net derivative gains and losses, which can fluctuate significantly within or outside the range and from period to period and may have a material impact on net income.
Our definitions of non-GAAP and other financial measures discussed in this report may differ from those used by other companies.
Adjusted earnings
This measure is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also our GAAP measure of segment performance. Adjusted earnings allows analysis of our performance and facilitates comparisons to industry results.
The adoption of LDTI impacted the Company’s calculation of adjusted earnings. With the adoption of LDTI, the measurement model was simplified for DAC and VOBA, and most embedded derivatives were reclassified as MRBs. As a result, the Company updated its calculation of adjusted earnings to remove certain adjustments related to the amortization of DAC, VOBA and related intangibles and adjusted for changes in measurement of certain guarantees. Under LDTI, adjusted earnings excludes changes in fair value associated with MRBs, changes in discount rates on certain annuitization guarantees, losses at contract inception for certain single premium business, and asymmetrical accounting associated with in-force reinsurance. All periods presented herein reflect the updated calculation of adjusted earnings.
Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted loss is defined as negative adjusted earnings. For information relating to adjusted revenues and adjusted expenses, see “Financial Measures and Segment Accounting Policies” in Note 2 of the Notes to the Interim Condensed Consolidated Financial Statements.
The following additional information is relevant to an understanding of our performance results:
We sometimes refer to sales activity for various products. These sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.
Near-term represents one to three years.
Risk Management
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Risk Management” in the 2022 Annual Report for information on our risk management.
Subsequent Events
See Note 18 of the Notes to the Interim Condensed Consolidated Financial Statements.
115123

Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The following discussion on market risk should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Risk Management.”
Market Risk Exposures
We regularly analyze our exposure to interest rate, foreign currency exchange rate and equity market price risk. As a result of that analysis, we have determined that the estimated fair values of certain assets and liabilities are materially exposed to changes in interest rates, foreign currency exchange rates and equity markets. We have exposure to market risk through our insurance operations and investment activities. For purposes of this disclosure, “market risk” is defined as the risk of loss due to potential changes in the value of assets and liabilities arising from fluctuation in the financial markets and other economic factors.
Interest Rates
Our exposure to interest rate changes results most significantly from our holdings of fixed maturity securities available-for-sale (“AFS”), mortgage loans, derivatives, and our interest rate sensitive liabilities. The fixed maturity securities AFS include U.S. and foreign government bonds, securities issued by government agencies, corporate bonds, mortgage-backed securities and asset-backed securities and collateralized loan obligations,CLOs, all of which are mainly exposed to changes in medium- and long-term interest rates. The interest rate sensitive liabilities for purposes of this disclosure include FPBs, policyholder account balances related to certain investment type contracts, debt, and MRBs primarily consisting of variable annuities with guaranteed minimum benefits which have the same type of interest rate exposure (medium- and long-term interest rates) as fixed maturity securities AFS. See “Risk Factors — Economic Environment and Capital Markets Risks — We May Face Difficult Economic Conditions” included in the 2022 Annual Report.
Foreign Currency Exchange Rates
Our exposure to fluctuations in foreign currency exchange rates against the U.S. dollar results most significantly from our holdings in non-U.S. dollar denominated fixed maturity and equity securities, mortgage loans, and insurance liabilities. The principal currencies that create foreign currency exchange rate risk in our investment portfolios and insurance liabilities are the Japanese yen, the Euro and the British pound. We hedge foreign currency exchange rate risk with foreign currency swaps, forwards and options.
Equity Market
Along with investments in equity and fair value option securities (“FVO Securities”), we have exposure to equity market risk through certain liabilities that involve long-term guarantees on equity performance, such as MRBs for variable annuities with guaranteed minimum benefits and certain policyholder account balances. Equity exposures associated with real estate and limited partnership interests are excluded from this discussion as they are not considered financial instruments under GAAP.
Management of Market Risk Exposures
We use a variety of strategies to manage interest rate, foreign currency exchange rate and equity market risk, including the use of derivatives.
Interest Rate Risk Management
To managesupport management of interest rate risk, we analyze interest rate riskperform analysis using various models, including multi-scenario cash flow projection models that forecast cash flows of the liabilities and their supporting investments, including derivatives. These projections involve evaluating the potential gain or loss on most of our in-force business under various increasing and decreasing interest rate environments. The New York State Department of Financial Services regulations require that we perform some of these analyses annually as part of our review of the sufficiency of our regulatory reserves. We maintain segmented operating and surplus asset portfolios for the purpose of asset/liability management (“ALM”) and the allocation of investment income to product lines. In the U.S., for each segment, invested assets greater than or equal to the GAAP liabilities net of certain non-invested assets allocated to the segment are maintained, with any excess allocated to Corporate & Other. The business segments may reflect differences in legal entity, statutory line of business and any product market characteristic which may drive a distinct investment strategy with respect to duration, liquidity or credit quality of the invested assets.
116124

Table of Contents
We measure relative sensitivities of the value of our assets and liabilities to changes in key assumptions utilizing internal models. These models reflect specific product characteristics and include assumptions based on current and anticipated experience regarding lapse, mortality, morbidity and interest crediting rates. In addition, these models include asset cash flow projections reflecting interest payments, sinking fund payments, principal payments, bond calls, mortgage loan prepayments and defaults.
We employ product design, pricing and ALM strategies to reduce the potential effects of interest rate movements. Product design and pricing strategies include the use of surrender charges or restrictions on withdrawals in some products and the ability to reset crediting rates for certain products. ALM strategies include the use of derivatives. We also use reinsurance to mitigate interest rate risk.
We also use common industry metrics, such as duration and convexity, to measure the relative sensitivity of assets and liability values to changes in interest rates. In computing the duration of liabilities, we consider policyholder guarantees and how we intend to set indeterminate policy elements such as interest credits or dividends. Each asset portfolio or portfolio group has a duration target based on the liability duration and the investment objectives of that portfolio. Where a liability cash flow may exceed the maturity of available assets, we may support such liabilities with equity investments, derivatives or interest rate curve mismatch strategies.
Foreign Currency Exchange Rate Risk Management
MetLife has a well-established policy to manage foreign currency exchange rate exposures within its risk tolerance. In general, investments backing specific liabilities are currency matched. This is achieved through direct investments in matching currency or through the use of foreign currency exchange rate derivatives. Enterprise foreign currency exchange rate risk limits are established by the Enterprise Risk Committee. Management of each of the Company’s segments, with oversight from MetLife’s FX Working Group and the ALM committee for the respective segment, is responsible for managing any foreign currency exchange rate exposure. The general authorizations of the Investment Committee of the MLIC Board of Directors also set limits on unhedged foreign currency investment exposure.
We use foreign currency swaps, forwards and options to mitigate the liability exposure, risk of loss and financial statement volatility associated with foreign currency denominated fixed income investments and foreign currency insurance liabilities.
Equity Market Risk Management
We manage equity market risk on an integrated basis with other risks through our ALM strategies, including the dynamic hedging with derivatives of certain variable annuity guarantee benefits accounted for as MRBs, as well as reinsurance, in order to limit losses, minimize exposure to large risks, and provide additional capacity for future growth. We also manage equity market risk exposure in our investment portfolio through the use of derivatives. These derivatives include exchange-traded equity futures, equity index options contracts, TRRs and equity variance swaps.
Hedging Activities
We use derivative contracts primarily to hedge a wide range of risks including interest rate risk, foreign currency exchange rate risk, and equity market risk. Derivative hedges are designed to reduce risk on an economic basis while considering their impact on financial results under different accounting regimes, including GAAP and local statutory accounting. Our derivative hedge programs vary depending on the type of risk being hedged. Some hedge programs are asset or liability specific while others are portfolio hedges that reduce risk related to a group of liabilities or assets. Our use of derivatives by major hedge programs is as follows:
Risks Related to Guarantee Benefits — We use a wide range of derivative contracts to mitigate the risk associated with living guarantee benefits accounted for as MRBs. These derivatives include equity and interest rate futures, interest rate swaps, currency futures/forwards, equity indexed options, TRRs, interest rate option contracts and equity variance swaps.
Minimum Interest Rate Guarantees — For certain liability contracts, we provide the contractholder a guaranteed minimum interest rate. These contracts include certain fixed annuities and other insurance liabilities. We purchase interest rate caps and floors to reduce risk associated with these liability guarantees.
Reinvestment Risk in Long-Duration Liability Contracts — Derivatives are used to hedge interest rate risk related to certain long-duration liability contracts. Hedges include interest rate swaps, swaptions and Treasury bond forwards.
117

Table of Contents
Foreign Currency Exchange Rate Risk — We use foreign currency swaps, futures, forwards and options to hedge foreign currency exchange rate risk. These hedges are generally used to swap foreign currency denominated bonds or equity market exposures to U.S. dollars.
125

Table of Contents
General ALM Hedging Strategies — In the ordinary course of managing our asset/liability risks, we use interest rate futures, interest rate swaps, interest rate caps, interest rate floors, and inflation swaps. These hedges are designed to reduce interest rate risk or inflation risk related to the existing assets or liabilities or related to expected future cash flows.
Macro Hedge Program — We use equity options, equity TRRs, interest rate swaptions, interest rate swaps and Treasury locks to mitigate the potential loss of legal entity statutory capital under stress scenarios.
Risk Measurement: Sensitivity Analysis
We measure market risk related to our market sensitive assets and liabilities based on changes in interest rates, foreign currency exchange rates and equity market prices utilizing a sensitivity analysis. This analysis estimates the potential changes in estimated fair value based on a hypothetical 100 basis point change (increase or decrease) in interest rates, as well as a 10% change (increase or decrease) in foreign currency exchange rates and equity market prices. We believe these changes in market rates and prices are reasonably possible in the near term. In performing the analysis summarized below, we used market rates at March 31,June 30, 2023. The sensitivity analysis separately calculates each of our market risk exposures (interest rate, foreign currency exchange rate and equity market) relating to our assets and liabilities. We modeled the impact of changes (increases and decreases) in market rates and prices on the estimated fair values of our market sensitive assets and liabilities and present the results with the most adverse level of market risk impact to the Company for each of these market risk exposures as follows:
the net present values of our interest rate sensitive exposures resulting from a 100 basis point change (increase or decrease) in interest rates;
estimated fair values of our foreign currency exchange rate sensitive exposures due to a 10% change (appreciation or depreciation) in the value of the U.S. dollar compared to all other currencies; and
the estimated fair value of our equity market sensitive exposures due to a 10% change (increase or decrease) in equity market prices.
The sensitivity analysis is an estimate and should not be viewed as predictive of our future financial performance. We cannot ensure that our actual losses in any particular period will not exceed the amounts indicated in the table below. Limitations related to this sensitivity analysis include:
liabilities do not include $8.2$8.3 billion of other policy-related balances largely consisting of claims, unearned revenue liabilities and policyholder dividends;
the analysis excludes real estate holdings, private equity and hedge fund holdings;
the market risk information is limited by the assumptions and parameters established in creating the related sensitivity analysis, including the impact of prepayment rates on mortgage loans;
sensitivities do not include the impact on asset or liability valuation of changes in market liquidity or changes in market credit spreads;
foreign currency exchange rate risk is not isolated for certain MRBs for variable annuities with guaranteed minimum benefits, as the risk on these instruments is reflected as equity;
the impact on reported earnings may be materially different from the change in market values, most notably for fixed maturity securities AFS, mortgage loans, FPBs, and derivatives that qualify for hedge accounting; and
the model assumes that the composition of assets and liabilities remains unchanged throughout the period.
Accordingly, we use such models as tools and not as substitutes for the experience and judgment of our management. Based on our analysis of the impact of a 100 basis point change (increase or decrease) in interest rates, as well as a 10% change (increase or decrease) in foreign currency exchange rates and equity market prices, we have determined that such a change could have a material adverse effect on the estimated fair value of certain assets and liabilities from interest rate, foreign currency exchange rate and equity market exposures.
118126

Table of Contents
The table below illustrates the potential loss in estimated fair value for each market risk exposure based on market sensitive assets and liabilities at:
 March 31,June 30, 2023
 (In millions)
Interest rate risk$3,6973,461 
Foreign currency exchange rate risk$181125 
Equity market risk$7379 
The risk sensitivities derived used a 100 basis point increase to interest rates, a 10% weakening of the U.S. dollar against foreign currencies, and a 10% decrease in equity prices. The potential losses in estimated fair value presented are for non-trading securities.
119

Table of Contents
The table below provides additional detail regarding the potential loss in estimated fair value of our interest sensitive financial instruments due to a 100 basis point increase in interest rates at:
March 31, 2023June 30, 2023
Notional
Amount
Estimated
Fair
Value (1)
Assuming a
100 bps
Increase
in Interest Rates
Notional
Amount
Estimated
Fair
Value (1)
Assuming a
100 bps
Increase
in Interest Rates
(In millions)(In millions)
AssetsAssetsAssets
Fixed maturity securities AFSFixed maturity securities AFS$150,960 $(9,795)Fixed maturity securities AFS$149,072 $(9,459)
FVO SecuritiesFVO Securities$892 $(9)FVO Securities$937 $(9)
Mortgage loansMortgage loans$61,025 $(1,870)Mortgage loans$60,000 $(1,819)
Policy loansPolicy loans$6,177 $(163)Policy loans$6,107 $(155)
Short-term investmentsShort-term investments$2,046 $(51)Short-term investments$3,456 $(50)
Other invested assetsOther invested assets$2,320 $Other invested assets$2,124 $(2)
Cash and cash equivalentsCash and cash equivalents$5,225 $(2)Cash and cash equivalents$4,106 $(2)
Accrued investment incomeAccrued investment income$2,080 $— Accrued investment income$2,024 $— 
Premiums, reinsurance and other receivablesPremiums, reinsurance and other receivables$12,386 $(689)Premiums, reinsurance and other receivables$12,216 $(685)
Market risk benefitsMarket risk benefits$124 $— Market risk benefits$163 $— 
Other assets$820 $— 
Total assetsTotal assets$(12,575)Total assets$(12,181)
LiabilitiesLiabilitiesLiabilities
Future policy benefitsFuture policy benefits$128,198 $6,470 Future policy benefits$126,814 $6,305 
Policyholder account balancesPolicyholder account balances$85,569 $2,184 Policyholder account balances$84,948 $1,961 
Market risk benefitsMarket risk benefits$3,432 $1,068 Market risk benefits$2,942 $944 
Payables for collateral under securities loaned and other transactionsPayables for collateral under securities loaned and other transactions$13,443 $— Payables for collateral under securities loaned and other transactions$12,695 $— 
Short-term debtShort-term debt$99 $— Short-term debt$99 $— 
Long-term debtLong-term debt$1,942 $72 Long-term debt$1,934 $70 
Other liabilitiesOther liabilities$12,251 $752 Other liabilities$12,101 $742 
Total liabilitiesTotal liabilities$10,546 Total liabilities$10,022 
Derivative InstrumentsDerivative InstrumentsDerivative Instruments
Interest rate swapsInterest rate swaps$22,377 $1,896 $(1,242)Interest rate swaps$22,339 $1,420 $(1,144)
Interest rate floorsInterest rate floors$21,495 $128 $(66)Interest rate floors$18,246 $50 $(27)
Interest rate capsInterest rate caps$41,290 $698 $235 Interest rate caps$41,040 $749 $284 
Interest rate futuresInterest rate futures$265 $$(24)Interest rate futures$58 $— $(1)
Interest rate optionsInterest rate options$39,806 $393 $(207)Interest rate options$38,636 $266 $(104)
Interest rate forwardsInterest rate forwards$1,932 $(284)$(165)Interest rate forwards$1,687 $(292)$(135)
Synthetic GICsSynthetic GICs$10,525 $— $— Synthetic GICs$10,629 $— $— 
Foreign currency swapsForeign currency swaps$34,579 $2,032 $(149)Foreign currency swaps$35,780 $2,108 $(143)
Foreign currency forwardsForeign currency forwards$1,398 $(2)$— Foreign currency forwards$1,118 $$— 
Credit default swapsCredit default swaps$11,139 $104 $(1)Credit default swaps$11,714 $151 $(5)
Equity futuresEquity futures$1,110 $(14)$(2)Equity futures$1,214 $(11)$(2)
Equity index optionsEquity index options$15,756 $322 $(40)Equity index options$17,069 $199 $(25)
Equity variance swapsEquity variance swaps$90 $$— Equity variance swaps$90 $$— 
Equity total return swapsEquity total return swaps$1,980 $$(7)Equity total return swaps$1,980 $(88)$— 
Total derivative instrumentsTotal derivative instruments$(1,668)Total derivative instruments$(1,302)
Net ChangeNet Change$(3,697)Net Change$(3,461)
__________________
127

Table of Contents
(1)Separate account assets and liabilities, which are interest rate sensitive, are not included herein as any interest rate risk is borne by the contractholder.
Sensitivity to interest rates increased $0.6$0.4 billion to $3.7$3.5 billion at March 31,June 30, 2023 from $3.1 billion at December 31, 2022.
120

Table of Contents
The table below provides additional detail regarding the potential loss in estimated fair value of our portfolio due to a 10% depreciation in the U.S. dollar compared to all other currencies at:
March 31, 2023June 30, 2023
Notional
Amount
Estimated
Fair
Value (1)
Assuming a
10% Depreciation in the U.S. Dollar
Notional
Amount
Estimated
Fair
Value (1)
Assuming a
10% Depreciation in the U.S. Dollar
(In millions)(In millions)
AssetsAssetsAssets
Fixed maturity securities AFSFixed maturity securities AFS$150,960 $1,475 Fixed maturity securities AFS$149,072 $1,458 
FVO SecuritiesFVO Securities$892 $— FVO Securities$937 $— 
Mortgage loansMortgage loans$61,025 $268 Mortgage loans$60,000 $265 
Policy loansPolicy loans$6,177 $— Policy loans$6,107 $— 
Short-term investmentsShort-term investments$2,046 $84 Short-term investments$3,456 $84 
Other invested assetsOther invested assets$2,320 $122 Other invested assets$2,124 $113 
Cash and cash equivalentsCash and cash equivalents$5,225 $Cash and cash equivalents$4,106 $
Accrued investment incomeAccrued investment income$2,080 $17 Accrued investment income$2,024 $14 
Premiums, reinsurance and other receivablesPremiums, reinsurance and other receivables$12,386 $— Premiums, reinsurance and other receivables$12,216 $— 
Market risk benefitsMarket risk benefits$124 $— Market risk benefits$163 $— 
Other assets$820 $— 
Total assetsTotal assets$1,974 Total assets$1,942 
LiabilitiesLiabilitiesLiabilities
Future policy benefitsFuture policy benefits$128,198 $— Future policy benefits$126,814 $— 
Policyholder account balancesPolicyholder account balances$85,569 $(1,193)Policyholder account balances$84,948 $(1,358)
Market risk benefitsMarket risk benefits$3,432 $— Market risk benefits$2,942 $— 
Payables for collateral under securities loaned and other transactionsPayables for collateral under securities loaned and other transactions$13,443 $— Payables for collateral under securities loaned and other transactions$12,695 $— 
Long-term debtLong-term debt$1,942 $— Long-term debt$1,934 $— 
Other liabilitiesOther liabilities$12,251 $— Other liabilities$12,101 $— 
Total liabilitiesTotal liabilities$(1,193)Total liabilities$(1,358)
Derivative InstrumentsDerivative InstrumentsDerivative Instruments
Interest rate swapsInterest rate swaps$22,377 $1,896 $— Interest rate swaps$22,339 $1,420 $— 
Interest rate floorsInterest rate floors$21,495 $128 $— Interest rate floors$18,246 $50 $— 
Interest rate capsInterest rate caps$41,290 $698 $— Interest rate caps$41,040 $749 $— 
Interest rate futuresInterest rate futures$265 $$— Interest rate futures$58 $— $— 
Interest rate optionsInterest rate options$39,806 $393 $— Interest rate options$38,636 $266 $— 
Interest rate forwardsInterest rate forwards$1,932 $(284)$— Interest rate forwards$1,687 $(292)$— 
Synthetic GICsSynthetic GICs$10,525 $— $— Synthetic GICs$10,629 $— $— 
Foreign currency swapsForeign currency swaps$34,579 $2,032 $(862)Foreign currency swaps$35,780 $2,108 $(612)
Foreign currency forwardsForeign currency forwards$1,398 $(2)$(101)Foreign currency forwards$1,118 $$(99)
Credit default swapsCredit default swaps$11,139 $104 $Credit default swaps$11,714 $151 $
Equity futuresEquity futures$1,110 $(14)$— Equity futures$1,214 $(11)$— 
Equity index optionsEquity index options$15,756 $322 $— Equity index options$17,069 $199 $— 
Equity variance swapsEquity variance swaps$90 $$— Equity variance swaps$90 $$— 
Equity total return swapsEquity total return swaps$1,980 $$— Equity total return swaps$1,980 $(88)$— 
Total derivative instrumentsTotal derivative instruments$(962)Total derivative instruments$(709)
Net ChangeNet Change$(181)Net Change$(125)
__________________
(1)Does not necessarily represent those financial instruments solely subject to foreign currency exchange rate risk. Separate account assets and liabilities, which are foreign currency exchange rate sensitive, are not included herein as any foreign currency exchange rate risk is borne by the contractholder.
Sensitivity to foreign currency exchange rates decreased $80$136 million to $181$125 million at March 31,June 30, 2023 from $261 million at December 31, 2022.
121128

Table of Contents
The table below provides additional detail regarding the potential loss in estimated fair value of our portfolio due to a 10% decrease in equity prices at:
March 31, 2023

June 30, 2023
Notional
Amount
Estimated
Fair
Value (1)
Assuming a
10% Decrease
in Equity
Prices
Notional
Amount
Estimated
Fair
Value (1)
Assuming a
10% Decrease
in Equity
Prices
(In millions)(In millions)
AssetsAssetsAssets
FVO SecuritiesFVO Securities$892 $(64)FVO Securities$937 $(69)
Other invested assetsOther invested assets$2,320 $(46)Other invested assets$2,124 $(48)
Total assetsTotal assets$(110)Total assets$(117)
LiabilitiesLiabilitiesLiabilities
Policyholder account balancesPolicyholder account balances$85,569 $— Policyholder account balances$84,948 $— 
Market risk benefitsMarket risk benefits$3,432 $(375)Market risk benefits$2,942 $(348)
Total liabilitiesTotal liabilities$(375)Total liabilities$(348)
Derivative InstrumentsDerivative InstrumentsDerivative Instruments
Interest rate swapsInterest rate swaps$22,377 $1,896 $— Interest rate swaps$22,339 $1,420 $— 
Interest rate floorsInterest rate floors$21,495 $128 $— Interest rate floors$18,246 $50 $— 
Interest rate capsInterest rate caps$41,290 $698 $— Interest rate caps$41,040 $749 $— 
Interest rate futuresInterest rate futures$265 $$— Interest rate futures$58 $— $— 
Interest rate optionsInterest rate options$39,806 $393 $— Interest rate options$38,636 $266 $— 
Interest rate forwardsInterest rate forwards$1,932 $(284)$— Interest rate forwards$1,687 $(292)$— 
Synthetic GICsSynthetic GICs$10,525 $— $— Synthetic GICs$10,629 $— $— 
Foreign currency swapsForeign currency swaps$34,579 $2,032 $— Foreign currency swaps$35,780 $2,108 $— 
Foreign currency forwardsForeign currency forwards$1,398 $(2)$— Foreign currency forwards$1,118 $$— 
Credit default swapsCredit default swaps$11,139 $104 $— Credit default swaps$11,714 $151 $— 
Equity futuresEquity futures$1,110 $(14)$92 Equity futures$1,214 $(11)$91 
Equity index optionsEquity index options$15,756 $322 $113 Equity index options$17,069 $199 $78 
Equity variance swapsEquity variance swaps$90 $$— Equity variance swaps$90 $$— 
Equity total return swapsEquity total return swaps$1,980 $$207 Equity total return swaps$1,980 $(88)$217 
Total derivative instrumentsTotal derivative instruments$412 Total derivative instruments$386 
Net ChangeNet Change$(73)Net Change$(79)
__________________
(1)Does not necessarily represent those financial instruments solely subject to equity price risk. Additionally, separate account assets and liabilities, which are equity market sensitive, are not included herein as any equity market risk is borne by the contractholder.
Sensitivity to equity market prices increased $53$59 million to $73$79 million at March 31,June 30, 2023 from $20 million at December 31, 2022.
122129

Table of Contents
Item 4. Controls and Procedures
Management, with the participation of the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), as of the end of the period covered by this report. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective.
During the first quarter of 2023, the Company adopted LDTI resulting in material changes to certain measurement models and disclosures for periodic results and balances related to long-duration insurance contracts. To address the additional requirements under LDTI, the Company implemented changes to policies and processes for the estimation and disclosure of these periodic results and balances.
Except for the changes related to the adoption of LDTI, thereThere were no other material changes to the Company’s internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the quarter ended March 31,June 30, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Part II — Other Information
Item 1. Legal Proceedings
See Note 16 of the Notes to the Interim Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
Certain factors that may affect the Company’s business or operations are described under “Risk Factors” in Part I, Item 1A, of the 2022 Annual Report. Report. There have been no material changes to our risk factors from the risk factors previously disclosed in the 2022 Annual Report.
Item 5. Other Information
Insider trading arrangements
During the three months ended June 30, 2023, none of our Section 16 officers or directors (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Section 408(c) of Regulation S-K).
Iran activity
Pursuant to Section 13(r) of the Exchange Act, the Company is required to disclose in its periodic reports whether it or any of its affiliates knowingly conducted transactions or dealings with the Government of Iran, or any person or entity owned or controlled, directly or indirectly, by the Government of Iran or any of its subdivisions, agencies or instrumentalities (a “Government Related Entity”).
In the second quarter of 2023, an affiliate of the Company that is a subsidiary of MetLife, Inc. but not the Company (the “Affiliate”) issued a group medical policy to the Iranian Khadije Kobra School in Dubai, United Arab Emirates (“UAE”), an educational organization that appears to be owned or controlled, directly or indirectly, by a Government Related Entity. During the quarter, premiums received by the Affiliate attributable to the issuance of the policy were approximately $11,000, which reflects the total amount owed for the policy, and the Affiliate paid less than $150 in claims under the policy. These transactions do not have any impact on the Company’s interim condensed consolidated financial statements.
In the second quarter of 2023, the Affiliate issued a group medical policy to the Directorate of Iranian Schools in the UAE, an educational organization in the UAE that appears to be owned or controlled, directly or indirectly, by a Government Related Entity. During the quarter, premiums received by the Affiliate attributable to the issuance of the policy were approximately $67,000, which reflects the total amount owed for the policy, and the Affiliate paid less than $10,000 in claims under the policy. These transactions do not have any impact on the Company’s interim condensed consolidated financial statements.
In each case, MetLife does not intend to continue any services related to or involving the policies. MetLife continues to investigate the circumstances of issuance of each policy. MetLife does not intend to conduct any transactions or dealings not specifically authorized by a U.S. federal department or agency with a Government Related Entity.
123130

Table of Contents
Item 6. Exhibits
(Note Regarding Reliance on Statements in Our Contracts: In reviewing the agreements included as exhibits to this Quarterly Report on Form 10-Q, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about Metropolitan Life Insurance Company, its subsidiaries or affiliates, or the other parties to the agreements. The agreements contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and (i) should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; (iii) may apply standards of materiality in a way that is different from what may be viewed as material to investors; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about Metropolitan Life Insurance Company, its subsidiaries and affiliates may be found elsewhere in this Quarterly Report on Form 10-Q and Metropolitan Life Insurance Company’s other public filings, which are available without charge through the U.S. Securities and Exchange Commission website at www.sec.gov.)
Incorporated by Reference
Exhibit No.DescriptionFormFile NumberExhibitFiling DateFiled or Furnished Herewith
31.1X
31.2X
32.1X
32.2X
101.SCHInline XBRL Taxonomy Extension Schema Document.X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.X
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.X
104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).X
Incorporated by Reference
Exhibit No.DescriptionFormFile NumberExhibitFiling DateFiled or Furnished Herewith
10.18-K001-15787    10.1May 9, 2023
31.1X
31.2X
32.1X
32.2X
101.SCHInline XBRL Taxonomy Extension Schema Document.X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.X
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.X
104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).X
124131

Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

METROPOLITAN LIFE INSURANCE COMPANY
By:/s/ Tamara L. Schock
Name:  Tamara L. Schock
Title:    Executive Vice President
             and Chief Accounting Officer
             (Authorized Signatory and Principal
              Accounting Officer)

Date: May 9,August 8, 2023
125132